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Abstract 
 
 
Joseph N. Capilato 
SYNTHESIS AND BIOLOGICAL ACTIVITY OF NOVEL QUORUM SENSING 
COMPOUNDS 
2015-2016 
Lark J. Perez, Ph.D 
Master of Science in Pharmaceutical Science 
 
 
 
 
Bacteria communicate with chemical signals in a process known as quorum 
sensing. This population density-dependent process involves the bacterial production, 
release and detection of structurally specific small molecules and enables the bacterial 
pathogen to regulate its virulence on a population-wide level. Using a variety of chemical 
and biological techniques, I have studied various quorum sensing systems in several 
bacteria, including Vibrio cholera and Pseudomonas aeruginosa. A key principle of this 
research involves the design, synthesis and testing of novel compounds for their 
biological activity. These molecules are typically based off of an initial lead target, which 
is often identified from a high-throughput screen and serves as a template for further 
optimization. Specifically, I have researched quorum sensing compounds that affect Hfq- 
RNA interactions in V. cholera, the LasR receptor in P. aeuruginosa and HapR in V. 
cholera. Taken together, the results of these studies provide a basis for future 
investigations involving quorum sensing, and demonstrate how organic chemistry can be 
employed to study these fascinating biochemical systems. 
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Chapter 1 
 
Design of small molecule inhibitors of a protein-RNA interaction in Vibrio 
cholera 
Introduction 
 
Protein-RNA interactions facilitate various biochemical processes that are 
fundamental for life
1,2,3
. Chief among these is the translation of proteins, in which gene 
expression can be regulated by a specific protein-RNA interaction
2,3
. In theory, many of 
these protein-RNA complexes should represent a potential target for medicinal chemists, 
as the ability to modulate gene expression is scientifically and medically useful. For that 
reason, it is surprising how few drugs that are currently on the market take advantage of 
this untapped interaction. The ability to discover small molecules that interact specifically 
with protein-RNA complexes is of growing interest and while not entirely trouble-free, 
has been shown to be at the very least, possible. 
 
Recently, my collaborator Prof. Ng at Tufts University developed an assay to 
identify inhibitors of a specific protein-RNA interaction in V. cholera. Using high- 
throughput screening, Prog. Ng tested a library of small molecules and found several hit 
compounds that inhibit a protein-RNA complex of the protein Hfq. This widely 
conserved bacterial protein mediates the expression of important quorum sensing proteins 
through the binding of sRNAs known as the Qrrs
2,3,4
. In V. cholera, Hfq bound to sRNAs 
known as the Qrrs results in destabilization of the quorum sensing master regulator, 
HapR
2
. As HapR normally functions to suppress virulence, the inhibitory action of the 
Hfq- Qrr complex on HapR serves to upregulate virulence
2
. El-Mowafi et al. published a 
paper in 2014 on inhibitors of Hfq-RNA interactions, and was the only relevant precedent 
that could be found on this topic
1
. The active compounds from their study, however, were 
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cyclic peptides rather than small molecules, which benefit from enhanced pharmaceutical 
properties such as solubility and permeability
1
. In fact, the authors mentioned in the 
discussion section that a small molecule that binds to the site of RI20, their lead peptide, 
would be a "candidate anti-infective"
1
. They go on to mention that the compounds could 
be rationally designed once the crystal structure of the Hfq complex is known, or they 
could be discovered via high-throughput screening
1
. Having identified a small molecule 
that inhibits one of these particular protein-RNA interactions, Hfq is now a viable target 
to reduce bacterial virulence. After synthesizing and retesting the original hit compound 
1, I prepared a library of analogs and ultimately identified a derivative with significantly 
improved efficacy and reduced toxicity. 
 
Results and Discussion 
 
The dose-response relationship for Compound 1 is a bell curve. During the 
early attempts to test the biological activity of compound 1, the maximum concentration 
tested was 100 µM. The dose-response curves for these trials appeared to have a 
sigmoidal shape, increasing in magnitude up to 100 µM, and therefore, it was 
hypothesized that these curves would flatten out in a sigmoidal fashion if higher 
concentrations were tested. Upon performing another assay that included concentrations 
up to 300 µM, it was discovered that the dose-response relationship was not sigmoidal, 
but was actually a bell curve (or an inverted-U) (Fig. 2). For compound 1, before 100 µM 
seems to be the optimal concentration in which the highest response level is reached, 
while concentrations higher than 100 µM are in the decline section of the bell curve (Fig. 
2). To explain this phenomenon we looked at the luminescence and OD600 data 
separately, each plotted as a dose-response. From the OD600 plot (Fig. 5) it is apparent 
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that there is some growth inhibition at concentrations leading up to 100 µM, and the low 
OD600 values for concentrations higher than 100 µM suggest that those cells are dead. 
While it was discouraging to learn of this problem with toxicity at high concentrations, 
 
this was a critical observation that helped explain the unique dose-response relationship 
for compound 1. Other analogs that were synthesized and tested all repeated this bell 
curve effect, and accordingly also suffered from growth inhibition at high concentrations 
(some to a lesser extent, however). 
An aminal is required for biological activity. After becoming aware of how 
significantly instable the N, N-acetal truly was, a series of experiments were performed to 
test if the aminal was actually necessary for activity. Firstly, the breakdown products 
from the hydrolysis of the aminal, the free benzimidazole and piperazine portions, were 
tested individually in the assay along with 1. Neither of these fragments produced a 
significant response compared to 1, and therefore it was concluded that the coupled 
molecule is required for activity. However, while this assay supported the notion that the 
coupled benzimidazole-piperazine compound is required, it was still uncertain whether 
those portions needed to be coupled via the N, N-acetal. To test this, three new analogs 
were designed and synthesized, which utilized different linkers to couple the two portions 
of the molecule (Fig. 3). The first of these compounds is identical to 1, but with a 
carbonyl on the carbon involved in the aminal, resulting in a urea-type analog. This 
change has a negligible effect on the molecule's properties such as size, but the 
compound now becomes significantly more stable, no longer containing the acid-labile 
aminal. Similarly, two other new analogs of 1 were prepared, one that utilizes a 
sulfonamide linker, and another that contains a two-carbon linker (Fig. 3). These three 
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linker-derivatives were tested against 1 in the assay, and surprisingly none of them 
produced any measurable level of activity. Ultimately, these experiments taken together 
leads us to a somewhat paradoxical notion, that the coupled benzimidazole-piperazine 
molecule is required for activity but these two portions must be linked together via an N, 
N-acetal. Since the aminal is known to readily hydrolyze even under mild conditions, it is 
peculiar that this functional group would behave as a pharmacophore. One possible 
explanation is that the coupled aminal is not actually the active compound, but rather a 
pro-drug, which during hydrolysis generates reactive intermediates that function as the 
true biologically active species. Concluding that we could not avoid incorporating the 
aminal into the structure, we focused our attention on developing methods to synthesize, 
purify and handle theses sensitive molecules as best as possible. 
 
Development of truncated analogs establishes the unimportance of the aryl 
sulfonamide moiety. The initial SAR (structure-activity relationship) we obtained 
informed us that changes to the benzyl group of the benzimidazole were not tolerated. 
Analogs that were prepared and tested modified the benzyl to phenyl, cyclohexyl, 
pyridine, ortho-methoxybenzyl or para-bromobenzyl (Fig. 1). Of this small series, every 
compound was inactive with the exception of the pyridine analog, for which a response 
was observed that was negligible compared to 1. After this result, our strategy for 
rationale design of derivatives shifted to modifications of the cyanobenzene group. Being 
limited to the few aryl sulfonyl chlorides we had available, four analogs that made 
changes to this ring were synthesized and tested (Fig. 1). While all of these molecules 
were active in our assay, none of them were more efficacious than 1, although the ortho- 
nitro derivative produced the most comparable response. Most interesting was the result 
that not just small changes (i.e. ortho-nitro) were tolerated but also substantial alterations 
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(i.e. para-methyl, trichloro, pentafluoro) did not cause a loss in activity. The latter 
observation caused another reassessment of our synthetic rationale, as the importance of 
this cyanobenzene group was uncertain. To address this, an analog was designed which 
removed the aryl sulfanamide group entirely, changing the secondary amine involved in 
the N, N-acetal from the substituted piperazine to morpholine (2). Unexpectedly, this 
compound was not only active but was equally as potent and slightly more efficacious 
than 1 at the third highest concentration (Fig. 4). Building off this result, a couple more 
truncated analogs were prepared and tested in addition to the morpholine derivative, 
incorporating piperidine, N-methylpiperazine, and dimethylmorpholine into the aminal 
(Fig. 1). These compounds were also active but did not match the response level of 2 
(Fig. 6). Unfortunately, the truncated series also suffered from growth inhibition at the 
same concentrations as 1, although slightly higher OD600 values were recorded for the 
morpholine analog than for 1 (Fig. 5). Even though the toxicity issue still persisted, the 
fact that these four compounds maintained (and in one case, somewhat improved) activity 
after a large part of the molecular structure was removed was remarkable. Furthermore, 
the chemical properties of these new analogs are superior to 1 in regards to making the 
compound more drug-like. The truncated analogs are not only smaller molecules but also 
are more hydrophilic; for instance comparing 1 to 2, the molecular weight has been 
reduced from 472 to 323 g/mol and the cLogP value decreased from 4.85 to 3.60. Given 
the critical SAR that was provided by this series, subsequent analogs did not contain the 
sulfonamide cyanobenzene moiety. 
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Development of oxazolidinone derivatives addresses issue of stability and 
toxicity. Having experimented thoroughly with analogs based off of piperazine, an 
interest developed in testing N, N-acetals of other NH heterocycles. Attempts to form the 
aminal from the benzimidazole failed for pyrrole, imidazole, succinimide, tetrazole and 
several other substrates. Oxazolidinone, on the other hand, was identified to be capable of 
forming the aminal with benzimidazole, and the product could be isolated in an aqueous 
workup just as the piperazine-based analogs. Upon testing this new derivative, the 
somewhat impure sample produced promising data, reaching a higher Lux/OD600 value 
than 1. This preliminary result led to the development of several other oxazolidinone- 
based analogs. Several substituted oxazolidinones (isopropyl, phenyl and benzyl) were 
purchased relatively inexpensively, due to their common use as Evans chiral auxiliaries. 
Forming the aminal proceeded smoothly with these new substrates, as well as the 
unsubstituted oxazolidinone, and the coupled product seemed to be a bit more robust than 
the piperazine-based aminals such as 1. The enhanced stability of these derivatives was 
confirmed via the identification of a purification method that did not hydrolyze the 
aminal. Using alumina instead of silica, the oxazolidinone-based N, N-acetals could be 
purified, whereas the piperazine-based aminals hydrolyze on both alumina and silica. 
This change in stability is thought to be due to the decreased basicity of the nitrogen of 
the oxazolidinone, compared to the nitrogen in piperazine which protonates much more 
readily, thereby initiating the mechanism for hydrolysis of the aminal. Upon testing these 
more stable analogs it was interesting to see that they experienced significantly reduced 
growth inhibition at high concentrations in comparison to 1 (Fig. 8). This result supported 
our initial hypothesis that the instability/reactivity of the N, N-acetal was the cause for 
the toxicity issue. In regards to the biological response, surprisingly the unsubstituted 
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oxazolidinone analog was no longer active in its pure form. The other derivatives, 
however, were active, chief among them being the benzyl-substituted oxazolidinone 
analog (3). Shockingly, this analog produced a drastically higher level of efficacy than 1, 
having almost quadrupled the maximum Lux/OD600 value of 1 (Fig. 7). Perhaps even 
more important, though, was the decreased toxicity of this new analog. The OD600 plot of 
3 depicts no substantial growth inhibition at the three highest concentrations tested, 
whereas 1 is shown to have decreasing cell density starting at the third highest 
concentration, and the cells appear to be completely dead by the final two concentrations 
(Fig. 8). Taking these results together, this oxazolidinone derivative has addressed issues 
with stability, toxicity and efficacy, and thus has provided a stronger basis for ongoing 
SAR efforts. 
Identification of a higher potency compound. Up to this point in the project, 
several parameters of 1 had been optimized, including efficacy, toxicity, stability, 
solubility and molecular weight. Achieving potency that was superior to 1, however, was 
difficult and every analog that was tested had either the same potency as 1 or slightly 
worse. A new compound that I proposed aimed to address this concern by incorporating 
more than one aminal into the structure - as this reactive functional group was found to be 
vital for activity. Many potential approaches could be used to introduce an additional N, 
N-acetal into the structure of 1; however, the compound that was designed and ultimately 
synthesized was perhaps the most straightforward. By employing piperazine rather than 
morpholine or another mono-NH heterocycle, two N, N-acetals can be formed, resulting 
in a symmetrical molecule. This product was isolated in relatively high yield but could 
not be purified using alumina to remove the excess benzimidazole, and consequently was 
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used without purification in the assay. Excitingly, this analog did in fact have increased 
potency compared to 1 (Fig. 9). At around 10 µM 1 produces essentially no response 
(less than 1,000 Lux/OD600), whereas this new analog was found to be fairly effective at 
this concentration, having a Lux/OD600 value of around 12,000. While a greater increase 
in potency can likely still be obtained, this was a significant breakthrough as it was the 
first and only compound in the library to improve upon the potency of 1. 
 
Chemistry 
 
Although initially assumed to be relatively straightforward, synthesizing the high- 
throughput hit proved to be a complicated task. Retrosynthetically, the desired molecule 
is the coupled product of two different secondary amines linked via a methylene group, 
which originates from formaldehyde. The resulting N, N-acetal (or aminal) proved to be a 
major synthetic difficulty due to its acid lability, the degree of which was not initially 
understood until attempting to make these molecules. After many unsuccessful attempts 
to synthesize the high-throughput screen hit, it was assumed that the Mannich reaction 
that forms that aminal was not occurring for these substrates. To our surprise, it was 
discovered that the aminal was indeed forming, however was being fully hydrolyzed 
during the purification, thus regenerating the two starting materials. This observation was 
the first indication that these molecules were not particularly stable, since the stationary- 
phase used during the purifications (silica) is only very slightly acidic. While no universal 
solution was found to solve this problem of stability, several techniques were identified 
and developed to make it possible to work with this highly acid-labile functionality. 
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While forming the N, N-acetal to access the final compound was rather 
problematic, the prior reactions that form the necessary amines proceeded fairly well. The 
high-throughput screen hit was retrosynthetically split into two halves, a benzimidizole 
and a piperazine portion. These are both commonly synthesized heterocycles that are 
employed throughout medicinal chemistry, and for that reason, various methods were 
effectively identified to prepare them. The required substituted benzimidazole, 2-benzyl- 
1H-benzimidazol, was synthesized from ortho-phenylenediamine and phenylacetic acid 
(Fig. 10). Several methods were explored to facilitate this condensation reaction, each 
using a different reagent to activate the carboxylic acid for nucleophilic attack. Initially 
BH3 was used, in which the borate ester was formed and ultimately gave the desired 
product in decent yield. Alternatively, borane could be avoided by using a more common 
coupling reagent, like EDC, but this method was not preferred due to the fact that the 
monoamide intermediate had to be isolated as opposed to the one-pot approach using 
borane. A third method to form the benzimidazole that was investigated involved 
polyphosphoric acid, which was also a one-pot reaction
7
. This became the main 
approach, as it typically gave high yield and purity without any purification. Its only 
downside, being a potentially troublesome workup, is what led to the continued use of the 
other methods described. Typically, forming the benzimidazole was first attempted using 
polyphosphoirc acid, and if the product was not isolated then the other methods were 
employed. Synthesizing the piperazine portion of the molecule was a bit simpler; the 
reaction between the various substituted aryl sulfonyl chlorides and excess piperazine 
proceeded very well (Fig. 11). The desired mono-sulfonamide piperazine derivatives 
were isolated in extremely high yield and purity via an aqueous workup. 
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My initial efforts to form the aminal were carried out using common Mannich 
reaction conditions (Fig. 12, A). The reactions were usually done in methanol at room 
temperature and formalin was used as the formaldehyde source (37% in water). Two 
methods were explored in regards to addition of the secondary amines, one in which both 
are added simultaneously and another where the benzimidazole is added after the 
piperazine portion reacts with formaldehyde for a short period of time. Using either 
method, the material was purified using silica-gel flash chromatography after a normal 
workup, but the product was never isolated. We originally speculated that the aminal was 
not in fact forming due to the consistent isolation of the benzimidazole starting material. 
It wasn't until after numerous failed attempts to purify the compound that a crude H
1 
NMR was assessed. Surprisingly, it appeared that the aminal was forming as the 
characteristic methylene peak around 5-6 ppm was present, but since we did not observe 
this peak after purification it was concluded that the molecule was hydrolyzing on silica. 
While I did not have a solution for this problem at the time, it was reassuring to discover 
that the reaction was truly working on these substrates. 
After experimenting with those basic Mannich conditions for a while, I began 
researching new ways of forming N, N-acetals. My initial goals were to optimize the 
reaction in regard to yield and purity, and potentially identify a highly efficient procedure 
in which product could be isolated that did not need to be purified. Using SciFinder's 
Reaction Structure search, several interesting papers were found which detailed novel 
methods of forming aminals. The first paper we focused on, a paper published in 2010 in 
Journal of Organic Chemistry, described a method to access aminals via N, O-acetals. 
The secondary amine (piperazine) is reacted with paraformaldehyde and potassium 
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carbonate in methanol to generate the corresponding N, O-acetal (Fig. 11). This 
intermediate is then reacted with a NH heterocycle (benzimidazole in this case) in the 
presence of hafnium triflate to form the N, N-acetal (Fig. 12, B). According to the paper, 
if using indole instead of benzimidazole as the NH heterocycle, then using hafnium 
triflate as a Lewis acid catalyst regioselectively produces aminals whereas TMSCl 
generates 3-aminomethylated indoles. In the case of 2-benzyl-benzimidazole, the 
hafnium triflate conditions did produce the desired product in 64% yield. This marked the 
first time we isolated the aminal product and while it was exciting to learn that these 
compounds were at least stable enough to isolate, we still desired to optimize the 
conditions to improve yield and potency. 
The next method to synthesize N, N-acetals that we explored was based off of 
another Journal of Organic Chemistry paper which was published in 2006. The authors 
described a route to form aminals between secondary amines and NH heterocycles by 
first forming a bis-aminal of the secondary amine. This is accomplished by reacting two 
molar equivalence of the amine with 1 eq. of formaldehyde (as formalin) and then 
extracting the bis-aminal in an aqueous workup (Fig. 11). Subsequent reaction of this bis- 
aminal with an NH heterocycle in the presence of succinic anhydride provides the desired 
N, N-acetal (Fig. 12, C). In my attempts using this method, forming the bis-aminal 
worked well for simple secondary amines (piperazine-based) but not for many other 
amines that were tested. However, if I was able to produce the bis-aminal then the 
following step which forms the desired aminal always worked in my experience. 
Importantly, these conditions produced higher yield and purity than the N, O-acetal 
method, and in some cases the product did not require any further purification.  The 
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limitation to only piperazine-based secondary amines, however, is what led us to further 
explore alternatives to forming these aminals. 
A fourth method to prepare relevant N, N-acetals was focused on using 
chloroaminals as intermediates and therefore accessing the desired aminals via an SN2 
reaction. An efficient procedure was identified from a Tetrohedron Letters paper in which 
a secondary amine is reacted with paraformaldehyde in TMSCl to generate the 
chloroaminal (Fig. 11). An NH heterocycle is then deprotanated via NaH before the 
chloroaminal intermiediate is introduced to the reaction, which rapidly affords the N, N- 
acetal (Fig. 12, D). This preparation did not work with every substrate that were tested, as 
some of the amines did not readily form the chloroaminal. Nevertheless, several 
secondary amines could be converted to the chloroaminal and then the corresponding N, 
N-acetal product. Notable among these amines was the oxazolidinone class of 
heterocycles, which seemed to form N, Cl- and the N, N- acetals with high efficiency. 
Taking the results of all the aminal-forming methods together, it seems to be very 
substrate dependent, wherein a given NH substrate (piperazine vs. oxazolidinone) may 
favor one of the methods over another, or may work for one method but not for another. 
Luckily, many of the compounds I set out to make were in fact possible to synthesize 
using one of the methods described here. 
Conclusion 
 
Development of small molecule inhibitors of protein-RNA interactions is a 
difficult task, even when the active compounds are stable. In this study, a series of 
structurally related N, N-acetals were synthesized and tested for their biological activity. 
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Structure-activity relationships were determined for the various groups that constitute the 
target molecule, but ultimately most structural changes caused either a complete loss of 
activity or a level of activity comparable to the high-throughput screen hit. After many 
failed attempts, several analogs finally improved upon compound 1 by increasing 
efficacy, stability, potency and/or decreasing toxicity. Several advances were also made 
in regards to the synthesis of these compounds. Working with molecules containing 
unstable aminals presented a learning curve and therefore significant time was dedicated 
to studying various methods to forming and isolating compounds containing these 
groups. Eventually, several efficient synthetic approaches to form N, N-acetals were 
identified and adapted for our substrates, which is what enabled the production of a 
diverse compound library. In regards to medicinal impact, this project supports the notion 
that Hfq is a novel target to inhibit bacterial virulence. While more work needs to be done 
regarding Hfq and specifically Hfq-Qrr complexes, the wide range of activities that were 
observed throughout this compound library provides promise for future efforts of 
"drugging" this target. The work described here provides a basis for other projects 
involving small molecule inhibitors of protein-RNA interactions as well as others in 
which the lead compound contains an N, N-acetal. This project is currently being 
prepared for publication, as our collaborators are performing the last studies to identify 
the mechanism of action. 
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Figure 1. Structure of HTS hit (1) and examples of some analogs prepared 
 
 
 
 
 
Figure 2. Dose response curve for 1 
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Figure 3. Analogs developed using stable linkers 
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Figure 4. Dose response curve for 2 
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Figure 5. OD600 plot for 1 and 2 
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Figure 6. Biological activity of three truncated analogs 
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Figure 7. Dose response curve for high-efficacy oxazolidinone analog 
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Figure 8. OD600 plot of oxazolidinone analog 
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Figure 9. Dose-response curve for 4 
 
 
 
 
 
 
 
 
Figure 10. Methods employed for the synthesis of 2-substituted benzimidazoles 
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Figure 11. Synthesis of acetal intermediates 
 
 
 
 
Figure 12. Various methods utilized to form N, N-acetals 
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Experimental Section 
 
Bacterial reporter strain assay. Our collaborator Prof. Ng developed the 
biological assay for this project. A reporter strain was first produced using V. cholera in 
which the expression of a luminescent protein is controlled by Hfq-sRNA. For practical 
purposes, an increase in luminescence (or Lux/OD600) corresponds to an increase in 
inhibition of the Hfq-Qrr complex, whereas compounds that do not effect this protein- 
RNA interaction do not generate luminescence. To prepare for the assay, an overnight 
culture of the V. cholera reporter strain was incubated at 30 °C in LB media containing 
100 µg/mL of Kanamycin and 5 µg/mL of Tetracyclin. Following a 1:50 dilution of this 
culture into the same LB media, 175 µL was placed into each well of a clear bottom 96- 
well plate. Next, 10.5 µL of a 10 mM solution of each compound in DMSO was added in 
triplicate to the wells in the first column. A 2.4 fold dilution was then performed by 
transferring 125 µL from the first column to the next, and repeating this down the entire 
plate. Plates were incubated at 30 °C and luminescence (Lux) and OD600 were read at 4, 5 
and 6 hours. Dose response curves were generated using Prism software, and were 
plotted as Lux/OD600 vs. log[conc.]. 
General chemistry. All reagents and solvents were obtained from commercial 
sources and used without further purification or drying. Reactions were performed under 
a nitrogen gas atmosphere in flame-dried glassware. Unless otherwise noted, compounds 
were not purified. 
1
H and 
13
C NMR data was taken on a Varian AS400 (400 MHz), with 
chemical shifts being displayed in a ppm scale referenced to residual chloroform. 
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2-benzyl-1H-benzo[d]imidazole. Orthophenyllene diamine (1 g, 9.25 mmol) and 
phenyl acetic acid (1.25 g, 9.25 mmol) was added to poly phosphoric acid (4.4 mL, 1 
g/mmol) and the mixture was heated to 180 °C for 12 h. NaOH (1 M, 15 mL x 3) was 
added, after the flask was saturated with sand (while hot). Combined NaOH portions 
were neutralized with 1 M HCl, and the resulting aqueous solution was extracted with 
EtOAc (3 x 50 mL). Combined organic layers were washed with brine and dried with 
Na2SO4 to afford 1.77 g, 92% yield. NMR spectra are consistent with previously 
published data. 
2-phenyl-1H-benzo[d]imidazole. Prepared using the procedure described for 2- 
benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid. NMR spectra are 
consistent with previously published data. 
2-(cyclohexylmethyl)-1H-benzo[d]imidazole. Prepared using the procedure 
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid. 
NMR spectra are consistent with previously published data. 
2-(2-methoxybenzyl)-1H-benzo[d]imidazole. Prepared using the procedure 
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid. 
NMR spectra are consistent with previously published data. 
2-(pyridin-3-ylmethyl)-1H-benzo[d]imidazole. Prepared using the procedure 
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid. 
NMR spectra are consistent with previously published data. 
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2-(4-bromobenzyl)-1H-benzo[d]imidazole. Prepared using the procedure 
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid. 
NMR spectra are consistent with previously published data. 
2-((2,4-dichlorophenoxy)methyl)-1H-benzo[d]imidazole. Prepared using the 
procedure described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding 
carboxylic acid. 
1
H NMR (400 MHz, CDCl3) δ 9.94 (s, 1H), 7.75 (s, 1H), 7.50 (s, 1H), 
7.39 (dd, J = 2.5, 0.5 Hz, 1H), 7.32 – 7.27 (m, 2H), 7.18 (dd, 1H), 7.01 – 6.96 (m, 1H), 
5.43 (s, 2H). 
13
C NMR (101 MHz, CDCl3) δ 152.14, 149.16, 130.37, 128.15, 127.49, 
123.94, 114.94, 65.83. 
 
 
2-(benzylthio)-5-methoxy-1H-benzo[d]imidazole. Prepared using the procedure 
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding carboxylic acid. 
NMR spectra are consistent with previously published data. 
2-benzyl-4-nitro-1H-benzo[d]imidazole. Prepared using the procedure described 
for 2-benzyl-1H-benzo[d]imidazole, using the corresponding diamine. NMR spectra are 
consistent with previously published data. 
2-benzyl-1H-imidazo[4,5-c]pyridine. Prepared using the procedure described for 
2-benzyl-1H-benzo[d]imidazole, using the corresponding diamine. NMR spectra are 
consistent with previously published data. 
8-benzyl-9H-purine. Prepared using the procedure described for 2-benzyl-1H- 
benzo[d]imidazole, using the corresponding diamine. NMR spectra are consistent with 
previously published data. 
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2-benzyl-5,6-dichloro-1H-benzo[d]imidazole. Prepared using the procedure 
described for 2-benzyl-1H-benzo[d]imidazole, using the corresponding diamine. 
1
H 
NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 7.50 (s, 2H), 7.28 – 7.20 (m, 3H), 7.19 – 7.12 
(m, 2H), 4.16 (s, 2H). 
13
C NMR (101 MHz, CDCl3) δ 155.96, 137.67, 135.59, 129.20, 
129.00, 127.66, 126.63, 116.11, 35.67. 
 
2-(piperazin-1-ylsulfonyl)benzonitrile. 2-cyanobenzene sulfonyl chloride (0.5 g, 
 
2.48 mmol) was added to piperazine (1.07 g, 12.4 mmol) in DCM (24 mL, 0.1 M) at 0 
 
°C. Reaction stirred for 30 min at 0 °C and was quenched with sat. NaHCO3 (25 mL). 
The mixture was diluted with DCM (25 mL) and separated, and the organic layer was 
washed with brine (25 mL) and then dried with Na2SO4. The product was used without 
purification, 0.59 g, 96% yield. 
 
1-((2-nitrophenyl)sulfonyl)piperazine. Prepared using the procedure described 
for 2-(piperazin-1-ylsulfonyl)benzonitrile, using the corresponding sulfonyl chloride. 
NMR spectra are consistent with previously published data. 
 
1- tosylpiperazine. Prepared using the procedure described for 2-(piperazin-1- 
ylsulfonyl)benzonitrile, using the corresponding sulfonyl chloride. NMR spectra are 
consistent with previously published data. 
1-((2,4,6-trichlorophenyl)sulfonyl)piperazine. Prepared using the procedure 
described for 2-(piperazin-1-ylsulfonyl)benzonitrile, using the corresponding sulfonyl 
chloride. NMR spectra are consistent with previously published data. 
2-((4-(methoxymethyl)piperazin-1-yl)sulfonyl)benzonitrile. Paraformaldehyde 
(2.12 g, 8.82 mmol) was added to a mixture of 2-(piperazin-1-ylsulfonyl)benzonitrile 
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(1.11 g, 4.41 mmol), K2CO3 (1.22 g, 8.82 mmol) and Na2SO4 (1.25 g, 8.82 mmol) in 
methanol (14.7 mL, 0.3 M). The mixture stirred at room temperature overnight, and then 
was filtered and washed with ether. Removal of solvent in vacuo yielded 1.16 g of the N, 
O-acetal, 89% yield. This intermediate was used crude in the next step. 
 
1-(methoxymethyl)-4-((2-nitrophenyl)sulfonyl)piperazine. Prepared using the 
procedure described for 2-((4-(methoxymethyl)piperazin-1-yl)sulfonyl)benzonitrile, 
using the corresponding piperazine derivative. 
1-(methoxymethyl)-4-tosylpiperazine. Prepared using the procedure described 
for 2-((4-(methoxymethyl)piperazin-1-yl)sulfonyl)benzonitrile, using the corresponding 
piperazine derivative. 
1-(methoxymethyl)-4-((2,4,6-trichlorophenyl)sulfonyl)piperazine. Prepared 
using the procedure described for 2-((4-(methoxymethyl)piperazin-1- 
yl)sulfonyl)benzonitrile, using the corresponding piperazine derivative. 
Dimorpholinomethane. Morpholine (2.0 g, 22.96 mmol) was added to formalin 
(0.86 mL, 11.48 mmol) at 0 °C and the mixture stirred at room temperature overnight. 
Water (25 mL) was added to the mixture, which was then extracted with EtOAc (25 mL x 
3). The combined organic layers were washed with brine and then dried with Na2SO4. 
Crude bis- N, N-acetal was used without purification, 1.94 g, 91% yield. 
1
H NMR (400 
MHz, CDCl3) δ 3.62 (t, 9H), 2.84 (s, 2H), 2.47 – 2.36 (m, 8H). 
13
C NMR (101 MHz, 
CDCl3) δ 81.67, 67.02, 52.02. 
Di(piperidin-1-yl)methane. Prepared using the procedure described for 
dimorpholinomethane, using the corresponding secondary amine. 
1
H NMR (400 MHz, 
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CDCl3) δ 2.78 (s, 2H), 2.40 – 2.30 (m, 8H), 1.54 – 1.44 (m, 8H), 1.42 – 1.33 (m, 4H). 
13
C 
NMR (101 MHz, CDCl3) δ 82.86, 53.14, 26.03, 25.03. 
 
Bis(4-methylpiperazin-1-yl)methane. Prepared using the procedure described 
for dimorpholinomethane, using the corresponding secondary amine. 
Bis(2,6-dimethylmorpholino)methane. Prepared using the procedure described 
for dimorpholinomethane, using the corresponding secondary amine. 
3-(chloromethyl)oxazolidin-2-one. Paraformaldehyde (86 mg, 2.87 mmol) was 
added to a mixture of 2-oxazolidinone (250 mg, 2.87 mmol) in TMSCl (1.45 mL, 2.0 M). 
The resulting mixture stirred at room temperature for 2 h. Removal of TMSCl in vacuo 
afforded the chloro-acetal, which was used crude (quant. yield). 
1
H NMR (400 MHz, 
CDCl3) δ 5.19 (s, 2H), 4.35 – 4.29 (m, 2H), 3.71 – 3.64 (m, 2H). 
13
C NMR (101 MHz, 
CDCl3) δ 156.94, 62.16, 56.20, 42.50. 
 
(R)-3-(chloromethyl)-4-isopropyloxazolidin-2-one. Prepared using the 
procedure described for 3-(chloromethyl)oxazolidin-2-one, using the corresponding 
oxazolidinone derivative. 
(S)-3-(chloromethyl)-4-isopropyloxazolidin-2-one. Prepared using the 
procedure described for 3-(chloromethyl)oxazolidin-2-one, using the corresponding 
oxazolidinone derivative. 
(S)-3-(chloromethyl)-4-phenyloxazolidin-2-one. Prepared using the procedure 
described for 3-(chloromethyl)oxazolidin-2-one, using the corresponding oxazolidinone 
derivative. 
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(R)-4-benzyl-3-(chloromethyl)oxazolidin-2-one. Prepared using the procedure 
described for 3-(chloromethyl)oxazolidin-2-one, using the corresponding oxazolidinone 
derivative. 
2- bromo-1-(4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethan-1-one. To 1-((2- 
nitrophenyl)sulfonyl)piperazine (0.150 g, 0.553 mmol) in DCM (2.6 mL, 0.2 M) was 
added DIPEA (0.1 mL, 0.553 mmol). The mixture was cooled to 0 °C and bromoacetyl 
chloride (0.05 mL, 0.608 mmol) was added dropwise, and then the mixture reacted 
overnight at room temperature. After quenching with HCl (5 mL, 0.1 M), more water was 
added and the product was extracted with EtOAc (25 mL x 3). The combined organic 
layers were washed with brine and then dried with Na2SO4. Silica-gel column 
chromatography (product elutes at 65% EtOAc) yielded 181 mg of the desired 
compound, 83% yield. 
1
H NMR (400 MHz, CDCl3) δ 7.97 (dd, 1H), 7.77 – 7.68 (m, 2H), 
7.64 (dd, J = 7.3, 1.8, 0.8 Hz, 1H), 4.05 (s, 1H), 3.84 (s, 1H), 3.70 (t, J = 5.2 Hz, 2H), 
3.61 (t, J = 5.9, 3.5 Hz, 2H), 3.40 (t, J = 5.8 Hz, 2H), 3.30 (t, 2H). 
13
C NMR (101 MHz, 
 
CDCl3) δ 165.50, 148.35, 134.31, 131.94, 131.05, 131.00, 124.42, 46.58, 45.93, 45.74, 
 
45.57, 25.49. 
 
2-((4-(2-bromoacetyl)piperazin-1-yl)sulfonyl)benzonitrile. Prepared using the 
procedure described for 2-bromo-1-(4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethan-1- 
one, using the corresponding piperazine derivative. 
4-((2-cyanophenyl)sulfonyl)piperazine-1-sulfonyl chloride. Chlorosulfonic acid 
(0.400 mL, 5.88 mmol) was added dropwise to 2-(piperazin-1-ylsulfonyl)benzonitrile 
(0.492 g, 1.96 mmol) in chloroform at 0 °C. The reaction was allowed to warm to room 
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temperature as it stirred for 30 min. Sat. NaHCO3 was added and the mixture was 
extracted with EtOAc (25 mL x 3), and then the combined organic layers were washed 
with brine and dried with Na2SO4. This intermediate (0.152 g, 0.459 mmol) was 
dissolved in benzene (9.2 mL, 0.05 M) and PCl5 (0.096 g, 0.459 mmol) was added. The 
resulting mixture was refluxed for 24 h, filtered and concentrated to dryness, and the 
sulfonyl chloride was used crude without purification. 
 
4-((2-cyanophenyl)sulfonyl)piperazine-1-carbonyl chloride. Triphosgene 
(0.082 g, 0.277 mmol) was dissolved in DCM (4.1 mL) and pyridine (0.045 mL, 0.553 
mmol) was added at 0 °C. 2-(piperazin-1-ylsulfonyl)benzonitrile (0.150 g, 0.553 mmol) 
in DCM (4.1 mL) was slowly added and the mixture stirred at room temperature 
overnight. After quenching with HCl (5 mL, 1 M) the product was extracted with DCM, 
washed with brine and dried with Na2SO4. The product was used crude without 
purification. 
2-((4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1- 
yl)sulfonyl)benzonitrile. To 2-benzyl-1H-benzo[d]imidazole (43 mg, 0.207 mmol) and 
2-((4-(methoxymethyl)piperazin-1-yl)sulfonyl)benzonitrile (61 mg, 0.207 mmol) in DCM 
(1.4 mL, 0.15 M) was added Hf(OTf)4 (8 mg, 0.0104 mmol). The reaction was allowed to 
stir at room temperature for 2 h and then was quenched with sat. NaHCO3. The mixture 
was diluted with more DCM, and the organic layer was separated and then dried with 
Na2SO4. The product was obtained as a mixture of the desired aminal and starting 
materials, and could not be purified. 
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2-benzyl-1-((4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)methyl)-1H- 
benzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1H- 
benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the 
corresponding benzimidazole and N,O-acetal. 
2-benzyl-1-((4-tosylpiperazin-1-yl)methyl)-1H-benzo[d]imidazole. Prepared 
using the procedure described for 2-((4-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the corresponding benzimidazole 
and N,O-acetal. 
1
H NMR (400 MHz, CDCl3) δ 7.85 (dd, J = 6.3, 1.9, 1.0 Hz, 1H), 7.73 – 
7.63 (m, 2H), 7.49 – 7.17 (m, 10H), 4.58 (s, 2H), 4.40 (s, 2H), 2.97 (t, 4H), 2.55 (t, 4H), 
 
2.55 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 153.69, 143.97, 142.44, 136.43, 136.01, 
132.60, 129.88, 128.79, 128.54, 127.91, 127.03, 122.84, 122.38, 119.77, 109.70, 64.89, 
 
49.73, 45.70, 34.79, 21.71. 
 
2-benzyl-1-((4-((2,4,6-trichlorophenyl)sulfonyl)piperazin-1-yl)methyl)-1H- 
benzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1H- 
benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the 
corresponding benzimidazole and N,O-acetal. 
2-((4-((2-(2-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1- 
yl)sulfonyl)benzonitrile. Prepared using the procedure described for 2-((4-((2-benzyl- 
1H-benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the 
corresponding benzimidazole and N,O-acetal. 
2-(2-methoxybenzyl)-1-((4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)methyl)- 
1H-benzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1H- 
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benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the 
corresponding benzimidazole and N,O-acetal. 
2-(2-methoxybenzyl)-1-((4-tosylpiperazin-1-yl)methyl)-1H- 
benzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1H- 
benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the 
corresponding benzimidazole and N,O-acetal. 
2-(benzylthio)-5-methoxy-1-((4-tosylpiperazin-1-yl)methyl)-1H- 
benzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1H- 
benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the 
corresponding benzimidazole and N,O-acetal. 
2-((4-((2-(benzylthio)-5-methoxy-1H-benzo[d]imidazol-1-yl)methyl)piperazin- 
1-yl)sulfonyl)benzonitrile. Prepared using the procedure described for 2-((4-((2-benzyl- 
1H-benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the 
corresponding benzimidazole and N,O-acetal. 
2-(benzylthio)-5-methoxy-1-((4-((2-nitrophenyl)sulfonyl)piperazin-1- 
yl)methyl)-1H-benzo[d]imidazole. Prepared using the procedure described for 2-((4-((2- 
benzyl-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the 
corresponding benzimidazole and N,O-acetal. 
2-((4-((2-phenyl-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1- 
yl)sulfonyl)benzonitrile. Prepared using the procedure described for 2-((4-((2-benzyl- 
1H-benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the 
corresponding benzimidazole and N,O-acetal. 
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2-((4-((2-((2,4-dichlorophenoxy)methyl)-1H-benzo[d]imidazol-1- 
yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile. Prepared using the procedure described 
for 2-((4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1- 
yl)sulfonyl)benzonitrile, using the corresponding benzimidazole and N,O-acetal. 
2-((2,4-dichlorophenoxy)methyl)-1-((4-tosylpiperazin-1-yl)methyl)-1H- 
benzo[d]imidazole. Prepared using the procedure described for 2-((4-((2-benzyl-1H- 
benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile, using the 
corresponding benzimidazole and N,O-acetal. 
4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine. 2-benzyl-1H- 
benzo[d]imidazole (42 mg, 0.205 mmol), dimorpholinomethane (42 mg, 0.226 mmol) 
and K2CO3 (31 mg, 0.226 mmol) were suspended in DCM (1.25 mL, 0.167 M). Succinic 
anhydride (23 mg, 0.226 mmol) was added and the reaction stirred at room temperature 
for 1 h. The reaction was diluted with more DCM (25-50 mL) and washed with 1 M 
NaOH (25 mL x 2), followed by brine (10 mL). The organic layer was dried over Na2SO4 
and concentrated to dryness, affording the desired product, which was not purified. 
1
H 
 
NMR (400 MHz, CDCl3) δ 7.79 – 7.72 (m, 1H), 7.42 – 7.34 (m, 1H), 7.32 – 7.16 (m, 
 
7H), 4.46 (s, 2H), 4.40 (s, 2H), 3.59 (t, 4H), 2.37 (t, 4H). 
13
C NMR (101 MHz, CDCl3) δ 
153.78, 142.31, 136.36, 136.05, 128.73, 128.53, 126.93, 122.57, 122.10, 119.50, 109.74, 
 
66.47, 65.44, 50.81, 34.71. 
 
2-benzyl-1-(piperidin-1-ylmethyl)-1H-benzo[d]imidazole. Prepared using the 
procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine, 
using the corresponding bis- N, N-acetal. 
1
H NMR (400 MHz, CDCl3) δ 7.81 – 7.72 (m, 
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1H), 7.43 – 7.34 (m, 1H), 7.31 – 7.15 (m, 7H), 4.43 (s, 4H), 2.36 (t, J = 5.2 Hz, 4H), 1.56 
 
– 1.45 (m, 4H), 1.46 – 1.37 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 154.08, 142.37, 
136.59, 136.32, 128.68, 128.66, 126.82, 122.35, 121.86, 119.39, 109.90, 66.01, 51.85, 
 
34.75, 25.58, 24.21. 
 
2-benzyl-1-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazole. Prepared 
using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)morpholine, using the corresponding bis- N, N-acetal. 
1
H NMR (400 MHz, 
CDCl3) δ 7.81 – 7.71 (m, 1H), 7.43 – 7.34 (m, 1H), 7.35 – 7.17 (m, 7H), 4.47 (s, 2H), 
4.41 (s, 2H), 2.49 – 2.31 (m, 8H), 2.26 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 153.68, 
142.02, 136.19, 135.84, 128.52, 128.41, 126.70, 122.34, 121.85, 119.15, 109.69, 65.00, 
 
54.33, 50.15, 45.71, 34.43. 
 
4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-2,6-dimethylmorpholine. 
 
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)morpholine, using the corresponding bis- N, N-acetal. 
1
H NMR (400 MHz, 
CDCl3) δ 7.70 – 7.63 (m, 1H), 7.34 – 7.26 (m, 1H), 7.22 – 7.02 (m, 7H), 4.36 (s, 2H), 
4.29 (s, 2H), 3.50 – 3.36 (m, 2H), 2.46 – 2.35 (m, 2H), 1.65 (t, 2H), 0.98 (d, 6H). 13C 
 
NMR (101 MHz, CDCl3) δ 153.73, 142.25, 136.35, 135.97, 128.73, 128.57, 126.96, 
 
122.61, 122.15, 119.37, 110.05, 71.37, 65.25, 56.44, 34.63, 18.97. 
 
4-((2-(cyclohexylmethyl)-1H-benzo[d]imidazol-1-yl)methyl)morpholine. 
 
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal.
1
H 
NMR (400 MHz, CDCl3) δ 7.73 – 7.68 (m, 1H), 7.42 – 7.37 (m, 1H), 7.24 – 7.19 (m, 
2H), 4.66 (s, 2H), 3.65 (t, 4H), 2.80 (d, J = 7.1 Hz, 2H), 2.51 (t, J = 5.7, 3.7 Hz, 4H), 2.05 
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– 1.94 (m, 1H), 1.83 – 1.60 (m, 4H), 1.30 – 0.99 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 
155.25, 142.60, 135.74, 122.19, 122.05, 119.26, 109.85, 66.69, 65.49, 51.08, 37.54, 
 
35.39, 33.56, 26.39, 26.24. 
 
4-((2-(2-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)methyl)morpholine. 
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal. 
4-((2-(pyridin-3-ylmethyl)-1H-benzo[d]imidazol-1-yl)methyl)morpholine. 
 
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal. 
4-((2-(4-bromobenzyl)-1H-benzo[d]imidazol-1-yl)methyl)morpholine. 
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal. 
4-((2-benzyl-4-nitro-1H-benzo[d]imidazol-1-yl)methyl)morpholine. Prepared 
using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal. 
4-((2-benzyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl)morpholine. Prepared 
using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal. 
4-((8-benzyl-9H-purin-9-yl)methyl)morpholine. Prepared using the procedure 
described for 4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine, using the 
corresponding benzimidazole and bis- N, N-acetal. 
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4-((2-benzyl-5,6-dichloro-1H-benzo[d]imidazol-1-yl)methyl)morpholine. 
 
Prepared using the procedure described for 4-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)morpholine, using the corresponding benzimidazole and bis- N, N-acetal. 
3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2-one. 2-benzyl-1H- 
benzo[d]imidazole (58 mg, 0.279 mmol) was dissolved in DMF (1.4 mL, 0.2 M) and 
NaH was added in two portions (7 mg, 0.294 mmol). The mixture was allowed to stir at 
room temperature for 30-45 min. 3-(chloromethyl)oxazolidin-2-one (40 mg, 0.294 mmol) 
was added dropwise (in DMF) and the reaction stirred at room temperature for 2 h. Water 
(50 mL) was added and the product was extracted with EtOAc (25 mL x3), and then the 
combined organic layers were washed with brine (50 mL x 3). After drying on Na2SO4 
the product was purified using alumina column chromatography. 
1
H NMR (400 MHz, 
CDCl3) δ 7.83 – 7.76 (m, 1H), 7.49 – 7.43 (m, 1H), 7.37 – 7.21 (m, 7H), 5.53 (s, 2H), 
4.41 (s, 2H), 4.07 (t, 2H), 3.01 (t, 2H). 
13
C NMR (101 MHz, CDCl3) δ 157.65, 153.15, 
142.66, 136.21, 134.95, 129.07, 128.70, 127.40, 123.49, 122.98, 119.94, 109.67, 61.95, 
 
52.57, 42.73, 34.28. 
 
3-((2-(pyridin-3-ylmethyl)-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2- 
one. Prepared using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)oxazolidin-2-one, using the corresponding benzimidazole. 
3-((2-benzyl-3H-imidazo[4,5-c]pyridin-3-yl)methyl)oxazolidin-2-one. Prepared 
using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)oxazolidin-2-one, using the corresponding benzimidazole. 
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3-((8-benzyl-7H-purin-7-yl)methyl)oxazolidin-2-one. Prepared using the 
procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2- 
one, using the corresponding benzimidazole. 
(R)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-isopropyloxazolidin-2- 
one. Prepared using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)oxazolidin-2-one, using the corresponding oxazolidinone derivative. 
1
H NMR 
(400 MHz, CDCl3) δ 7.79 – 7.73 (m, 1H), 7.43 – 7.37 (m, 1H), 7.30 – 7.17 (m, 7H), 5.81, 
5.20 (ABq, JAB= 14.9 Hz, 2H), 4.46, 4.31 (ABq, JAB= 15.9 Hz, 2H), 3.96 (dd, J = 9.1, 3.8 
 
Hz, 1H), 3.77 (t, J = 9.0 Hz, 1H), 3.35 – 3.28 (m, 1H), 1.98 - 1.86 (m, 1H), 0.73 (dd, J = 
 
19.8, 6.9 Hz, 6H). 
13
C NMR (101 MHz, CDCl3) δ 157.73, 153.05, 142.66, 136.05, 
135.05, 128.97, 128.33, 127.19, 123.38, 122.82, 119.93, 109.38, 62.69, 57.69, 50.50, 
 
33.91, 27.56, 17.77, 13.72. 
 
(S)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-isopropyloxazolidin-2- 
one. Prepared using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)oxazolidin-2-one, using the corresponding oxazolidinone derivative. 
1
H NMR 
(400 MHz, CDCl3) δ 7.79 – 7.72 (m, 1H), 7.42 – 7.36 (m, 1H), 7.32 - 7.15 (m, 7H), 5.81, 
5.20 (ABq, JAB= 14.9 Hz, 2H), 4.46, 4.29 (ABq, J = 15.8 Hz, 2H), 3.97 (dd, J = 9.1, 3.7 
 
Hz, 1H), 3.77 (t, J = 9.0 Hz, 1H), 3.35 - 3.27 (m, 1H), 1.96 – 1.87 (m, 1H), 0.73 (dd, J = 
 
20.8, 6.8 Hz, 6H). 
13
C NMR (101 MHz, CDCl3) δ 157.78, 153.11, 142.72, 136.10, 
135.11, 129.03, 128.38, 127.25, 123.45, 122.90, 120.01, 109.41, 62.74, 57.73, 50.54, 
 
33.99, 27.63, 17.83, 13.78. 
 
(S)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-phenyloxazolidin-2-one. 
 
Prepared using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1- 
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yl)methyl)oxazolidin-2-one, using the corresponding oxazolidinone derivative. 
1
H NMR 
(400 MHz, CDCl3) δ 7.77 – 7.72 (m, 1H), 7.52 – 7.46 (m, 2H), 7.33 – 7.27 (m, 2H), 7.24- 
7.15 (m, 7H), 6.97 – 6.91 (m, 2H), 5.79, 4.97 (ABq, JAB= 14.8 Hz, 2H), 4.43 – 4.31 (m, 
 
2H), 4.24, 3.61 (ABq, JAB= 15.9 Hz, 2H), 4.01 (dd, J = 7.4, 5.1 Hz, 1H).  
13
C NMR (101 
MHz, CDCl3) δ 157.82, 153.43, 142.73, 136.97, 136.12, 130.08, 130.05, 129.27, 129.24, 
 
129.03, 128.35, 127.25, 127.06, 123.44, 123.05, 119.88, 110.16, 70.42, 58.07, 50.63, 
 
33.91. 
 
(R)-4-benzyl-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2-one. 
 
Prepared using the procedure described for 3-((2-benzyl-1H-benzo[d]imidazol-1- 
yl)methyl)oxazolidin-2-one, using the corresponding oxazolidinone derivative. 
1
H NMR 
(400 MHz, CDCl3) δ 7.86 – 7.78 (m, 1H), 7.46 – 7.39 (m, 1H), 7.36 – 7.19 (m, 10H), 
6.98 – 6.91 (m, 2H), 5.83, 5.41 (ABq, JAB= 15.0 Hz, 2H), 4.49, 4.31 (ABq, JAB = 15.8 
 
Hz, 2H), 3.89 (dd, J = 8.9, 3.6 Hz, 1H), 3.70 (t, J = 8.5 Hz, 1H), 3.65 – 3.56 (m, 1H), 
 
2.97 (dd, J = 13.6, 4.2 Hz, 1H), 2.50 (dd, J = 13.6, 9.4 Hz, 1H). 
13
C NMR (101 MHz, 
 
CDCl3) δ 157.60, 153.50, 142.93, 136.27, 135.32, 134.82, 129.37, 129.34, 129.19, 
 
128.66, 127.79, 127.43, 127.19, 123.63, 123.20, 120.32, 109.50, 67.01, 54.94, 51.13, 
 
38.35, 34.06. 
 
2-((4-(2-benzyl-1H-benzo[d]imidazole-1-carbonyl)piperazin-1- 
yl)sulfonyl)benzonitrile. To 2-benzyl-1H-benzo[d]imidazole (173 mg, 0.832 mmol) in 
DCM (2.8 mL, 0.3 M) was added 4-((2-cyanophenyl)sulfonyl)piperazine-1-carbonyl 
chloride (261 mg, 0.832 mmol) and DIPEA (0.3 mL, 1.664 mmol). The mixture was 
heated in a sealed flask overnight at 40 °C and then cooled to room temperature, diluted 
with more DCM and washed with sat. NaHCO3. The organic layer was dried on Na2SO4, 
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concentrated and purified via silica-gel column chromatography. 
1
H NMR (400 MHz, 
CDCl3) δ 8.00 (dd, 1H), 7.88 (dd, 1H), 7.80 – 7.68 (m, 3H), 7.32 – 7.08 (m, 8H), 3.72 (s, 
2H), 3.72 (t, J = 5.0 Hz, 2H), 3.55 (t, J = 5.1 Hz, 2H), 3.15 (t, J = 5.1 Hz, 2H), 3.06 (t, J = 
 
5.0 Hz, 2H). 
13
C NMR (101 MHz, CDCl3) δ 169.71, 139.85, 135.79, 134.48, 133.17, 
130.56, 129.03, 128.81, 128.59, 127.59, 127.21, 126.91, 116.15, 111.03, 109.56, 49.88, 
 
45.79, 45.74, 45.61, 41.17. 
 
2-((4-((2-benzyl-1H-benzo[d]imidazol-1-yl)sulfonyl)piperazin-1- 
yl)sulfonyl)benzonitrile. To 2-benzyl-1H-benzo[d]imidazole (152 mg, 0.730 mmol) in 
DMF (3.0 mL, 0.25 M) was added NaH (21 mg, 0.876 mmol). The reaction stirred at 
room temperature for 30 min and then 4-((2-cyanophenyl)sulfonyl)piperazine-1-sulfonyl 
chloride (255 mg, 0.730 mmol) was added dropwise (in DMF), after which the reaction 
was allowed to stir overnight. Water (50 mL) was added and the product was extracted 
with EtOAc (25 mL x3), and then the combined organic layers were washed with brine 
(50 mL x 3). After drying on Na2SO4 the product was purified using silica-gel column 
chromatography. 
2-((4-(2-(2-benzyl-1H-benzo[d]imidazol-1-yl)acetyl)piperazin-1- 
yl)sulfonyl)benzonitrile. To 2-((4-(2-bromoacetyl)piperazin-1-yl)sulfonyl)benzonitrile 
(83 mg, 0.223 mmol) in acetone (2.5 mL, 0.09 M) was added 2-benzyl-1H- 
benzo[d]imidazole (47 mg, 0.223 mmol) and KOH (25 mg, 0.446 mmol). The reaction 
stirred at 60 °C for 2 h. Solvent was removed in vacuo, and the residue was diluted in 
water and extracted with chloroform (25 mL x 3). The combined organic layers were 
dried on Na2SO4 and concentrated to dryness. Silica-gel column chromatography yielded 
the desired product, 42% yield. 
1
H NMR (400 MHz, CDCl3) δ 8.04 (dd, J = 7.7, 1.4 Hz, 
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1H), 7.92 (dd, 1H), 7.83 – 7.69 (m, 3H), 7.25 – 7.05 (m, 8H), 4.60 (s, 2H), 4.26 (s, 2H), 
 
3.54 (t, 2H), 3.31 (t, 2H), 3.20 (t, 2H), 3.08 (t, 2H). 
13
C NMR (101 MHz, CDCl3) δ 
164.20, 153.10, 142.50, 139.91, 135.93, 135.85, 133.40, 133.32, 130.66, 128.99, 128.70, 
 
127.22, 122.83, 122.34, 119.83, 116.21, 110.90, 108.98, 45.58, 45.39, 44.89, 44.39, 
 
41.55, 34.95. 
 
2-(2-benzyl-1H-benzo[d]imidazol-1-yl)-1-(4-((2- 
nitrophenyl)sulfonyl)piperazin-1-yl)ethanone. Prepared using the procedure described 
for 2-((4-(2-(2-benzyl-1H-benzo[d]imidazol-1-yl)acetyl)piperazin-1- 
yl)sulfonyl)benzonitrile, using the corresponding alkyl bromide derivative. 
1
H NMR (400 
MHz, CDCl3) δ 7.91 (dd, 1H), 7.74 – 7.65 (m, 3H), 7.61 (dd, J = 7.1, 2.1 Hz, 1H), 7.21 – 
7.03 (m, 8H), 4.55 (s, 2H), 4.21 (s, 2H), 3.47 (t, J = 4.8 Hz, 2H), 3.20 (t, J = 4.8 Hz, 2H), 
 
3.15 – 3.08 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 164.11, 153.19, 148.25, 142.39, 
135.85, 134.38, 131.93, 131.03, 128.84, 128.67, 128.64, 127.07, 124.28, 122.67, 122.17, 
 
119.58, 109.09, 45.52, 45.42, 44.65, 44.36, 41.56, 34.73. 
 
1,4-bis(methoxymethyl)piperazine. Paraformaldehyde (697 mg, 23.22 mmol 
mmol) was added to a mixture piperazine (500 mg, 5.81 mmol), K2CO3 (3.21 g, 23.22 
mmol) and Na2SO4 (3.30 g, 23.22 mmol) in methanol (20 mL, 0.3 M). The mixture 
stirred at room temperature overnight, and then was filtered and washed with ether. 
Removal of solvent in vacuo yielded 613 mg of the bis- N, O-acetal, 71% yield. This 
intermediate was used crude in the next step. 
1,4-bis((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)piperazine. To 2-benzyl- 
1H-benzo[d]imidazole (196 mg, 0.941 mmol) and 1,4-bis(methoxymethyl)piperazine (82 
mg, 0.471 mmol) in DCM (3.2 mL, 0.15 M) was added Hf(OTf)4 (36 mg, 0.0471 mmol). 
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The reaction was allowed to stir at room temperature for 2 h and then was quenched with 
sat. NaHCO3. The mixture was diluted with more DCM, and the organic layer was 
separated and then dried with Na2SO4. The product was obtained as a mixture of the 
desired aminal and starting materials, and could not be purified. 
4-((5-benzyl-1H-tetrazol-1-yl)methyl)morpholine. To 5-benzyl-1H-tetrazole 
(94 mg, 0.587 mmol) in methanol (3 mL, 0.2 M) at 0 °C was added morpholine (0.056 
mL, 0.645 mmol). The mixture stirred at 0 °C for 15 min and then formalin (0.053 mL, 
0.704 mmol) was added. Reaction was kept at 0 °C for 1 h and then was allowed to warm 
to room temperature overnight. The product was obtained after removal of solvent in 
vacuo, and was not purified. 
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(R)-4-benzyl-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2-one 
 
40  
(S)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-phenyloxazolidin-2-one 
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(R)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-isopropyloxazolidin-2-one 
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(S)-3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-4-isopropyloxazolidin-2-one 
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3-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)oxazolidin-2-one 
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4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine 
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2-benzyl-1-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazole 
 
 
 
 
46  
2-benzyl-1-(piperidin-1-ylmethyl)-1H-benzo[d]imidazole 
 
 
 
 
47  
4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)-2,6-dimethylmorpholine 
 
 
48  
4-((2-(cyclohexylmethyl)-1H-benzo[d]imidazol-1-yl)methyl)morpholine 
 
 
 
 
49  
2-((4-(2-benzyl-1H-benzo[d]imidazole-1-carbonyl)piperazin-1-yl)sulfonyl)benzonitrile 
 
 
50  
2-((4-(2-(2-benzyl-1H-benzo[d]imidazol-1-yl)acetyl)piperazin-1-yl)sulfonyl)benzonitrile 
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2-(2-benzyl-1H-benzo[d]imidazol-1-yl)-1-(4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethanone 
 
 
 
52  
2-benzyl-1-((4-tosylpiperazin-1-yl)methyl)-1H-benzo[d]imidazole 
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2-((4-((2-benzyl-1H-benzo[d]imidazol-1-yl)methyl)piperazin-1-yl)sulfonyl)benzonitrile 
 
2-benzyl-1-((4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazole 
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2-benzyl-5,6-dichloro-1H-benzo[d]imidazole 
 
 
 
55  
2-((2,4-dichlorophenoxy)methyl)-1H-benzo[d]imidazole 
 
 
56  
Dimorpholinomethane 
 
57  
Di(piperidin-1-yl)methane 
 
 
 
58  
3-(chloromethyl)oxazolidin-2-one 
 
59  
2-bromo-1-(4-((2-nitrophenyl)sulfonyl)piperazin-1-yl)ethan-1-one 
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Chapter 2 
 
Development of photolabile protecting groups for a bioactive compound 
Introduction 
Quorum sensing (QS) is a communication mechanism that occurs in many 
bacteria. An underlying principle of QS is that bacteria utilize their population density to 
modify the collective behavior of the group. Organisms that are involved in QS produce 
small molecule signals known as autoinducers, which are released into their environment 
after they are synthesized intracellularly. The bacteria, using specific receptors, can then 
recognize these autoinducers in order to probe the population density. Binding of these 
signal molecules typically brings forth changes to gene expression, which is the driving 
factor that allows a given population of cells to modify their behavior in unison. 
Importantly, many known virulence factors are produced as a result of QS, and so this 
signaling mechanism controls how/when a bacterium becomes pathogenic or virulent. 
Coupled to the issue of growing antibiotic resistance, QS has recently gained exposure as 
a potential alternative to these medicines. While no QS drugs are currently on the market, 
much research has been published on the topic, and several studies have provided support 
for the idea of using these molecules as a novel means of dealing with bacterial 
infections. 
Photoremovable protecting groups, or "photocages", are a relatively new tool that 
has successfully been employed to study various biological and biochemical 
systems1,
15,16
. After a photocage has been applied to a biologically active molecule, that 
compound is said to be "caged", and decaging (photorelease) is achieved via irradiation 
of light at a certain wavelength. Light-activation is an optimal control element, as it can 
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be managed in regard to location, timing, and magnitude
1,2,3
. Additionally, photodecaging 
provides a concentration surge, in which the amount of active compound jumps from zero 
to a maximum level in seconds (or even milli/micro seconds). While the concept as a 
whole is without doubt scientifically practical, the degree of effectiveness usually 
depends on the specific photocage that is chosen for the given assay. Many examples of 
photocages are known and most differ in the various photorelease characteristics, such as 
optimal release wavelength, quantum yield, time required for photorelease and solubility. 
Ortho-nitrobenzyl (ONB) photocages are a class that has been widely explored due to the 
fact that they possess several ideal properties, including synthetic straightforwardness
1
. A 
subset of this ONB class was employed in this investigation to study QS. 
 
The specific goals of this experiment were to utilize a riboswitch, which is 
activated by a photocaged organic molecule (theophylline), to study QS in biofilms. The 
riboswitch controls production of a protein known as HapR, an important QS regulator in 
V. cholera
5,6
. We were interested in caging theophylline with a certain ONB known as 
 
NPOM, which was developed as a cage for NH heterocycles that improved upon similar 
cages in regards to stability, decaging time, and the production of less toxic byproducts. 
A previous study has employed NPOM-caged theophylline to activate a ribozyme, and 
thus has provided a basis for a similar system to be used to photochemically control gene 
expression
1
. 
Results and Discussion 
 
Development of the HapR-riboswitch construct. Initial attempts to set up the 
riboswitch with the other necessary components proved to be somewhat problematic. The 
riboswitch was first linked to a fluorescent protein, mKate, in E. coli. While this was 
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successful, the ultimate goal was to have a construct consisting of the riboswitch with 
mKate and HapR in V. cholera. Conjugating the plasmid containing the HapR riboswitch 
from E. coli to V. cholera was an issue, and as a result, initial assays were performed in 
the E. coli strain. Eventually, a V. cholera strain was produced that contained the desired 
construct (the riboswitch connected to HapR and mKate), and phenotypic data was 
produced for confirmation. The characteristic rugose morphology of the HapR strain is 
complemented when grown on plates containing theophylline, changing to a smooth 
morphology as a result of the expression of HapR. Having constructed the necessary 
bacterial strain, we focused our attention on developing a means of photochemical 
control for the riboswitch. 
Analysis of NPOM-caged theophylline. Early trials involving the NPOM-caged 
theophylline produced promising results; the compound decaged as hoped and 
photorelease could indeed be monitored via fluorescence measurements. The compound, 
unfortunately, was only able to produce a modest increase in gene expression (4-5 fold) 
when tested in vitro. In comparison, free theophylline induced a 150-fold increase in gene 
expression. The level of response from the caged molecules most likely does not need to 
be this intense, and so we aimed for around a 20-fold increase. As we further assessed the 
NPOM-caged theophylline it was observed to be poorly soluble in polar solvents, 
specifically methanol (used to make stock solutions) and water (used in the LB media). 
The compound was only partially soluble at the working concentration (2 mM), and thus 
it was hypothesized that this lack of solubility was causing the caged theophylline to 
under-perform in the assay. Photorelease was tested in solution without cells and 
determined to occur to an appreciable extent, which supported the idea that aqueous 
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solubility was limiting the caged compound's ability to cause a significant biological 
response. 
Discovery and evaluation of new photocages. To test this theory, several new 
photocages were prepared and linked to theophylline. Since the NPOM cage experienced 
poor solubility in polar solvents, these new cages were designed to contain some type of 
polar functionality. Since the ortho-nitro group is essential for photorelease, we decided 
to focus on the substituents on the other side of the ring. Initially, it was thought that 
changing the methylenedioxy group to a diol (a cathecol derivative) would significantly 
increase polarity. This analog was ultimately abandoned due to synthetic difficulties, as it 
was determined that the cage could not contain any exposed nucleophiles in order to 
complete the last steps of the route. Following this revelation, three new photocages were 
successfully prepared, each derived from the NPOM starting material. Surprisingly, these 
derivatives all underwent decaging at 365 nm, and produced a range of both solubility 
and riboswitch activation. 2, theophylline caged by an ONB analog containing an ortho- 
methoxy-thiomethyl moiety, was found to have the lowest solubility of the four 
compounds prepared, and accordingly, caused the smallest increase of gene expression. 
In contrast, 4, another ONB analog that contained an ortho-di-diethyleneglycol- 
monomethyl ether group, was observed to be fully soluble in polar solvents at a range of 
concentrations, including the working concentration of the assay. Unfortunately, the 
fluorescence response level of this compound was not substantially different from that of 
the original NPOM-theophylline. Finally, an additional ONB cage was synthesized and 
linked to theophylline, containing an ortho-methoxy nitrile moiety (2). Similar to 4, this 
new nitrile compound also possessed improved aqueous solubility, being fully soluble at 
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2 mM. On the other hand, this molecule was found to have unique photorelease 
properties, producing a biological response that was nearly quadruple that of NPOM- 
theophylline, after one minute of irradiation. Since the highly polar diethyleneglycol 
derivative did not perform well in vitro, it can be assumed that solubility does not entirely 
explain the high response level in 2. Instead, the electronic effect of the nitrile on the 
decaging process is likely to play an important role as well. 
Chemistry 
 
Synthesis of NPOM-theophylline was based of a previously published route to 
NPOM-Cl, with minor adjustments. Rather than starting with the nitrated secondary 
alcohol substrate, which was fairly expensive (>$100/g), we choose start a few steps 
prior, with 3′,4′-(Methylenedioxy)acetophenone, which is significantly cheaper. Nitration 
at the desired position ortho to the ketone was achieved in 74% yield. Although 
selectivity was a concern, no other regioisomers were isolated after purification. 
Reduction of the ketone to the secondary alcohol via sodium borohydride proceeded 
either very well or poorly, depending on the batch of NaBH4 that was used. Ultimately it 
was concluded that the reaction would give all product if one had access to fresh sodium 
borohydride. Converting the alcohol to the chloro-acetal proved to be somewhat 
troublesome. Initial attempts focused on obtaining the desired intermediate in one step 
from the alcohol, using paraformaldehyde and TMSCl. After a couple failed trials, this 
transformation was performed via a two step procedure, first converting the alcohol to a 
O, S-acetal (using a MTM ether protecting group), and then reacting this O, S-acetal with 
sulfuryl chloride to obtain the chloro-acetal. Finally, theophylline was reacted with NaH 
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in order to facilitate the SN2 reaction with NPOM-Cl, which typically proceeded very 
smoothly. 
Analogs of NPOM were prepared using NPOM (or one of its precursors) as a 
starting material, keeping the ONB core consistent. Initial efforts focused on cleaving the 
methylenedioxy group to the diol, forming a catechol derivative. After several failed 
attempts using BBr3, we switched focuses to making the ortho-methoxy phenol. While 
this compound was indeed obtained, it was discovered that the sulfuryl chloride step of 
the route did not tolerate any exposed nucleophiles, as sulfonyl esters/amides formed 
preferentially to the S, O-acetal reacting to give the desired chloro-acetal. Accordingly, 
other NPOM analogs were designed and prepared that did not possess any exposed 
nuclephiles, yet still maintained the desired photorelease characteristics. Performing 
nucleophilic aromatic substitution on NPOM, three new analogs were synthesized using 
either, sodium cyanide, sodium methoxide or the alkoxide salt of diethyleneglycol 
monomethylether. Interestingly, it found that SNAr occurred selectively at the position 
para to the nitro group. The resulting free phenol that was produced in each case was 
functionalized with either a methyl group or another diethyleneglycol monomethylether 
chain. 
Conclusion 
 
Based off of precedent for the activation of a ribozyme using NPOM-caged 
theophylline, a similar study was performed. The previous paper was expanded upon by 
using the concept to photochemically control gene expression in a V. cholera strain 
consisting of a riboswitch connected to a QS master regulator, HapR, and a fluorescent 
protein, mKate. In addition to developing novel biological methods, several new 
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photocages were prepared based off of the common NPOM cage, some of which 
improved upon solubility as well as in vitro photorelease. These new cages are likely to 
be useful in other studies that utilize NPOM-caged compounds, or ONB cages in general, 
although they are not completely synthetically straightforward to make. Current goals 
include a more detailed investigation into QS in biofilms (specifically in V. cholera 
HapR) using the photochemical approach described here. Meanwhile, additional nitrile- 
containing ONB caging groups are being developed and will be assessed, as the presence 
of that functional group appears to have a positive effect on the decaging process. 
Experimental Section 
 
General chemistry 
 
1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethanone. 3,4-methylenedioxyacetophenone 
(750 mg, 4.57 mmol) was dissolved in TFA (6.75 ml, 0.67 M) and the solution was 
cooled to 0 °C. Sodium nitrite (946 mg, 13.71 mmol) was added portion wise (in 3 
portions, CAUTION: very exothermic, reaction foams up significantly after third addition 
of NaNO2). The mixture stirred at room temperature for 4 h and then was quenched with 
water (50 mL). Product was extracted with EtOAc (25 mL x 3) and the combined organic 
layers were washed with sat. NaHCO3 and brine, and then dried with Na2SO4. 
Purification via silica-gel flash chromatography (product elutes around 30% EtOAc) 
 
afforded 649 mg of the desired product, 68% yield. 
 
1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethanol. To 1-(6-nitrobenzo[d][1,3]dioxol-5- 
yl)ethanone (350 mg, 1.67 mmol) in a mixture of ethanol and THF (1:1, 18 mL total, 0.1 
M) was added NaBH4 (69.5 mg, 1.84 mmol). The reaction stirred overnight at room 
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temperature and then HCl was added (5 mL, 1 M). After removal of solvent in vacuo, the 
residue was dissolved in EtOAc, washed with brine and dried over Na2SO4. Purification 
via silica-gel flash chromatography (product elutes around 30% EtOAc) afforded 342 mg 
of the desired alcohol, 97% yield. 
 
5-(1-((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole. To 1-(6- 
nitrobenzo[d][1,3]dioxol-5-yl)ethanol (224 mg, 1.06 mmol) dissolved in acetic acid (2.5 
mL, 42.43 mmol) was added DMSO (1.51 mL, 21.22 mmol), followed by acetic 
anhydride (2.0 mL, 21.22 mmol) dropwise. The reaction stirred at room temperature for 
72 h. Sat. NaHCO3 (50 mL) was added dropwise and the mixture was then extracted with 
EtOAc (25 mL x 3). The combined organic layers were washed with brine and dried over 
Na2SO4. Purification via silica-gel flash chromatography (product elutes around 25% 
EtOAc) afforded 240 mg of the desired alcohol, 83% yield. 
5-(1-(chloromethoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole. 5-(1- 
 
((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole (240 mg, 0.885 mmol) was 
dissolved in DCM (6 mL, 0.15 M) and the solution was cooled to 0 °C. Sulfuryl chloride 
(0.07 mL, 0.885 mmol) was added dropwise and the reaction stirred at 0 °C for 1 h. 
Solvent was removed in vacuo, and the product was used crude in the subsequent 
reaction, without a workup or purification. 
2-hydroxy-5-(1-hydroxyethyl)-4-nitrobenzonitrile. To 1-(6- 
 
nitrobenzo[d][1,3]dioxol-5-yl)ethanol (116 mg, 0.549 mmol) in HMPA (1.1 mL, 0.5 M) 
was added NaCN (27 mg, 0.549 mmol). The reaction stirred at 150 °C for 3 min and then 
three additional portions of NaCN was added (0.275 mmol x 3) every 5 minutes. After 
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stirring an additional 10 minutes at 150 °C, the reaction was quenched with water and 
NaOH. The product was extracted with EtOAc (25 mL x 3) and the combined organic 
layers were washed with brine and dried on Na2SO4. Purification via silica-gel flash 
chromatography (product elutes around 95% EtOAc) afforded 30 mg of the desired diol, 
26% yield. 
5-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-hydroxy-4-nitrobenzonitrile. 2- 
hydroxy-5-(1-hydroxyethyl)-4-nitrobenzonitrile (272 mg, 1.31 mmol) was dissolved in 
DCM (13 mL, 0.1 M) and cooled to 0 °C. Triethylamine (0.27 mL, 1.97 mmol) was 
added followed by TBSCl (196 mg, 1.31 mmol) and DMAP (cat.). The mixture was 
allowed to warm to room temperature as it stirred overnight. Additional DCM (50 mL) 
was added and the mixture was washed with HCl (25 mL, 1.0 M) and brine, and then was 
dried over Na2SO4. Purification via silica-gel flash chromatography (product elutes 
around 15% EtOAc) afforded 300 mg of the desired phenol, 71% yield. 
5-(1-hydroxyethyl)-2-methoxy-4-nitrobenzonitrile. Prepared using the 
procedure described for 2-methoxy-5-(1-((methylthio)methoxy)ethyl)-4-nitrobenzonitrile, 
using the corresponding phenol derivative. 
2-hydroxy-5-(1-((methylthio)methoxy)ethyl)-4-nitrobenzonitrile. To 5-(1- 
((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole (283 mg, 1.05 mmol) in HMPA 
(2.1 mL, 0.5 M) was added NaCN (51.5 mg, 1.05 mmol). The reaction stirred at 150 °C 
for 3 min and then three additional portions of NaCN was added (0.502 mmol x 3) every 
5 minutes. After stirring an additional 10 minutes at 150 °C, the reaction was quenched 
with water and NaOH. The product was extracted with EtOAc (25 mL x 3) and the 
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combined organic layers were washed with brine and dried on Na2SO4. Purification via 
silica-gel flash chromatography (product elutes around 55% EtOAc) afforded 51 mg of 
the desired phenol, 17% yield. 
 
2-methoxy-5-(1-((methylthio)methoxy)ethyl)-4-nitrobenzonitrile. To 2- 
 
hydroxy-5-(1-((methylthio)methoxy)ethyl)-4-nitrobenzonitrile (51 mg, 0.181 mmol) in 
 
DMF (2 mL, 0.1 M) was added K2CO3 (50 mg, 0.362 mmol) and methyl iodide (0.02 
mL, 0.362 mmol). The mixture stirred at room temperature overnight, and then the 
reaction was quenched with water. The product was extracted with EtOAc (25 ml x 3), 
and the combined organic layers were washed with brine (50 mL x 3). 
5-(1-(chloromethoxy)ethyl)-2-methoxy-4-nitrobenzonitrile. Prepared using the 
procedure described for 5-(1-(chloromethoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole, using 
the corresponding MTM ether derivative. 
2-(methylthio)-4-(1-((methylthio)methoxy)ethyl)-5-nitrophenol. To 5-(1- 
((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole (283 mg, 1.05 mmol) in HMPA 
(2.1 mL, 0.5 M) was added NaCN (51.5 mg, 1.05 mmol). The reaction stirred at 150 °C 
for 3 min and then three additional portions of NaCN was added (0.502 mmol x 3) every 
5 minutes. After stirring an additional 10 minutes at 150 °C, the reaction was quenched 
with water and NaOH. The product was extracted with EtOAc (25 mL x 3) and the 
combined organic layers were washed with brine and dried on Na2SO4. Purification via 
silica-gel flash chromatography (product elutes around 45% EtOAc) afforded 65 mg of 
the desired phenol, 20% yield. 
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(2-methoxy-5-(1-((methylthio)methoxy)ethyl)-4-nitrophenyl)(methyl)sulfane. 
Prepared using the procedure described for 2-methoxy-5-(1-((methylthio)methoxy)ethyl)- 
4-nitrobenzonitrile, using the corresponding phenol derivative. 
(5-(1-(chloromethoxy)ethyl)-2-methoxy-4-nitrophenyl)(methyl)sulfane. 
 
Prepared using the procedure described for 5-(1-(chloromethoxy)ethyl)-6- 
nitrobenzo[d][1,3]dioxole, using the corresponding MTM ether derivative. 
4-(1-hydroxyethyl)-2-(2-(2-methoxyethoxy)ethoxy)-5-nitrophenol. To 
diethylene glycol monomethylether (0.28 mL, 2.38 mmol) in DMSO (1.5 mL, 0.5 M) 
was added NaH (114 mg, 2.86 mmol) in two portions. The mixture was stirred at 150 °C 
for 20 min and then 5-(1-((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole (323 
mg, 1.191 mmol) was added dropwise (in 1 mL DMSO). After stirring at 150 °C for an 
additional 15 min, the mixture was cooled to room temperature and quenched with water 
and 1 M HCl. The product was extracted with EtOAc (30 mL x 3) and then the combined 
organic layers were washed with NaHCO3 and brine (x 2), and then dried over Na2SO4, 
affording 326 mg of the desired phenol, 90% yield. 
4-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-(2-(2-methoxyethoxy)ethoxy)-5- 
nitrophenol. Prepared using the procedure described for 5-(1-((tert- 
butyldimethylsilyl)oxy)ethyl)-2-hydroxy-4-nitrobenzonitrile, using the diol derivative. 
Purification via silica-gel flash chromatography (product elutes around 15% EtOAc) 
afforded 179.4 mg of the desired phenol, 40% yield. 
2-(2-methoxyethoxy)ethyl 4-methylbenzenesulfonate. Solid NaOH (0.583 g, 
 
14.56 mmol) was dissolved in water (2.91 mL) and the solution was chilled to 0 °C. 
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Diethyleneglycol monomethylether (500 mg, 0.489 mL, 4.16 mmol) was added dropwise 
(in 1.25 mL THF), followed by tosyl chloride (0.952 g, 4.994 mmol) also dropwise, in 
2.9 mL THF. The mixture stirred overnight at room temperature and then the solvent was 
removed in vacuo. EtOAc (50 mL) was added and the mixture was washed with 1 M 
NaOH and then brine. After drying over Na2SO4 the product was used crude in the 
subsequent step. 
 
1-(4,5-bis(2-(2-methoxyethoxy)ethoxy)-2-nitrophenyl)ethanol. A solution of 2- 
(2-methoxyethoxy)ethyl 4-methylbenzenesulfonate (85 mg, 0.3084 mmol) in 2 mL ACN 
was added to a mixture of 4-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-(2-(2- 
methoxyethoxy)ethoxy)-5-nitrophenol (106.6 mg, 0.257 mmol) and K2CO3 (43 mg, 0.384 
mmol) in 3.2 mL ACN. The reaction was refluxed at 70 °C overnight and then was 
concentrated to dryness. EtOAc (50 mL) was added and then the mixture was washed 
with sat. NaHCO3 and then brine. Drying over Na2SO4 and concentration in vacuo 
afforded 122.2 mg of the desired product, which was used crude without purification. 
((1-(4,5-bis(2-(2-methoxyethoxy)ethoxy)-2- 
nitrophenyl)ethoxy)methyl)(methyl)sulfane. Prepared using the procedure described 
for 5-(1-((methylthio)methoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole, using the 
corresponding alcohol derivative. 
1-(1-(chloromethoxy)ethyl)-4,5-bis(2-(2-methoxyethoxy)ethoxy)-2- 
nitrobenzene. Prepared using the procedure described for 5-(1-(chloromethoxy)ethyl)-6- 
nitrobenzo[d][1,3]dioxole, using the corresponding MTM ether derivative. 
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1,3-dimethyl-7-((1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethoxy)methyl)-1H- 
purine-2,6(3H,7H)-dione. NaH (25.5 mg, 1.062 mmol) was added (in two portions) to 
theophylline (160 mg, 0.885 mmol) in DMF (3 mL) and the mixture stirred at room 
temperature for 45 min. 5-(1-(chloromethoxy)ethyl)-6-nitrobenzo[d][1,3]dioxole (229 
mg, 0.885 mmol) was dissolved in DMF (1.5 mL) and added dropwise to the stirring 
mixture, and then the reaction continued stirring for 1.5 h at room temperature. EtOAc 
(50 mL) was added and the mixture was washed with sat. NaHCO3 and brine (30 mL x 
3). After drying over Na2SO4 the product was purified via alumina flash chromatography, 
eluting after 75% EtOAc. 
1
H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.41 (s, 1H), 7.02 
(s, 1H), 6.07 (s, 2H), 5.63 (s, 2H), 5.35 (q, J = 6.3 Hz, 1H), 3.54 (s, 3H), 3.37 (s, 3H), 
1.48 (d, J = 6.3 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 155.12, 152.27, 151.58, 148.69, 
147.19, 141.97, 141.75, 136.52, 106.18, 106.14, 105.00, 103.16, 74.25, 73.32, 29.94, 
 
28.16, 23.75. 
 
7-((1-(4-methoxy-5-(methylthio)-2-nitrophenyl)ethoxy)methyl)-1,3-dimethyl- 
1H-purine-2,6(3H,7H)-dione. Prepared using the procedure described for 1,3-dimethyl- 
7-((1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethoxy)methyl)-1H-purine-2,6(3H,7H)-dione, 
using the corresponding chloro-acetal derivative. 
1
H NMR (400 MHz, CDCl3) δ 7.64 (s, 
1H), 7.30 (s, 1H), 7.02 (s, 1H), 5.74, 5.63 (ABq, JAB = 11.2 Hz, 2H), 5.44 (q, 1H), 3.89 (s, 
3H), 3.49 (s, 3H), 3.33 (s, 3H), 2.40 (s, 3H), 1.53 (d, J = 6.4 Hz, 3H). 
13
C NMR (101 
 
MHz, CDCl3) δ 155.07, 154.18, 151.39, 148.52, 143.95, 141.53, 137.20, 132.79, 121.11, 
 
121.08, 104.32, 75.18, 74.81, 56.50, 29.84, 28.03, 24.05, 13.88. 
 
5-(1-((1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)methoxy)ethyl)- 
2-methoxy-4-nitrobenzonitrile. Prepared using the procedure described for 1,3- 
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dimethyl-7-((1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethoxy)methyl)-1H-purine-2,6(3H,7H)- 
dione, using the corresponding chloro-acetal derivative. 
1
H NMR (400 MHz, CDCl3) δ 
7.83 (s, 1H), 7.73 (s, 1H), 7.49 (s, 1H), 5.63, 5.59 (ABq, JAB = 11.2 Hz, 2H), 5.25 (q, J = 
6.3 Hz, 1H), 4.00 (s, 3H), 3.56 (s, 3H), 3.35 (s, 3H), 1.49 (d, J = 6.3 Hz, 3H). 
13
C NMR 
 
(101 MHz, CDCl3) δ 160.33, 155.27, 151.44, 150.90, 148.74, 142.11, 133.50, 131.89, 
 
114.31, 107.12, 106.98, 106.66, 73.73, 72.48, 57.08, 29.95, 28.10, 23.82. 
 
7-((1-(4,5-bis(2-(2-methoxyethoxy)ethoxy)-2-nitrophenyl)ethoxy)methyl)-1,3- 
dimethyl-1H-purine-2,6(3H,7H)-dione. Prepared using the procedure described for 1,3- 
dimethyl-7-((1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethoxy)methyl)-1H-purine-2,6(3H,7H)- 
dione, using the corresponding chloro-acetal derivative. 
1
H NMR (400 MHz, CDCl3) δ 
7.66 (s, 1H), 7.51 (s, 1H), 6.96 (s, 1H), 5.71, 5.55 (ABq, JAB = 11.0 Hz, 2H), 5.44 (q, J = 
6.2 Hz, 1H), 4.26 – 4.11 (m, 4H), 3.93 – 3.84 (m, 4H), 3.76 – 3.69 (m, 4H), 3.60 – 3.53 
 
(m, 4H), 3.51 (s, 3H), 3.38 (s, 6H), 3.33 (s, 3H), 1.48 (d, J = 6.3 Hz, 3H). 
13
C NMR (101 
MHz, CDCl3) δ 155.04, 153.36, 151.48, 148.61, 147.50, 141.77, 140.13, 134.30, 109.78, 
109.75, 109.29, 74.58, 73.86, 72.06, 70.98, 69.53, 69.41, 69.15, 68.83, 59.17, 29.82, 
 
28.05, 23.80. 
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Figure 13. TheoRS-hapR-mKate construct in V.c. 
 
 
 
Figure 14. Photolysis of new nitrile photocage 
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Figure 15. Photolysis of bis-PEG analog 
 
 
 
 
 
Figure 16. Synthesis of caged-theophylline 
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Chapter 3 
 
Gem-dinitro enols: Discovery and application of a new reaction for methyl ketones 
Introduction 
Due to the promising results of the nitrile-containing ONB photocage, additional 
efforts were focused on optimizing the synthesis of this compound. The original synthetic 
route employed a nucleophilic aromatic substitution on 1-(6-nitrobenzo[d][1,3]dioxol-5- 
yl)ethanol and suffered from a low yield (<30%) and a difficult workup/purification. 
Accordingly, a new substrate was identified and purchased in an attempt to improve both 
the yield and overall efficiency of the route. This starting material, 1-(3-fluoro-4- 
methoxyphenyl)ethanone, was superior in regard to possessing a better leaving group, 
being a fluorine atom rather than a methylene dioxy group, and also already had the 
methoxy substituent that was required for the final compound, thus eliminating the 
methylation of the phenol step. 
A major assumption that this new substrate depended on was that the first step of 
the route, an aromatic nitration, would be selective and high yielding to the extent that it 
was for the original methylene dioxy substrate. Upon performing a nitration on the fluoro 
substrate however, it was observed that nitration of the ring did not occur. While all three 
aromatic hydrogen atoms were accounted for by H1 NMR, the hydrogens on the alpha 
carbon of the methyl ketone were absent. At this point in time this unknown product was 
assumed to be the carboxylic acid, although this idea was not fully consistent with the 
polarity and solubility of this compound, which seemed to be much less polar than the 
acid would likely be. 
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Several reactions and publications were identified after an in-depth search for 
similar types of C-C bond cleavage reactions. The haloform reaction was discovered by 
Adolf Lieben in 1870, although its history goes back a bit further to 18221. Employing 
successive halogenation of an alpha carbon under basic conditions, the reaction is used to 
produce carboxylic acids from methyl ketones, with a trihalomethane serving as a leaving 
group. Similar to this, for our reaction we envisioned nitration of an alpha carbon 
resulting with either mono/di/tri-nitromethane acting as a leaving group. Some precedent 
exists for the transformation of mono alpha-nitro methyl ketones into esters and amides 
from Sarma et al and Ballini et al2,3. After review of these publications, it seemed unlikely 
that the mechanism of our reaction proceeded through the same mono-nitro ketone 
intermediate, due to differences in conditions and substrate scope. An additional paper 
was found regarding the conversion of methyl ketones in esters via an oxidative 
mechanism using CuO2 that provided another example of this type of reaction, but also 
likely differs in mechanism from ours4. 
 
Results and Discussion 
 
Isolation of key intermediates leads to the elucidation of the reaction 
mechanism. A key possibility that was being explored in regard to mechanism included 
mono, di and tri nitration of the alpha carbon, leading to mono, di or tri-nitro methane 
serving as the leaving group. While precedent existed for the conversion of alpha mono- 
nitro ketones to amides, the conditions for this reaction were significantly different and 
harsher than those for our reaction. Additionally, these alpha mono-nitro ketones were 
commercially available and thus stable enough to isolate. Through dozens of reactions 
and purifications, I had not isolated or observed any of these compounds, which are 
easily identified by a singlet around 5-6 ppm in H1 NMR. In the case of alpha gem-di and 
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tri-nitro ketones, little to no precedent exists in the literature which gave us doubts that 
either of these were the intermediate that we have been looking for. 
 
During the course of exploring the nucleophile substrate scope for para-bromo 
acetophenone, an unknown molecule was obtained from a purification as a minor 
byproduct, although in high purity. This compound looked like the corresponding 
carboxlyic acid by H1 NMR, having the four hydrogen atoms in the aromatic ring but 
lacking the three hydrogens of the methyl. A C13 NMR, on the other hand, suggested that 
this mystery product was not the carboxylic acid, as it did indeed still have the carbon of 
the methyl (in addition to the carbonyl carbon). Based off of the specific locations of the 
peaks in the C13 NMR it was determined that this sample was the gem-di nitro 
intermediate that was previously hypothesized. Given both the H1 and C13 NMR data, it 
appears that this ketone derivative exists entirely in the enol form. This idea is consistent 
with the lack of one hydrogen in the H1 NMR and the location of the carbonyl carbon in 
the C13 NMR, being around 180 ppm rather than 200. 
To further demonstrate that this compound was in fact the gem-di nitro enol and 
also a competent intermediate, I subjected the molecule to a reaction with an amine in 
attempt to produce an amide. Surprisingly, two distinct products were isolated after a 
purification in similar amounts, both of which could be characterized by NMR. As we 
had hoped, the desired amide product was indeed isolated, providing support for the 
proposed intermediate. The other isolated product strongly resembled the amide product 
by H1 NMR, with the exception that the two sets of doublets (arising from the 1,4- 
disubstituted benzene ring) were shifted to a much higher ppm. C13 NMR spectra for this 
unknown product did not have a carbonyl or enol peak present, but did have two peaks 
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around 150 ppm (one of which belonging to the carbon of the dinitromethane). This shift 
is consistent with an enamine carbon, which in fact is a plausible secondary intermediate 
that could form after the gem-dinitro enol reacts with an NH-nucleophile. Similarly in the 
case of the enol, the enamine tautotomer seems to preferred over the imine when the 
alpha carbon is dinitro substituted. 
While we did not necessarily expect to be able to isolate and purifiy intermediates 
of this type, this breakthrough does suggest that these gem-dinitro enols and enamines are 
stable to some degree. Still, more work needs to be done in order to obtain a more 
complete understanding of the stability and reactivity of these currently unreported 
intermediates. 
 
Nucleophile substrate scope is wide-ranging. The first nucleophile tested in the 
reaction was hydroxide, thus generating a carboxylic acid from 4-bromoacetophenone. 
Due to the inherent difficulties in isolating and purifying acids, I shifted my focus on 
attempting to produce the methyl ester of 4-bromoacetophenone (using methanol rather 
than hydroxide as the nucleophile). This reaction proceeded smoothly, providing a 
product that was both easier to isolate and purify than the carboxlic acid, and in higher 
yield (81.0% yield instead of 69.6%). Two additional esters were then synthesized, a 
benzyl and phenyl ester, using benzyl alcohol and phenol, respectively. While these 
nucleophiles resulted in slightly lower yields than the methanol, the desired ester was 
indeed produced, demonstrating some substrate inclusiveness for -OH nucleophiles. 
Next I turned my attention to -NH nucleophiles in hopes of forming amides from 
the methyl ketone of 4-bromoacetophenone. The first amine substrate that was attempted 
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was 1-butylamine, which produced the corresponding amide in high yield (80.8%). After 
that initial success several other amines were subjected to the reaction, and amides were 
synthesized from benzyl amine, aniline, piperidine, N,O-dimethyl hydroxylamine, and 
oxazolidinone. Yields from this series followed a general trend based on expected 
nucleophilicity; primary amines were better than secondary and poor nucleophiles such 
as aniline and oxazolidinone produced lower yields. Based off of these six amines, it 
appears that substrate universality also exists for -NH nucleophiles in this reaction, most 
of which proceed in moderate to high yields. 
In addition to this list of -OH and -NH nucleophiles, a -SH nucleophile was tested 
in order to produce a thioester. Thiophenol was employed for this purpose, however the 
desired product was not isolated after several trials and purifications. The major 
compounds obtained seemed to be the disulfide of thiophenol and another species that 
could not be characterized. Ultimately, a different thiol (aliphatic) should be tested before 
concluding that the thioeseters are not able to be produced from the reaction. 
Ketone substrate scope includes both aromatic and alkyl methyl ketones. 
Following the realization of the nucleophile substrate class, I turned my attention to 
investigating the scope of ketone substrates. Based off of the success using 4- 
bromoaceotophenone, other acetophenone derivates were the first to be tested. It become 
apparent almost immediately, however, that many aromatic ketones would not be 
competent in the reaction. For instance, in the case of acetophenone, para-methoxy 
acetophenone and ortho-hydroxy acetophenone, nitrations of the aromatic ring were 
observed thus inhibiting the desired nitration reaction from occuring. Heterocyclic methyl 
ketones followed the same trend, as substrates containing pyridine, pyrrole, indole, 
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thiophene and benzothiophene did not produce any desired product. In general, electron- 
rich aromatics and heteroaromatics appear to be non-ideal for this reaction, as many of 
these substrates will preferably undergo aromatic nitration rather than alpha nitration. 
With this limitation in mind, I focused on identifying new aromatic methyl ketone 
substrates in order to demonstrate that the reaction does not only work for 4-bromo 
acetophenone. Accordingly, I performed bromination reactions on the substrates that 
failed, and was able to isolate and purify several mono-bromo products. After subjecting 
these news compounds to my reaction it was found that the desired amide was produced 
in many cases. For example, 1-(3-bromo-4-methylphenyl)ethanone and 1-(3,4- 
dibromophenyl)ethanone participated in the reaction and produced amides in good yields. 
Interestingly, in the case of 1-(3-bromo-4-methoxyphenyl)ethanone, while the compound 
did not nitrate the ring and thus did indeed generate the gem-dinitro enol, addition of an - 
NH nucleophile and subsequent stirring overnight did not produce the amide as expected. 
This observation potentially clues us into the affect of the substituent that is para to the 
ketone, as the para methoxy allows the alpha nitration to occur but not the nucleophilic 
substitution. Since alpha nitration occurs in the enol form, while the substitution reaction 
occurs in the keto form, it can be hypothesized that an electron-donating substituent at the 
para position stabilizes the enol form during the reaction. Ultimately, more aromatic 
substrates need to be tested to confirm this trend and also to demonstrate better substrate 
inclusiveness for acetophenones. 
Next I became interested in testing aliphatic ketones in the reaction, since these 
would in theory not be hindered by the side reactions seen in the aromatic substrates. 
Pinacolone became the first aliphatic methyl ketone subjected to the reaction and was 
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shown to be competent in the reaction, producing an amide in 58.4% yield. Acetone, on 
the other hand, also worked but with much lower yield. This disparity could be due in 
part to the keto/enol ratio for pinacolone and acetone, as pinacolone would supposedly 
have lower yield due to the steric hindrance around the carbonyl carbon from the tert 
butyl group. Nonetheless, these two examples provide good support for the claim that the 
reaction works for aliphatic methyl ketones and not just aromatic substrates. 
Another alkyl methyl ketone substrate that was tested was 4-(4-nitrophenyl)butan- 
2-one, which produced a very peculiar result. In addition to the desired amide product 
that was obtained in about 25% yield, an unknown compound was isolated from 
purification that appeared to have the para nitro-substituted benzene ring but was missing 
the rest of the structure. It was unable to be determined what the other substituent on the 
1,4 disubstituted benzene was or how aromatic dealkyation took place. This remains an 
area of interest that could potentially lead to a side project after this work gets published, 
but further investigation of this strange result is not a priority. 
Application of this new reaction to produce medicinally relevant 
compounds. In order to further validate the usefulness of this new reaction, I next 
utilized it to synthesize pharmaceutically pertinent moieties. Using ortho-phenyllene 
diamine as the nucleophile and heating the reaction overnight, I was able to obtain a 
benzimidazole from 4-bromoacetophenone in moderate yield. Benzimidazoles are 
important heterocycles found in a variety of drugs and are almost exclusively synthesized 
from carboxlic acids or aldehydes. Generation of these molecules from methyl ketones is 
far less common, with only a small number of procedures existing for this transformation. 
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For that reason, this has the potential to become a separate publication, pending further 
investigations regarding substrate scope and practicality. 
Another class of biologically relevant compounds that can be produced from this 
reaction are methyl ketone-containing steroids such as progesterone derivatives. Since 
several semi-synthetic steroids are/were availabe as drugs, this one-step transformation 
from progesterone could provide an assortment of amide and ester analogs with unique 
properties and applications. A reaction with benzyl amine demonstrated that this substrate 
was able to participate in the dinitro enol reaction, but the yield is currently not known. 
At any rate, the fact progesterone is cheap and widely available makes the one-step 
process worthwhile even if yields are moderately low. 
Conclusion 
 
A new reaction for methyl ketones provides carboxylic acids, esters and amides 
from a simple one-pot procedure. A large variety of -NH and -OH nucleophiles are 
tolerated, and both aromatic and aliphatic methyl ketones have been demonstrated to 
participate in the reaction. Through the isolation of previously unreported intermediates, 
a plausible mechanism has been suggested involving gem-dinitro enols that are formed 
via alpha-nitration of a methyl ketone. The reaction has great potential to be employed 
for the synthesis of biologically active compounds such as benzimidazoles and steroid 
derivatives. Currently, this work is being concluded and will be submitted for publication 
in due time. 
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Figure 17. Reaction scheme and examples of nucleophile substrate scope 
 
 
 
 
 
 
 
 
 
Figure 18. Proposed reaction mechanism 
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Experimental Section 
 
General chemistry. All reagents and solvents were obtained from commercial 
sources and used without further purification or drying. Reactions were performed under 
a nitrogen gas atmosphere in flame-dried glassware. Unless otherwise noted, compounds 
were not purified. 
1
H and 
13
C NMR data was taken on a Varian AS400 (400 MHz), with 
chemical shifts being displayed in a ppm scale referenced to residual chloroform. 
4-bromobenzoic acid. 4-bromoacetophenone (139.3 mg, 0.700 mmol) was 
dissolved in ACN (1.4 mL, 0.5 M) and cooled to 0 ºC. Acetic anhydride (0.20 mL, 3.0 
EQ, 3.58 M) was added, followed by 90% nitric acid dropwise (0.20 mL, 6.0 EQ, 3.58 
M). The solution was allowed to warm to room temperature and stir overnight. After 
cooling to 0 ºC, the reaction was quenched with DIPEA dropwise (12 EQ). KOH (19.6 
mg, 0.5 EQ) was added and the mixture was allowed to stir at room temperature 
overnight. The product was isolated after standard workup and purified by silica-gel 
column chromatography, affording 96.7 mg of the desired product, 69.6% yield. 
Methyl 4-bromobenzoate. Prepared using the procedure described for 4- 
bromobenzoic acid, using the corresponding nucleophile (methanol), 81.0% yield. 
Phenyl 4-bromobenzoate. Prepared using the procedure described for 4- 
bromobenzoic acid, using the corresponding nucleophile (phenol), 64.0% yield. 
Benzyl 4-bromobenzoate. Prepared using the procedure described for 4- 
bromobenzoic acid, using the corresponding nucleophile (benzyl alcohol), 55.8% yield. 
4-bromo-N-butylbenzamide. Prepared using the procedure described for 4- 
bromobenzoic acid, using the corresponding nucleophile (1-butyl amine), 80.8% yield. 
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N-benzyl-4-bromobenzamide. Prepared using the procedure described for 4- 
bromobenzoic acid, using the corresponding nucleophile (benzyl amine), 79.4% yield. 
(4-bromophenyl)(piperidin-1-yl)methanone. Prepared using the procedure 
described for 4-bromobenzoic acid, using the corresponding nucleophile (piperidine), 
59.3% yield. 
4-bromo-N-methoxy-N-methylbenzamide. Prepared using the procedure 
described for 4-bromobenzoic acid, using the corresponding nucleophile (N,O dimethyl 
hydroxylamine HCl), 77.7% yield. 
4-bromo-N-phenylbenzamide. Prepared using the procedure described for 4- 
bromobenzoic acid, using the corresponding nucleophile (aniline), 40.3% yield. 
3-(4-bromobenzoyl)oxazolidin-2-one. Prepared using the procedure described 
for 4-bromobenzoic acid, using the corresponding nucleophile (oxazolidinone), 11.1% 
yield. 
2-(4-bromophenyl)-1H-benzo[d]imidazole. Prepared using the procedure 
described for 4-bromobenzoic acid, using the corresponding nucleophile (ortho- 
phenyllene diamine), 35.4% yield. 
N-benzylpivalamide. Prepared using the procedure described for N-benzyl-4- 
bromobenzamide, using the corresponding ketone (pinocolone), 58.4% yield. 
N-butyl-3-(4-nitrophenyl)propanamide. Prepared using the procedure described 
for 4-bromo-N-butylbenzamide, using the corresponding ketone, 25.3% yield. 
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4-bromobenzoic acid 
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Methyl 4-bromobenzoate 
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Phenyl 4-bromobenzoate 
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Benzyl 4-bromobenzoate 
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4-bromo-N-butylbenzamide 
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N-benzyl-4-bromobenzamide 
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(4-bromophenyl)(piperidin-1-yl)methanone 
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4-bromo-N-methoxy-N-methylbenzamide 
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4-bromo-N-phenylbenzamide 
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3-(4-bromobenzoyl)oxazolidin-2-one 
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2-(4-bromophenyl)-1H-benzo[d]imidazole 
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N-benzylpivalamide 
103  
N-butyl-3-(4-nitrophenyl)propanamide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104  
1-(4-bromophenyl)-2,2-dinitroethenol 
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N-(1-(4-bromophenyl)-2,2-dinitrovinyl)butan-1-amine 
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Chapter 4 
 
Structure-activity relationship of a triphenyl scaffold for the LasR receptor in 
Pseudomonas aeruginosa 
 
Introduction 
 
Due to the array of medically relevant cellular processes that are under the control 
of LuxR-type quorum sensing circuits, significant effort has been directed toward the 
identification of antagonist molecules in several different bacterial pathogens
1-3
. These 
efforts have led to the identification of antagonists from natural sources
4
, diversity- 
oriented compound libraries
5-6
, and focused library synthesis
7-8
. The most broadly 
explored class of LuxR-type receptor antagonists are based on the structural features 
found in the native HSLs, maintaining the homoserine lactone while changing the 
functionality of the acyl-tail. Some initial attempts to inhibit HSL-mediated quorum 
sensing in Gram-negative bacteria have yielded promising results. In studies of P. 
aeruginosa,
9 
a significant bacterial pathogen associated with cystic fibrosis lung  
infection, bacterial keratitis (eye infection), and third degree burn associated skin 
infections, several antagonists have been identified that inhibit the HSL receptor,  LasR
10-
 
12. 
A major obstacle that remains in the development of an anti-quorum sensing 
strategy targeting LasR and other LuxR-type receptors is ligand potency
10
. The high 
levels of affinity and specificity that the receptor displays for its native HSL ligand 
complicates this challenge. As the result, studies of antagonism (inhibition) are typically 
performed using synthase mutants where the native autoinducer is added exogenously at 
minimal concentrations. The approach of using synthase mutants with minimal 
concentrations  of  the  quorum  sensing  agonist  provides  valuable  information     about 
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antagonism of LuxR-type receptors but is misleading in terms of potency as the systems 
studied are often not representative of wild-type bacteria. Strategies to overcome the 
limitation of inhibitor potency are expected to be significant in the development of anti- 
quorum sensing therapeutics. Further, many of the inhibitors that have been identified 
maintain the physiologically labile homoserine lactone functionality, limiting the  
potential of these antagonists for development as therapeutic agents. 
 
The inhibition of quorum sensing with small molecules offers a unique strategy 
for the treatment and prevention of a number of acute and chronic bacterial infections, a 
fact that is of particular significance given the rapid and ongoing spread of antimicrobial- 
resistant bacteria
2,13,14
. Research in this area has been defined as a Category C Priority by 
the NIAID
15
. Through the inhibition of quorum sensing, control over expression of 
virulence factors and biofilm formation is achieved, rendering the bacteria benign while 
not directly affecting viability. This anti-infective approach is conceptually distinct from 
traditional approaches for the treatment of bacterial infection that typically utilize 
bactericidal or bacteriostatic molecules, targeting critical cellular processes. As 
exemplified by the spread of bacterial resistance, these treatments provide a considerable 
growth advantage to bacteria that can resist the drug. Contrasting this approach, the 
inhibition of quorum sensing does not affect cellular viability, decreasing the growth 
advantage of resistance
16
. Rather, this approach targets cellular signaling, inhibiting the 
expression of virulence factors necessary for successful infection, rendering the bacteria 
benign until the hosts immune system can clear the pathogen
2,17-19
. 
Recently  a  highly  potent  activator  of  quorum-sensing  in  P.  aeruginosa   was 
 
identified from a high-throughput screen (2, Figure 2)
2
. While the activation of  virulence 
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factor expression in this bacterial pathogen is not therapeutically desirable our rationale  
to obtain the desired inhibitory function for this potent agonist through analog synthesis 
is based on precedent. Most notably, a large number of inhibitors have been discovered  
by systematic modification of HSLs, molecules which serve as natural QS activators. The 
agonist discovered (2) bears many structural and pharmacological properties that make it 
superior to HSLs as a lead compound for the development of an anti-virulence therapy, 
including the absence of a metabolically labile homoserine lactone. Additionally, the 
potency  of  this  molecule  for  activation  of  LasR  exceeds  the  potency  of  the natural 
signaling molecule and compounds of this structure type have never been systematically 
analyzed for the effect of their structure-activity relationships (SARs)
5-20
. Accordingly, 
our goal is to take advantage of the high potency and the more desirable pharmacological 
properties of this lead compound and optimize the structure to possess the function that 
we desire, the inhibition of virulence. 
109  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. A) Detail of the crystal structure of 3-oxo-C12-HSL (PDB 3IX3) and 2 complexed 
to LasR (PDB 3IX4). B) Two scaffolds targeted for library synthesis and structure-activity 
relationship studies. C) Modular chemical synthesis pathways for library assembly.  
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Results and Discussion 
Synthesis. Challenging our efforts toward the goal of identifying inhibitors of 
LasR based on the structure of 2 is the number of synthetic steps required for its assembly 
(Figure 2B). To prepare a library of molecules related to 2 requires a more efficient 
synthetic route. Identification of an effective approach to the synthesis of our target 
molecules was informed by examination of the recently published crystal structure of the 
QS receptor in P. aeruginosa, LasR, in the presence of 2
21
. Analysis of the binding  
pocket for the ligand suggested that a subtle structural change in the orientation of the 
amide bond in 2 (Figure 2B, highlighted in red) may be tolerated. 
 
 
 
Based on these target scaffolds, we have successfully identified two efficient and  
modular synthetic routes to analogs containing the core scaffold as in 2 (Scaffold #1) 
analogs containing the core scaffold as in 3 (Scaffold #2) We have begun to 
systematically optimize the structural features of the targeted molecules to modify the 
potency and the function of this class of potential anti-virulence therapeutic agents. To 
date we have prepared and evaluated the biological activity of more than 50 analogs of 2 
and 3. These efforts will be discussed in greater detail below and additional analogs will 
be prepared to support and expand on our preliminary findings during the timeframe of 
this proposal. 
Analysis of the crystal structure of LasR complexed to 2
21 
suggests that the two 
 
terminal aromatic rings (Figure 2B, labeled “A” and “C”) play an important role by 
interacting with LasR whereas the central ring appears to play primarily a scaffolding  
role in ligand binding. Therefore, we have focused our initial efforts on identifying the 
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structure activity correlations of the pendant ring structures (“A-ring” and “C-ring”)  
while maintaining the structure of the central ring (“B-ring”). While the two scaffolds 
differ only in the orientation of one amide bond, we have observed some notable 
differences in biological activity for analogs prepared on the two different scaffolds  
which will be discussed further below. 
“A-ring” Structure Activity Relationship Studies. To validate our systematic 
strategy for optimization of the biological properties of 3, a small library of structural 
analogs were prepared. Reaction of intermediate 7 (Figure 2) with a series of structurally 
related acid chlorides (analogous to 8) provided library of “A-ring” analogs (Table 1). 
From this series of structural analogs, we observe a consistent dependence of substitution 
in this ring structure on the potency of the molecules. We discovered that substitution in 
the ortho-position of the arene (entries 1, 4, 7, 9, 10, and 13-15) is critical for potency. 
Substitution in the meta- or para-position of the “A-ring” (entries 2-3, 5-7 and 11-12) 
leads to the complete loss of potency as measured by comparing the EC50 values of the 
compounds determined using the bacterial reporter strain described earlier. In support of 
the significance of ortho-substitution, an analog was prepared containing chlorine atoms 
at both of the ortho-positions of the “A-ring” (entry 16) increasing the potency of this 
LasR agonist. Interestingly, the activity of the analogs bearing ortho-substitution appears 
to be largely independent of the nature of the substituent. Analogs with electon- 
withdrawing substituents (halogen, nitro, trifluoromethyl) and electron-donating groups 
(methyl, methoxy) in the ortho-position all are agonists with EC50 values between 0.1 and 
1.3 uM. Generally we find that analogs with substituents in the ortho-position are   potent 
 
agonists whereas the meta- or para-substituted analogs are universally not active. This 
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may suggest that the binding pocket in LasR for this portion of the molecule is not able to 
accommodate substituents in either the meta- or para-position. Further, the comparable 
activities of the analogs containing electronically and sterically diverse substituents in the 
ortho-position suggests that this substitution does not have a direct role interacting with 
the receptor (no specific hydrogen-bonding or electronic interactions with the receptor) 
but rather may simply play an anchoring role for the overall positioning of the “A-ring”. 
In support of this hypothesis, we have found that while the nature of the substituent in the 
ortho-position does not lead to significant changes in potency (EC50) or function (most  
are agonists) the absence of an ortho-substituent results in the complete loss of activity. 
Entry 18, in which the “A-ring” bears no substitution is completely inactive. 
“C-ring” Structure Activity Relationship Series. While most analogs that we 
have analyzed with changes in the structure of the “A-ring” were found to be either 
agonists or to have no activity (i.e. changes in potency), analogs with structural changes  
in the “C-ring” (Table 2) have both changes in potency and changes in function (agonism 
vs. antagonism). We first assessed the impact of the position of the nitro-substituent on 
the activity of the molecules (entries 1-3), revealing the necessity of an ortho-nitro 
substituent. We then prepared a series of analogs in which the ortho-nitro group on the 
“C-ring” of the parent compound (3) was exchanged for functionality that had been 
previously found to be a suitable bioisostere of an aromatic nitro group
22
. While the 2- 
 
pyridine was observed to have no agonist activity (entry 4) the di-fluoro bioisostere was 
found to show enhanced activity as a LasR agonist (entry 5). Introducing additional 
electron-withdrawing substituents onto the ring (entry 6) had minimal effect on activity 
however, interestingly, the pyrimidine analog (entry 7) was found to be active as an 
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agonist. Combining the 2-nitro substitution with a ring nitrogen at the 4-position (entry 8) 
also provided an agonist of comparable activity to the parent compound. Therefore within 
the series of aromatic and heteroaromatic analogs of this ring highest agonist activity was 
noted with the di-fluoro analog (entry 5) and the 2-pyridine and meta- and para-nitro 
analogs were found to be inactive. Based on published crystal-structure analysis from 
which the ortho-nitro ring serves the role of a mimic of the homoserine lactone 
characteristic of this class of signaling molecules, we replaced this ring with a  
homoserine lactone. Notably, this analog (entry 10) displays significantly enhanced 
potency to the natural LasR signaling molecule, 3-oxo-C12-HSL, with an EC50 value of 
0.9 nM. 
 
We next turned our attention to evaluating the structure-activity relationships 
surrounding changes to the amide bond linking the “C-ring” to the “B-ring” (Table 3). 
While we found that converting the amide bond into a benzimidzole linker (entry 2) 
provided an analog with no activity, several sulfonamides we prepared showed potent 
agonist activity (entries 5 and 6), successfully serving as structural mimics for the amide 
bond found in the parent compound. 
We next turned our attention to evaluation of the role of the orientation of the  
amide bond linking the “B-ring” and the “C-ring” on the activity of several of the “C- 
ring” analogs prepared. We selected the new 2-pyridine, di-fluoro and pyrimidine “C- 
ring” analogs for this analysis as these analogs displayed a range of agonist activities in 
our initial library. Therefore, we prepared analogs XX-XX and evaluated them for both 
their agonist and antagonist activity in the LasR quorum sensing reporter strain (Figure 
2). In our analysis, we found that 2-pyridine analog XX, earlier observed to show no 
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agonist activity against LasR (Table 2, entry 4) possessed potent antagonist activity with 
an IC50 of 42uM. The potency of this inhibitor of LasR compares favorably with the “best 
in class” inhibitors of this quorum sensing circuit and represents one of the most potent 
inhibitors discovered
6-8,23-26
. We additionally prepared this analog with the amide linker 
between the “B-ring” and the “C-ring” reversed and observed that this analog (XX) had 
similarly low LasR agonist and high LasR antagonist activity to XX. We next prepared 
an analog containing a reversed amide corresponding to the potent difluoro arene full 
LasR agonist XX (EC50 = 46nM). To our surprise, this analog (XX) was not an agonist of 
LasR, instead it displayed a change in function, instead acting as an antagonist of LasR 
QS with an IC50 of 65uM (80% maximal inhibition). In contrast to this finding, when we 
prepared the reversed amide analog of the weak agonist pyrimidine XX (EC50 = 0.6uM) 
we found the new analog (XX) to similarly be a weak agonist of LasR with an EC50 of 
1.3uM. 
Given the antagonist activity of the pyridine analog and our previous success with 
the design of irreversible inhibitors of LasR we evaluated a series of chloropyridines and 
electron poor arenes as potential irreversible antagoinsts of LasR (Table 3). While we 
found two analogs with potent antagonist activity (entries 1,2 and 4) these analogs do not 
appear to be irreversible inhibitors of LasR based on competition binding assays with the 
native agonist 3-oxo-C12HSL. While the mechanism of inhibition does not appear to 
require irreversible attachment to LasR, we note that only analogs containing a chlorine 
ortho to the ester linker showed activity as antagonists. Entry 3, which only has  a 
chlorine meta to the ester linkage showed no activity in our assay. 
In  an  effort  to  enhance  the  potency  of  the  series  of  irreversible       maleimide 
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containing LasR antagoinsts we had previously identified we prepared two targeted 
inhibitors combining structural changes in the “C-ring” with the appropriate chain-length 
tether to a maleimide in place of the “A-ring” based on our previous studies. For this 
investigation we selected the most potent “C-ring” LasR antagonist analog on the 
reversed amide backbone (amide as in TP-1, 2) and the most potent “C-ring” LasR 
agonist analog on the amide backbone as in 3. We rationalized that we might enhance the 
antagonist activity of the 2-pyridine analog (XX, Figure 2) by combining this feature with 
the appropriately positioned maleimide for irreversible modification of a conserved 
cysteine in the LasR ligand binding pocket. In the event, the designed analog XX 
underperformed our expectations, showing antagonist activity however with an increased 
IC50 value (116uM with 2-pyridine vs. 1.5uM with the 2-nitro analog). We next prepared 
an analog containing the HSL headgroup as the “C-ring” structure based on an analog 
which we had observed to provide significant agonist activity against LasR (Table 2,  
entry 10). We rationalized that if the more potent EC50 observed this “C-ring” analog was 
attributed to a lower KD, then combining this enhanced binding of the analog effect with 
the introduction of a maleimide appropriately positioned to irreversibly react with LasR 
should provide enhanced antagonist activity. In the analysis, the designed analog XX did 
indeed demonstrate potent antagonist activity (IC50 = 13.1uM). This analog represents 
one of the most potent antagonists if LasR discovered being comparable to the “best in 
class” potency we had previously identified for analog XX. 
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Table 1. Structure-activity relationships of “A-ring” analogs. 
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Table 2. Structure-activity relationships of “C-ring” analogs. 
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Table 3. Structure-activity relationships of alternative linkers. 
 
 
 
 
 
 
 
 
 
Entry Structure 
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Table 4. Chloropyridine analogs as antagonists of LasR. 
Entry Structure IC50 (μM) 
% 
Max 
Entry Structure IC50 (μM) 
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Figure 20. Effect of amide bond configuration and identification of potent LasR 
antagonists. 
 
Figure 21. Hybrid analogs combining optimized structural features identified in this 
study with a maleimide for LasR irreversible inhibition. 
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Conclusion 
 
We have evaluated a series of synthetic libraries of non-natural modulators of 
LasR-mediated QS in Pseusomonas aeruginosa. The compounds prepared are significant 
as they represent a novel drug-like scaffold for the preparation of inhibitors of bacterial 
virulence. We have identified several notable stricture-activity relationships and in so 
doing have paved the way for the rational design of potent inhibitors of LasR QS. We 
have demonstrated several series of analogs which possess the therapeutically desirable 
LasR antagonist activity and have defined structural features which contribute positively 
to both this desirable function of the ligands evaluated while simultaneously 
characterizing structural features which positively contribute to the potency of the 
molecules tested. 
While I did not prepare all of the compounds presented in this Chapter, I have 
played an active role in this project since its inception. The summary of our progress 
described here represents a collaborative effort and I am grateful for the contributions of 
my co-workers in the Perez group who have worked with me on this project. During the 
time-period of my Masters thesis research not only did I personally prepare a large 
percentage of the molecules to complete the analysis described above but I additionally 
played an active role designing targets, training and trouble-shooting synthetic challenges 
faced by my co-workers in this project. Therefore, here I present a comprehensive 
overview of the progress we have made in this area. 
121  
Experimental Section 
 
Bacterial reporter strain assay. Our collaborator Prof. Ng developed the 
biological assay for this project. A reporter strain was first produced using V. cholera in 
which the expression of a luminescent protein is controlled by Hfq-sRNA. For practical 
purposes, an increase in luminescence (or Lux/OD600) corresponds to an increase in 
inhibition of the Hfq-Qrr complex, whereas compounds that do not effect this protein- 
RNA interaction do not generate luminescence. To prepare for the assay, an overnight 
culture of the V. cholera reporter strain was incubated at 30 °C in LB media containing 
100 µg/mL of Kanamycin and 5 µg/mL of Tetracyclin. Following a 1:50 dilution of this 
culture into the same LB media, 175 µL was placed into each well of a clear bottom 96- 
well plate. Next, 10.5 µL of a 10 mM solution of each compound in DMSO was added in 
triplicate to the wells in the first column. A 2.4 fold dilution was then performed by 
transferring 125 µL from the first column to the next, and repeating this down the entire 
plate. Plates were incubated at 30 °C and luminescence (Lux) and OD600 were read at 4, 5 
and 6 hours. Dose response curves were generated using Prism software, and were 
plotted as Lux/OD600 vs. log[conc.]. 
General chemistry. All reagents and solvents were obtained from commercial 
sources and used without further purification or drying. Reactions were performed under 
a nitrogen gas atmosphere in flame-dried glassware. Unless otherwise noted, compounds 
were not purified. 
1
H and 
13
C NMR data was taken on a Varian AS400 (400 MHz), with 
chemical shifts being displayed in a ppm scale referenced to residual chloroform. 
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3,5-dibromo-2-hydroxybenzamide. Salicylamide (10.0 g, 72.9 mmol) was 
dissolved in glacial acetic acid (146 mL, 0.5 M) and Br2 (11.2 mL, 218.7 mmol) was 
added dropwise. The reaction stirred overnight at room temperature and then was 
quenched with water (500 mL). Product was filtered and washed with a small amount of 
water and then dried in a dessicator, affording 20.2 g of the desired product, which was 
used crude in the subsequent step, 93.5% yield. 
2-(benzyloxy)-3,5-dibromobenzamide. 3,5-dibromo-2-hydroxybenzamide (10.0 
g, 33.7 mmol) was dissolved in acetone (337 mL, 0.1 M) and K2CO3 (5.58 g, 40.4 mmol) 
was added, followed by benzyl bromide (4.80 mL, 40.4 mmol) dropwise. The mixture 
was stirred at reflux overnight and then was cooled to room temperature. Potassium 
carbonate was filtered off (filtrate was washed with more acetone) and the solvent was 
removed in vacuo. The product was recrystallized in acetone, affording 11.3 g of the 
desired product, 87.1% yield. 
(2-(benzyloxy)-3,5-dibromophenyl)methanamine. 2-(benzyloxy)-3,5- 
dibromobenzamide (1.0 g, 2.58 mmol) was dissolved in BH3
.
THF (13.24 mL, 13.24 
mmol) under N2 and the mixture was heated to reflux. The reaction stirred for 48 h at 75 
°C and was monitored by TLC (10 mL additional BH3
.
THF was added at 30 h). Methanol 
(10 mL x 2) was added dropwise to quench the reaction, and then the solvent was 
removed in vacuo. The product was used crude in the subsequent step without 
purification, quant. yield. 
1
H NMR (400 MHz, DMSO-d6) δ 7.95 (d, J = 2.5 Hz, 1H), 
7.91 (s, 1H), 7.74 (s, 1H), 7.60 (d, J = 2.4 Hz, 1H), 7.48 – 7.42 (m, 2H), 7.40 – 7.29 (m, 
3H), 4.95 (s, 2H), 4.36 (t, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 151.79, 136.32, 
136.20, 134.68, 131.19, 128.40, 128.39, 119.03, 116.67, 60.79, 29.25. 
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N-(2-(benzyloxy)-3,5-dibromobenzyl)-2-nitrobenzamide. 2-nitrobenzonic acid 
(534.8 mg, 3.20 mmol) was dissolved in CH2Cl2 and the solution was cooled to 0 °C 
under N2. Oxalyl chloride (0.550 mL, 6.40 mmol) was added dropwise, followed by 
DMF (1 drop). The reaction was allowed to warm to room temperature as it stirred for 2 
h. Solvent and excess oxalyl chloride was removed in vacuo and then the residue was 
resuspended in CH2Cl2. This acid chloride was added dropwise to a solution of (2- 
(benzyloxy)-3,5-dibromophenyl)methanamine (655 mg, 1.60 mmol) in CH2Cl2 (32 mL, 
0.1 M). Triethylamine (1.56 mL, 11.2 mmol) was added, followed by DMAP (cat.) and 
the mixture stirred overnight at room temperature. After quenching the reaction with 
water (25 mL), more CH2Cl2 was added (50 mL) and the organic layer was washed with 
HCl (50 mL, 1 M), sat. NaHCO3 (50 mL) and then brine (50 mL), and then was dried 
over Na2SO4. Purification via silica-gel column chromatography (product elutes around 
30% EtOAc) afforded 354 mg of the desired product, 42.5% yield. 
1
H NMR (400 MHz, 
CDCl3) δ 8.04 (dd, 1H), 7.69 (d, J = 2.4 Hz, 1H), 7.66 – 7.59 (m, 1H), 7.59 – 7.53 (m, 
2H), 7.44 – 7.40 (m, 2H), 7.37 – 7.29 (m, 3H), 7.26 – 7.20 (m, 1H), 5.81 (t, J = 6.1 Hz, 
 
1H), 5.05 (s, 2H), 4.46 (d, J = 6.1 Hz, 2H). 
13
C NMR (101 MHz, CDCl3) δ 166.46, 
153.03, 146.43, 136.07, 135.70, 134.99, 133.83, 132.54, 132.45, 130.73, 129.03, 128.89, 
 
128.87, 128.75, 124.72, 118.29, 117.99, 75.85, 39.21. 
 
N-(3,5-dibromo-2-hydroxybenzyl)-2-nitrobenzamide. N-(2-(benzyloxy)-3,5- 
dibromobenzyl)-2-nitrobenzamide (354 mg, 0.681 mmol) was dissolved in CH2Cl2 (4.54 
mL, 0.15 M) and cooled to -78 °C in a dry ice/acetone bath. BBr3 (65 µL, 0.681 mmol) 
was added dropwise and the mixture stirred for 3 h while the temperature was kept 
between -20 and -60 °C. The reaction was quenched with sat. NaHCO3 (25 mL) and was 
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extracted with CH2Cl2 (50 mL). This organic layer was washed with brine and then dried 
over Na2SO4. Purification via silica-gel column chromatography (product elutes around 
40% EtOAc) afforded 129.5 mg of the desired product, 30.2% yield. 
1
H NMR (400 MHz, 
DMSO-d6) δ 9.25 (t, J = 6.2 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 
 
7.70 – 7.56 (m, 3H), 7.34 (d, J = 2.2 Hz, 1H), 4.37 (d, J = 5.1 Hz, 2H). 13C NMR (101 
 
MHz, DMSO-d6) δ 166.33, 151.20, 147.18, 133.78, 133.02, 131.85, 131.14, 130.27, 
 
130.03, 129.20, 124.28, 112.36, 110.97, 38.51. 
 
2-(2-methoxyphenyl)-N-(2-nitrophenyl)acetamide. 2-methoxyphenyl acetic 
acid (6.75 g, 40.62 mmol) and 2-nitroaniline (3.76 g, 27.07 mmol) were dissolved in 
ACN (90 mL, 0.3 M). Thionyl chloride (2.86 mL, 40.62 mmol) was added dropwise and 
the mixture stirred at reflux for 24 h. Solvent was removed in vacuo and the residue was 
resuspended in EtOAc (150 mL) and washed with sat. NaHCO3 and then brine. After 
drying over Na2SO4, the product was purified via silica-gel column chromatography 
(product elutes around 30% EtOAc) affording 5.313 g of the desired product, 68.6% 
yield. 
1
H NMR (400 MHz, CDCl3) δ 10.37 (s, 1H), 8.76 (dd, J = 8.6, 1.3 Hz, 1H), 8.12 
(dd, J = 8.5, 1.6 Hz, 1H), 7.64 – 7.53 (m, 1H), 7.39 – 7.27 (m, 2H), 7.18 – 7.07 (m, 1H), 
 
7.04 – 6.93 (m, 2H), 3.91 (s, 3H), 3.82 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 170.72, 
157.24, 136.58, 135.73, 134.97, 131.43, 129.54, 125.65, 123.09, 122.45, 122.13, 121.19, 
 
110.86, 55.50, 40.69. 
 
2-(2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide. 2-(2-methoxyphenyl)-N-(2- 
nitrophenyl)acetamide (6.927 g, 24.2 mmol) was dissolved in CH2Cl2 (161.3 mL, 0.15 
M) and cooled to -78 °C in a dry ice/acetone bath. BBr3 (2.29 mL, 24.2 mmol) was added 
 
dropwise and the mixture stirred for 4 h while the temperature was kept between -20 and 
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-60 °C. The reaction was quenched with sat. NaHCO3 (100 mL) and was extracted with 
more CH2Cl2 (100 mL). This organic layer was washed with brine and then dried over 
Na2SO4. Purification via silica-gel column chromatography (product elutes around 40% 
EtOAc) afforded 3.98 g of the desired product, 60.5% yield. 
1
H NMR (400 MHz, CDCl3) 
δ 10.60 (s, 1H), 8.72 (dd, J = 8.6, 1.3 Hz, 1H), 8.16 (dd, J = 8.4, 1.6 Hz, 1H), 7.66 – 7.59 
(m, 1H), 7.50 (s, 1H), 7.24 – 7.13 (m, 3H), 6.98 – 6.90 (m, 2H), 3.84 (s, 2H). 13C NMR 
(101 MHz, CDCl3) δ 171.92, 154.90, 136.82, 136.01, 134.33, 131.33, 129.68, 125.84, 
123.92, 122.63, 121.28, 120.58, 117.08, 41.86. 
 
2-(3,5-dibromo-2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide. 2-(2- 
hydroxyphenyl)-N-(2-nitrophenyl)acetamide (2.363 g, 8.68 mmol) was dissolved in 
glacial acetic acid (173.6 mL, 0.05 M) and Br2 (1.33 mL, 26.0 mmol) was added 
dropwise. The reaction stirred for 1 h at room temperature and then was quenched with 
water (100 mL). The product was extracted with CH2Cl2 (50 mL x 3) and then the 
combined organic layers were washed with sat. NaHCO3 and then brine, and then dried 
over Na2SO4. Purification via silica-gel column chromatography (product elutes around 
40% EtOAc) afforded 3.34 g of the desired product, 89.5% yield. 
1
H NMR (400 MHz, 
CDCl3) δ 10.58 (s, 1H), 8.73 (dd, J = 8.5, 1.3 Hz, 1H), 8.19 (dd, J = 8.5, 1.6 Hz, 1H), 
 
7.67 – 7.60 (m, 1H), 7.59 (d, J = 2.3 Hz, 1H), 7.37 (d, J = 2.3 Hz, 1H), 7.22 – 7.16 (m, 
 
1H), 6.76 (s, 1H), 3.83 (s, 2H). 
13
C NMR (101 MHz, CDCl3) δ 169.59, 150.37, 136.68, 
136.12, 134.46, 134.19, 133.51, 125.93, 123.89, 123.42, 122.45, 113.01, 111.92, 41.18. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2- 
chlorobenzoate. To 2-(3,5-dibromo-2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide (53.0 
mg, 0.123 mmol) in CH2Cl2 (2.46 mL, 0.05 M) under N2 was added 2-chlorobenzoyl 
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chloride (19 µL, 0.148 mmol), followed by Et3N (41 µL, 0.295 mmol) and then DMAP 
(1.5 mg, 0.0123 mmol). The mixture was allowed to stir overnight at room temperature 
and then was diluted with CH2Cl2 (50 mL) and washed with HCl (25 mL, 1 M), sat. 
NaHCO3 (25 mL) and then brine (25 mL). After drying over Na2SO4, the material was 
purified via silica-gel flash chromatography, affording XX mg of the desired product 
(XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.67 (dd, J = 8.5, 1.1 Hz, 1H), 
8.17-8.10 (m, 2H), 7.81 (d, J = 2.2 Hz, 1H), 7.63-7.56 (m, 2H), 7.50-7.45 (m, 2H), 7.36- 
7.30 (m, 1H), 7.16 (ddd, J = 8.5, 7.3, 1.3 Hz, 1H), 3.78 (s, 2H). 
13
C-NMR (125MHz, 
 
CDCl3)  169.8, 162.2, 146.6, 136.6, 136.2, 135.9, 135.1, 134.5, 134.2, 133.8, 132.6, 
 
131.7, 130.7, 127.6, 127.1, 125.9, 123.9, 122.4, 120.6, 118.9, 40.8. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3- 
chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.35 (s, 1H), 8.68 (d, J = 8.4 Hz, 
1H), 8.15 (dd, J = 8.5, 1.3 Hz, 1H), 8.09-8.05 (m, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.79 (d, J 
= 2.2Hz, 1H), 7.63 (ddd, J = 8.5, 7.2, 1.0 Hz, 1H), 7.60-7.54 (m, 2H), 7.39 (t, J = 7.9 Hz, 
 
1H), 7.18 (ddd, J = 8.4, 7.3, 1.1 Hz, 1H), 3.71 (s, 2H). 
13
C-NMR (125MHz, CDCl3) 

167.8, 162.6, 146.6, 136.4, 136.3, 135.8, 135.2, 134.6, 134.5, 133.8, 130.8, 130.6, 130.3, 
 
129.7, 128.8, 126.0, 123.9, 122.2, 120.6, 118.8, 41.0. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4- 
chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.33 (s, 1H), 8.67 (dd, J = 8.5, 1.1 
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Hz, 1H), 8.15 (dd, J = 8.5, 1.5 Hz, 1H), 8.08-8.03 (m, 2H), 7.79 (d, J = 2.2 Hz, 1H), 7.62 
 
(ddd, J = 8.6, 7.2, 1.4 Hz, 1H), 7.57 (d, J = 2.2 Hz, 1H), 7.43-7.37 (m, 2H), 7.18 (ddd, J = 
 
8.5, 7.2, 1.2 Hz, 1H), 3.71 (s, 3H). 
13
C-NMR (125MHz, CDCl3)  167.9, 163.0, 146.7, 
 
141.2, 136.4, 136.2, 135.8, 134.5, 133.7, 132.0, 130.8, 129.4, 126.4, 126.0, 123.9, 122.2, 
 
120.5, 118.8, 41.0. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2- 
bromobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.68 (dd, J = 8.5, 1.0 
Hz, 1H), 8.17-8.11 (m, 2H), 7.81 (d, J = 2.2 Hz, 1H), 7.71-7.66 (m, 1H), 7.63-7.57 (m, 
2H), 7.41-7.36 (m, 2H), 7.16 (ddd, J = 8.5, 7.2, 1.2 Hz, 1H), 3.79 (s, 2H). 
13
C-NMR 
 
(125MHz, CDCl3)  167.8, 162.7, 146.6, 136.6, 136.1, 135.9, 135.1, 134.5, 134.1, 133.8, 
 
132.7, 130.7, 129.5, 127.6, 126.0, 123.9, 123.1, 122.4, 120.6, 118.8, 40.8. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3- 
bromobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.35 (s, 1H), 8.68 (dd, J = 8.5, 1.0 
Hz, 1H), 8.22 (t, J = 1.0 Hz, 1H), 8.15 (dd, J = 8.4, 1.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 
7.79 (d, J = 2.2 Hz, 1H), 7.75-7.71 (m, 1H), 7.64-7.61 (m, 1H), 7.57 (d, J = 2.1 Hz, 1H), 
 
7.33 (t, J = 8.7 Hz, 1H), 7.18 (t, J = 8.6 Hz, 1H), 3.71 (s, 2H). 
13
C-NMR (125MHz, 
 
CDCl3)  167.8, 162.5, 146.6, 137.5, 136.3, 135.8, 134.5, 133.8, 133.5, 130.8, 130.5, 
 
129.9, 129.3, 126.0, 124.0, 123.0, 122.2, 120.6, 118.7, 41.0. 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4- 
bromobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.34 (s, 1H), 8.68 (dd, J = 8.5, 0.9 
Hz, 1H), 8.16 (dd, J = 8.4, 1.0 Hz, 1H), 7.98 (d, J = 8.5 Hz), 7.79 (d, J = 2.3 Hz, 1H), 
7.65-7.54 (m, 3H), 7.18 (t, J = 8.4 Hz, 1H), 3.71 (s, 2H). 
13
C-NMR (125MHz, CDCl3) 

167.9, 163.1, 146.7, 136.3, 135.8, 134.5, 133.7, 132.4, 132.1, 130.8, 130.0, 126.8, 126.0, 
 
123.9, 122.2, 120.6, 118.8, 41.0. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2- 
fluorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.67 (dd, J = 8.4, 0.9 
Hz, 1H), 8.15 (dd, J = 8.5, 1.0 Hz, 1H), 8.06 (dt, J = 8.4, 0.9 Hz, 1H), 7.79 (d, J = 2.2 Hz, 
1H), 7.64-7.55 (m, 2H), 7.24-7.11 (m,2H), 3.75 (s, 2H). 
13
C-NMR (125MHz, CDCl3) 
167.8, 163.7, 161.6, 161.2, 161.1, 136.3, 136.2, 136.2, 135.8, 134.5, 133.7, 133.0, 130.7, 
 
125.9, 124.5, 124.5, 123.9, 122.4, 120.5, 118.8, 117.6, 117.4, 116.7, 116.6, 40.8. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4- 
fluorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.33 (s, 1H), 8.67 (d, J = 8.3 Hz, 
1H), 8.20-8.11 (m, 2H), 7.79 (d, J = 1.9 Hz, 1H), 7.62 (t, J = 8.4 Hz, 1H), 7.57 (d, J = 1.8 
Hz, 1H), 7.18 (t, J = 8.4 Hz, 1H), 7.14-7.07 (m, 2H), 3.71 (s, 2H). 
13
C-NMR (125MHz, 
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CDCl3) 167.9, 167.8, 165.7, 162.8, 146.7, 136.5, 136.2, 135.7, 134.5, 133.7, 133.5, 
 
133.4, 130.8, 126.0, 124.2, 123.9, 122.2, 120.5, 118.8, 116.4, 116.2, 40.9. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2- 
methylbenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.33 (s, 1H), 8.68 (d, J = 8.4 Hz, 
1H), 8.16 (d, J = 8.4 Hz, 1H), 8.13 (dd, J = 8.4, 0.9 Hz, 1H), 7.80 (d, J = 2.0 Hz, 1H), 
7.60 (t, J = 8.2 Hz, 1H), 7.57 (d, J = 1.9 Hz, 1H), 7.44 (t, J = 8.2 Hz, 1H), 7.27-7.13 (m, 
 
2H), 3.73 (s, 2H), 2.53 (s, 3H). 
13
C-NMR (125MHz, CDCl3) 168.0, 163.9, 147.0, 142.4, 
 
136.5, 136.1, 135.7, 134.5, 133.7, 133.7, 132.3, 131.8, 130.9, 126.8, 126.2, 125.9, 123.8, 
 
122.2, 120.2, 119.1, 41.0, 22.1. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3- 
methylbenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.33 (s, 1H), 8.70 (dd, J = 8.4, 0.8 
Hz, 1H), 8.13 (dd, J = 8.4, 0.9 Hz), 7.94-7.89 (m, 2H), 7.78 (d, J = 2.1, Hz, 1H), 7.61 (t, J 
= 8.2 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.43-7.37 (m, 1H), 7.30 (t, J = 8.4 Hz, 1H), 7.16 
 
(t, J = 8.4 Hz, 1H), 3.71 (s, 2H), 2.33 (s, 3H). 
13
C-NMR (125MHz, CDCl3)  167.9, 
 
163.9, 146.9, 138.9, 136.4, 136.2, 135.7, 135.4, 134.6, 133.7, 131.1, 130.9, 128.8, 127.9, 
 
127.8, 125.9, 123.8, 122.2, 120.3, 118.9, 40.9, 21.4. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4- 
methylbenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
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nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.69 (dd, J = 8.4, 0.9 
Hz, 1H), 8.13 (dd, J = 8.4, 0.9 Hz, 1H), 8.00 (d, J = 8.5 Hz, 2H), 7.78 (d, J = 2.1 Hz, 1H), 
7.61 (t, J = 8.3 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.20 (d, J = 8.5 Hz, 2H), 7.17 (t, J = 8.4 
 
Hz, 1H), 3.71 (s, 2H), 2.40 (s, 3H). 
13
C-NMR (125MHz, CDCl3)  168.0, 163.8, 146.9, 
 
145.6, 136.4, 136.2, 135.7, 134.6, 133.6, 131.0, 130.8, 129.6, 125.9, 125.1, 123.8, 122.3, 
 
120.2, 118.9, 40.9, 22.1. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,6- 
dichlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2- 
((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the 
desired product (XX% yield). 
1
H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.70 (d, J = 
8.4 Hz, 1H), 8.16 (dd, J = 8.4, 1.0 Hz, 1H), 7.83 (d, J = 2.1 Hz, 1H), 7.64-7.57 (m, 2H), 
7.41-7.31 (m, 2H), 7.16 (t, J = 8.4 Hz, 1H), 3.98 (s, 2H). 
13
C-NMR (125MHz, CDCl3) 

167.9, 161.9, 146.1, 136.6, 136.3, 136.2, 134.5, 134.1, 133.0, 132.2, 131.2, 130.5, 128.9, 
 
126.0, 123.9, 122.3, 121.1, 118.6, 40.5. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,6- 
dibromobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2- 
((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the 
desired product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.32 (s, 1H), 8.72 (dd, J = 
8.6, 1.3 Hz, 1H), 8.17 (dd, J = 8.5, 1.6 Hz, 1H), 7.85 (d, J = 2.3 Hz, 1H), 7.65 – 7.59 (m, 
4H), 7.24 – 7.13 (m, 2H), 4.06 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.97, 145.95, 
136.66, 136.20, 136.04, 135.00, 134.45, 133.99, 132.64, 132.56, 130.68, 125.88, 123.79, 
 
122.36, 120.91, 118.45, 40.70.  MISSING A C=O & SOME Ar 
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2,4-dibromo-6-(2-((4,5-difluoro-2-nitrophenyl)amino)-2-oxoethyl)phenyl 2- 
chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.41 (s, 1H), 8.74 (dd, J = 12.6, 
7.5 Hz, 1H), 8.14 (dd, J = 7.9, 0.9 Hz, 1H), 8.07 (dd, J = 10.1, 7.9 Hz, 1H), 7.85 (d, J = 
2.3, 0.7 Hz, 1H), 7.59 (d, 1H), 7.55 – 7.49 (m, 2H), 7.41 – 7.35 (m, 1H), 3.81 (s, 2H). 13C 
 
NMR (101 MHz, CDCl3) δ 167.90, 162.12, 146.58, 136.02, 135.00, 134.18, 133.71, 
 
132.55, 131.71, 130.14, 127.47, 127.05, 120.64, 118.93, 115.14, 114.93, 111.01, 110.76, 
 
40.75. 
 
2,4-dibromo-6-(2-oxo-2-(pyridin-2-ylamino)ethyl)phenyl 2-chlorobenzoate. 
 
Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.27 – 8.19 (m, 2H), 8.19 – 8.10 (m, 
2H), 7.77 (d, J = 2.3 Hz, 1H), 7.70 – 7.64 (m, 1H), 7.58 (d, J = 2.3 Hz, 1H), 7.53 – 7.48 
(m, 2H), 7.40 – 7.32 (m, 1H), 7.05 – 6.99 (m, 1H), 3.73 (s, 2H). 13C NMR (101 MHz, 
 
CDCl3) δ 167.23, 162.64, 151.12, 147.96, 146.34, 138.49, 135.47, 135.01, 134.05, 
 
133.44, 132.56, 131.66, 131.15, 127.73, 127.03, 120.48, 120.20, 118.56, 114.21, 39.73. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-nitrobenzoate. 
 
Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.35 (s, 1H), 8.68 (dd, J = 8.6, 1.3 
Hz, 1H), 8.13 (dd, J = 8.5, 1.2 Hz, 1H), 8.10 (dd, J = 7.4, 1.6 Hz, 1H), 8.01 (dd, J = 7.8, 
1.4 Hz, 1H), 7.79 (d, 1H), 7.77 – 7.69 (m, 2H), 7.63 (d, 1H), 7.62 – 7.56 (m, 1H), 7.20 – 
132  
7.12 (m, 1H), 3.96 (s, 2H). 
13
C NMR (101 MHz, CDCl3) δ 167.90, 162.39, 147.98, 
145.87, 136.78, 135.86, 135.52, 134.37, 134.16, 133.47, 132.80, 131.18, 130.53, 126.30, 
 
125.74, 124.55, 123.71, 122.51, 120.82, 118.26, 39.85. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl benzoate. 
 
Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.34 (s, 1H), 8.70 (dd, J = 8.5, 1.3 
Hz, 1H), 8.18 – 8.12 (m, 3H), 7.81 (d, J = 2.2 Hz, 1H), 7.67 – 7.57 (m, 3H), 7.49 – 7.41 
(m, 2H), 7.22 – 7.15 (m, 1H), 3.74 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.85, 
163.71, 136.07, 135.65, 134.50, 134.45, 133.57, 130.85, 130.64, 128.87, 127.94, 125.86, 
123.76, 122.23, 120.28, 40.83. POSSIBLY MISSING SOME Ar 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2- 
methoxybenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2- 
((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the 
desired product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.29 (s, 1H), 8.70 (dd, J = 
8.5, 1.3 Hz, 1H), 8.15 (dd, J = 8.4, 1.6 Hz, 1H), 8.02 (dd, J = 7.8, 1.8 Hz, 1H), 7.80 (d, J 
= 2.3 Hz, 1H), 7.66 – 7.47 (m, 3H), 7.21 – 7.11 (m, 1H), 7.03 – 6.91 (m, 2H), 3.86 (s, 
 
3H), 3.80 (s, 2H). 
13
C NMR (101 MHz, CDCl3) δ 168.09, 162.72, 160.18, 146.93, 
136.61, 135.95, 135.60, 135.16, 134.51, 133.54, 132.69, 130.81, 125.82, 123.71, 122.36, 
 
120.40, 120.06, 119.02, 117.52, 112.24, 56.10, 40.65. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-iodobenzoate. 
 
Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
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nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.33 (s, 1H), 8.70 (dt, J = 8.5, 1.2 
Hz, 1H), 8.23 – 8.13 (m, 2H), 8.05 (dt, J = 7.9, 1.2 Hz, 1H), 7.82 (dd, J = 2.4, 1.1 Hz, 
1H), 7.65 – 7.57 (m, 2H), 7.47 – 7.39 (m, 1H), 7.26 – 7.13 (m, 2H), 3.80 (d, J = 1.0 Hz, 
 
2H). 
13
C NMR (101 MHz, CDCl3) δ 167.72, 162.75, 142.23, 141.98, 136.02, 135.78, 
135.03, 134.46, 134.11, 133.74, 132.34, 132.11, 130.68, 129.74, 128.30, 125.88, 123.80, 
 
122.38, 120.54, 118.79, 40.81. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3,5-difluoro-2- 
nitrobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.34 (s, 1H), 8.67 (dd, J = 8.6, 1.3 
Hz, 1H), 8.17 (dd, J = 8.5, 1.6 Hz, 1H), 7.80 (d, J = 2.3 Hz, 1H), 7.75 – 7.71 (m, 1H), 
7.67 – 7.59 (m, 2H), 7.32 – 7.26 (m, 1H), 7.23 – 7.17 (m, 1H), 3.78 (s, 2H). 13C NMR 
 
(101 MHz, CDCl3) δ 167.34, 164.11, 163.99, 158.86, 153.63, 145.64, 136.72, 136.08, 
 
135.78, 134.30, 134.10, 133.52, 130.58, 125.85, 123.94, 122.42, 121.33, 118.13, 114.64, 
 
110.54, 40.37. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromo-3- 
fluoro-5-nitrobenzoate. Prepared according to the procedure provided for 2,4-dibromo- 
6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of 
the desired product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.39 (s, 1H), 8.80 (dd, 
J = 2.6, 1.5 Hz, 1H), 8.70 (dd, J = 8.5, 1.3 Hz, 1H), 8.21 – 8.15 (m, 2H), 7.86 (d, J = 2.3 
Hz, 1H), 7.67 – 7.60 (m, 2H), 7.23 – 7.16 (m, 1H), 3.80 (s, 2H). 13C NMR (101 MHz, 
 
CDCl3) δ 167.40, 161.16, 160.05, 158.65, 147.33, 146.06, 136.24, 136.01, 134.32, 
134  
134.00, 132.53, 130.44, 125.94, 124.02, 122.51, 122.19, 121.25, 118.48, 115.32, 115.04, 
 
41.16. 
 
(S)-2,4-dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl 
2-chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2- 
((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the 
desired product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.21 (dd, J = 7.9, 1.2 Hz, 
1H), 7.77 (dd, J = 2.3, 1.2 Hz, 1H), 7.59 – 7.53 (m, 3H), 7.47 – 7.40 (m, 1H), 6.18 (s, 
1H), 4.55 – 4.35 (m, 2H), 4.29 – 4.14 (m, 1H), 3.61 (s, 2H), 2.76 – 2.61 (m, 1H), 2.16 – 
 
1.99 (m, 1H). 
13
C NMR (101 MHz, CDCl3) δ 174.76, 169.16, 135.45, 135.02, 134.32, 
133.47, 132.70, 131.78, 131.23, 127.48, 127.21, 120.57, 118.45, 66.07, 49.53, 38.19, 
 
29.81. 
 
2,4-dibromo-6-(2-((3-nitropyridin-4-yl)amino)-2-oxoethyl)phenyl 2- 
chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.50 (s, 1H), 9.33 (s, 1H), 8.67 (s, 
2H), 8.13 (dd, 1H), 7.86 (d, J = 2.2 Hz, 1H), 7.59 (d, J = 2.3 Hz, 1H), 7.56 – 7.47 (m, 
2H), 7.41 – 7.34 (m, 1H), 3.84 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 168.31, 162.10, 
156.31, 155.69, 136.16, 134.22, 133.69, 132.54, 131.72, 129.85, 129.27, 128.07, 127.41, 
 
127.06, 120.70, 118.99, 114.62, 40.90. 
 
2,4-dibromo-6-(2-oxo-2-(pyrimidin-4-ylamino)ethyl)phenyl 2-chlorobenzoate. 
 
Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
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product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.83 (s, 1H), 8.61 (s, 1H), 8.34 (s, 
1H), 8.21 – 8.14 (m, 1H), 8.10 (dd, J = 5.8, 1.2 Hz, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.57 (d, 
J = 2.4 Hz, 1H), 7.55 – 7.52 (m, 2H), 7.42 – 7.36 (m, 1H), 3.76 (s, 2H). 13C NMR (101 
 
MHz, CDCl3) δ 168.19, 162.98, 158.59, 158.49, 156.87, 146.25, 135.79, 135.03, 134.27, 
 
133.32, 132.57, 131.73, 130.43, 127.54, 127.12, 120.67, 118.71, 110.42, 39.79. 
 
2-(3,5-dibromo-2-((2,6-dichlorobenzyl)oxy)phenyl)-N-(2- 
nitrophenyl)acetamide. Prepared according to the procedure provided for 2,4-dibromo- 
6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of 
the desired product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.13 (s, 1H), 8.62 (dd, 
J = 8.6, 1.3 Hz, 1H), 8.13 (dd, J = 8.5, 1.6 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.59 – 7.51 
(m, 1H), 7.34 (d, J = 2.4 Hz, 1H), 7.25 – 7.21 (m, 2H), 7.17 – 7.07 (m, 2H), 5.45 (s, 2H), 
 
3.54 (s, 2H). 
13
C NMR (101 MHz, CDCl3) δ 168.67, 153.71, 137.34, 136.56, 136.06, 
135.91, 134.66, 133.49, 132.13, 131.17, 131.00, 128.81, 125.79, 123.52, 122.35, 118.51, 
 
117.84, 70.16, 39.81. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,5- 
dichloroisonicotinate. Prepared according to the procedure provided for 2,4-dibromo-6- 
(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the 
desired product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.39 (s, 1H), 8.68 (dd, J = 
8.5, 1.3 Hz, 1H), 8.54 (s, 1H), 8.19 (dd, J = 8.5, 1.6 Hz, 1H), 7.95 (d, J = 0.7 Hz, 1H), 
7.85 (d, J = 2.2 Hz, 1H), 7.68 – 7.59 (m, 2H), 7.24 – 7.16 (m, 1H), 3.79 (s, 2H). 13C 
 
NMR (101 MHz, CDCl3) δ 167.37, 165.04, 151.43, 150.39, 145.91, 143.70, 142.51, 
 
138.80, 136.25, 135.99, 134.28, 133.96, 130.32, 125.99, 125.67, 124.04, 122.13, 121.27, 
 
118.40, 40.97. 
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2,4-dibromo-6-(2-((2,3-difluorophenyl)amino)-2-oxoethyl)phenyl 2- 
chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, Acetone-d6) δ 9.17 (s, 1H), 8.11 (dd, J = 7.9, 
1.6 Hz, 1H), 7.80 (t, J = 7.4 Hz, 1H), 7.76 (d, J = 2.3 Hz, 1H), 7.65 (d, J = 2.3 Hz, 1H), 
7.57 – 7.46 (m, 2H), 7.38 – 7.31 (m, 1H), 7.03 – 6.94 (m, 1H), 6.94 – 6.85 (m, 1H), 3.86 
 
(s, 2H). 
13
C NMR (101 MHz, CDCl3) δ 167.08, 162.99, 146.01, 135.52, 135.05, 134.31, 
133.18, 133.15, 132.57, 131.73, 131.12, 127.83, 127.46, 127.13, 124.21, 120.63, 118.48, 
 
117.08, 112.62, 112.45, 39.66. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3,6- 
dichloropicolinate. Prepared according to the procedure provided for 2,4-dibromo-6-(2- 
((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the 
desired product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.38 (s, 1H), 8.67 (dd, J = 
8.5, 1.8 Hz, 1H), 8.17 (dd, 1H), 7.83 – 7.78 (m, 2H), 7.65 – 7.58 (m, 2H), 7.46 (dd, J = 
8.5, 1.4 Hz, 1H), 7.22 – 7.14 (m, 1H), 3.85 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 
167.62, 159.73, 149.38, 146.28, 144.97, 141.72, 140.81, 139.18, 136.94, 135.92, 135.78, 
 
134.41, 133.85, 130.49, 128.73, 125.81, 123.86, 122.75, 120.80, 40.42. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 5-fluoro-2- 
nitrobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.36 (s, 1H), 8.68 (dd, J = 8.5, 1.3 
Hz, 1H), 8.18 – 8.10 (m, 2H), 7.81 (d, J = 2.3 Hz, 1H), 7.75 (dd, J = 7.7, 2.7 Hz, 1H), 
7.64 (d, J = 2.3 Hz, 1H), 7.64 – 7.58 (m, 1H), 7.43 – 7.34 (m, 1H), 7.20 – 7.13 (m, 1H), 
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3.98 (s, 2H). 
13
C NMR (101 MHz, CDCl3) δ 167.86, 166.07, 161.41, 145.64, 135.93, 
135.62, 134.41, 134.33, 131.20, 127.63, 127.53, 125.81, 123.78, 122.53, 121.10, 119.49, 
 
119.25, 118.20, 117.96, 117.70, 39.87. 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromo-4- 
fluorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 10.34 (s, 1H), 8.69 (dd, J = 8.5, 1.3 
Hz, 1H), 8.17 (dd, J = 8.5, 1.5 Hz, 1H), 7.99 – 7.92 (m, 1H), 7.83 (d, J = 2.3 Hz, 1H), 
7.63 – 7.58 (m, 2H), 7.45 – 7.30 (m, 2H), 7.22 – 7.15 (m, 1H), 3.81 (s, 2H). 13C NMR 
 
(101 MHz, CDCl3) δ 167.64, 161.84, 146.40, 138.59, 136.55, 136.08, 135.85, 134.37, 
 
133.80, 131.53, 130.52, 128.88, 128.80, 127.94, 125.89, 123.88, 122.26, 120.84, 120.60, 
 
118.68, 40.80. 
 
2,4-dibromo-6-(2-((3-nitrophenyl)amino)-2-oxoethyl)phenyl 2- 
chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.41 (t, J = 2.2 Hz, 1H), 8.26 (d, J = 
7.4 Hz, 1H), 8.02 (s, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.81 (d, J = 
2.3 Hz, 1H), 7.62 (d, J = 2.3 Hz, 1H), 7.60 – 7.53 (m, 2H), 7.51 – 7.38 (m, 2H), 3.74 (s, 
 
2H). 
 
2,4-dibromo-6-(2-((4-nitrophenyl)amino)-2-oxoethyl)phenyl 2- 
chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-(2-((2- 
nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
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product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.26 (dd, J = 8.1, 1.5 Hz, 1H), 8.20 
– 8.15 (m, 2H), 8.14 (s, 1H), 7.81 (d, J = 2.3 Hz, 1H), 7.74 – 7.67 (m, 2H), 7.64 – 7.54 
 
(m, 3H), 7.50 – 7.42 (m, 1H), 3.74 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.37, 
164.71, 145.84, 143.77, 143.73, 135.85, 135.35, 134.81, 133.17, 132.76, 131.93, 130.93, 
127.32, 127.00, 125.08, 121.14, 119.31, 118.63, 39.64. 
 
2,4-dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl 4- 
(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoate. Prepared according to the procedure 
provided for 2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2- 
chlorobenzoate, affording XX mg of the desired product (XX% yield). 
1
H NMR (400 
MHz, Chloroform-d) δ 7.67 (d, J = 2.3 Hz, 1H), 7.58 (d, J = 2.3 Hz, 1H), 7.14 (s, 1H), 
6.77 (s, 2H), 4.59 – 4.48 (m, 1H), 4.44 (t, 1H), 4.32 – 4.21 (m, 1H), 3.77 – 3.64 (m, 2H), 
 
2.89 – 2.79 (m, 1H), 2.84 – 2.67 (m, 2H), 2.20 – 2.01 (m, 2H). 13C NMR (101 MHz, 
 
Chloroform-d) δ 175.30, 171.77, 170.42, 169.82, 134.90, 134.56, 134.06, 131.72, 120.02, 
 
66.36, 49.73, 37.50, 36.68, 31.16, 30.62, 30.51, 23.69. 
 
2,4-dibromo-6-((2-nitrobenzamido)methyl)phenyl 2-chlorobenzoate. To 2- 
(benzyloxy)-3,5-dibromophenyl)methanamine (64.0 mg, 0.173 mmol) in CH2Cl2 (3.45 
mL, 0.05 M) under N2 was added 2-nitrobenzoyl chloride (35.5 mg, 0.191 mmol), 
followed by Et3N (58 µL, 0.415 mmol) and then DMAP (2.1 mg, 0.0173 mmol). The 
mixture was allowed to stir overnight at room temperature and then was diluted with 
CH2Cl2 (50 mL) and washed with HCl (25 mL, 1 M), sat. NaHCO3 (25 mL) and then 
brine (25 mL). After drying over Na2SO4, the material was purified via silica-gel flash 
chromatography, affording XX mg of the desired product (XX% yield). 
1
H and 
13
C-NMR 
match previously published spectra. 
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2,4-dibromo-6-(picolinamidomethyl)phenyl 2-chlorobenzoate. Prepared 
according to the procedure provided for 2,4-dibromo-6-((2 
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.54 (dd, J = 4.7, 1.4 Hz, 1H), 8.45 
(s, 1H), 8.21 (dd, J = 7.8, 1.1 Hz, 1H), 8.15 (dd, J = 7.8, 1.1 Hz, 1H), 7.84 (td, J = 7.8, 
1.8 Hz, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.58 (d, J = 2.3 Hz, 1H), 7.54 (d, 2H), 7.46 – 7.39 
 
(m, 2H), 4.66 (d, J = 6.1 Hz, 2H). 
13
C NMR (101 MHz, CDCl3) δ 164.56, 162.48, 149.41, 
148.35, 145.84, 137.52, 135.04, 134.94, 133.99, 132.61, 131.78, 131.65, 127.89, 127.00, 
 
126.59, 122.51, 120.33, 118.12, 38.74. 
 
2,4-dibromo-6-(((2-nitrophenyl)sulfonamido)methyl)phenyl 2- 
nitrobenzenesulfonate. Prepared according to the procedure provided for 2,4-dibromo- 
6-((2 nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.16 (dd, 1H), 8.08 – 8.05 (m, 1H), 
7.94 – 7.87 (m, 3H), 7.84 – 7.78 (m, 1H), 7.76 – 7.72 (m, 2H), 7.71 (d, J = 2.3 Hz, 1H), 
7.61 (d, J = 2.3 Hz, 1H), 6.21 (s, 1H), 4.48 (s, 2H). 
13
C NMR (101 MHz, CDCl3) δ 
147.80, 144.20, 136.18, 136.13, 135.12, 133.99, 133.51, 133.35, 133.14, 132.85, 131.98, 
 
131.00, 129.61, 125.78, 125.51, 121.88, 118.12, 43.26. 
 
2,4-dibromo-6-(picolinamidomethyl)phenyl 4-(2,5-dioxo-2,5-dihydro-1H- 
pyrrol-1-yl)butanoate. Prepared according to the procedure provided for 2,4-dibromo-6- 
((2 nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.53 (dd, J = 4.8, 1.3 Hz, 1H), 8.41 
(s, 1H), 8.19 (dd, J = 7.8, 1.2 Hz, 1H), 7.86 (td, J = 7.7, 1.7 Hz, 1H), 7.66 (d, J = 2.3 Hz, 
1H), 7.53 (d, J = 2.3 Hz, 1H), 7.47 – 7.39 (m, 1H), 6.72 (s, 2H), 4.59 (d, J = 6.4 Hz, 2H), 
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3.68 (t, J = 6.7 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.10 – 1.98 (m, 2H). 13C NMR (101 
 
MHz, CDCl3) δ 170.94, 170.02, 164.39, 149.49, 148.32, 146.02, 137.56, 134.94, 134.82, 
 
134.31, 132.05, 126.56, 122.53, 119.96, 118.15, 38.75, 36.98, 31.20, 23.79. 
 
2,4-dibromo-6-(picolinamidomethyl)phenyl 2-nitrobenzoate. Prepared 
according to the procedure provided for 2,4-dibromo-6-((2 
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.58 (t, J = 6.5 Hz, 1H), 8.55 – 8.50 
(m, 1H), 8.19 – 8.12 (m, 2H), 8.02 (dd, J = 7.7, 1.5 Hz, 1H), 7.86 – 7.71 (m, 3H), 7.70 (d, 
J = 2.3 Hz, 1H), 7.64 (d, J = 2.3 Hz, 1H), 7.44 – 7.39 (m, 1H), 4.75 (d, J = 6.5 Hz, 2H). 
 
13
C NMR (101 MHz, CDCl3) δ 164.74, 162.45, 149.46, 148.36, 148.18, 145.10, 137.43, 
135.61, 134.89, 133.39, 132.90, 132.19, 130.74, 126.50, 126.17, 124.46, 122.42, 120.79, 
 
117.70, 38.39. 
 
2,4-dibromo-6-((2-nitrobenzamido)methyl)phenyl 2-nitrobenzoate. Prepared 
according to the procedure provided for 2,4-dibromo-6-((2 
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.17 (dd, J = 7.5, 1.6 Hz, 1H), 8.00 
(td, J = 7.8, 1.3 Hz, 2H), 7.84 (d, J = 2.4 Hz, 1H), 7.83 – 7.75 (m, 2H), 7.75 (d, J = 2.3 
Hz, 1H), 7.64 (td, J = 7.5, 1.3 Hz, 1H), 7.59 – 7.47 (m, 2H), 6.63 (t, J = 6.1 Hz, 1H), 4.68 
 
(s, 2H). 
13
C NMR (101 MHz, CDCl3) δ 166.66, 162.90, 148.28, 146.81, 145.30, 135.43, 
134.56, 133.79, 133.72, 133.62, 133.15, 132.31, 130.88, 130.82, 128.80, 126.00, 124.70, 
 
124.53, 121.00, 117.52, 39.06. 
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2,4-dibromo-6-((2,3-difluorobenzamido)methyl)phenyl 2-chlorobenzoate. 
 
Prepared according to the procedure provided for 2,4-dibromo-6-((2 
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.21 (dd, 1H), 7.81 – 7.73 (m, 2H), 
7.62 (d, J = 2.3 Hz, 1H), 7.57 – 7.53 (m, 2H), 7.46 – 7.40 (m, 1H), 7.36 – 7.27 (m, 1H), 
7.21 – 7.14 (m, 1H), 7.04 (t, J = 11.4 Hz, 1H), 4.66 (s, 2H). 13C NMR (101 MHz, CDCl3) 
δ 162.73, 162.47, 145.94, 135.36, 134.98, 134.44, 134.12, 132.55, 132.25, 131.69, 
 
127.75, 127.09, 126.60, 126.57, 124.78, 124.72, 120.83, 120.65, 120.43, 118.16, 39.40. 
 
2,4-dibromo-6-((2-chloro-N-((2- 
nitrophenyl)sulfonyl)benzamido)methyl)phenyl 2-chlorobenzoate. Prepared 
according to the procedure provided for 2,4-dibromo-6-((2 
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.33 (dd, J = 7.9, 1.5 Hz, 1H), 8.12 
(dd, J = 7.6, 1.1 Hz, 1H), 7.87 (dd, J = 7.9, 1.5 Hz, 1H), 7.80 (td, J = 7.6, 1.5 Hz, 1H), 
7.76 – 7.69 (m, 2H), 7.57 – 7.51 (m, 3H), 7.46 – 7.39 (m, 1H), 7.37 – 7.30 (m, 1H), 7.24 
 
(dd, J = 8.2, 1.1 Hz, 1H), 7.18 (td, J = 7.5, 1.2 Hz, 1H), 7.15 – 7.10 (m, 1H), 5.08 (s, 2H). 
 
13
C NMR (101 MHz, CDCl3) δ 167.61, 165.85, 161.99, 148.04, 145.12, 135.52, 135.35, 
135.32, 134.91, 133.83, 133.26, 133.21, 132.52, 132.35, 132.01, 131.90, 131.45, 131.07, 
 
130.07, 127.98, 126.95, 126.86, 126.86, 125.08, 120.26, 118.13, 77.48, 77.16, 76.84, 
 
47.29. 
 
2,4-dibromo-6-(((2-nitrophenyl)sulfonamido)methyl)phenyl 2- 
chlorobenzoate. Prepared according to the procedure provided for 2,4-dibromo-6-((2 
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
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product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.22 (dd, 1H), 8.00 – 7.87 (m, 2H), 
7.86 – 7.80 (m, 2H), 7.66 (d, J = 2.4, 1.0 Hz, 1H), 7.64 (dd, 1H), 7.41 – 7.27 (m, 2H), 
7.06 (t, J = 6.4 Hz, 1H), 4.78 (d, J = 6.4 Hz, 2H). 
13
C NMR (101 MHz, CDCl3) δ 166.97, 
148.57, 144.57, 136.76, 136.07, 135.78, 134.50, 133.77, 132.81, 131.94, 131.64, 131.05, 
 
130.45, 130.14, 129.87, 127.19, 125.50, 121.89, 117.98, 39.45. 
 
2,4-dibromo-6-(nicotinamidomethyl)phenyl 2-chlorobenzoate. Prepared 
according to the procedure provided for 2,4-dibromo-6-((2 
nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording XX mg of the desired 
product (XX% yield). 
1
H NMR (400 MHz, CDCl3) δ 8.97 (s, 1H), 8.71 (s, 1H), 8.21 (dd, 
1H), 8.07 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 2.3 Hz, 1H), 7.62 (d, J = 2.3 Hz, 1H), 7.58 – 
7.50 (m, 2H), 7.47 – 7.39 (m, 1H), 7.39 – 7.33 (m, 1H), 6.80 (t, 1H), 4.63 (s, 2H). 13C 
 
NMR (101 MHz, CDCl3) δ 165.40, 163.37, 152.55, 148.24, 146.10, 135.58, 135.21, 
 
135.00, 134.32, 132.79, 132.64, 131.74, 127.52, 127.17, 123.63, 120.52, 118.19, 39.50. 
 
2,4-dibromo-6-((pyrimidine-4-carboxamido)methyl)phenyl 2-chlorobenzoate. 
 
1
H NMR (400 MHz, Chloroform-d) δ 9.22 (d, J = 1.4 Hz, 1H), 8.96 (d, J = 5.0 Hz, 1H), 
 
8.38 (t, 1H), 8.20 (d, 1H), 8.06 (d, 1H), 7.76 (d, J = 2.3 Hz, 1H), 7.61 – 7.52 (m, 2H), 
 
7.48 – 7.38 (m, 1H), 4.66 (d, J = 6.3 Hz, 2H). 13C NMR (101 MHz, Chloroform-d) δ 
 
162.91, 162.64, 159.41, 157.96, 155.96, 146.08, 135.49, 134.27, 134.21, 132.72, 132.17, 
 
131.77, 127.84, 127.15, 126.84, 120.46, 118.87, 118.39, 39.10. 
 
2,4-dibromo-6-(((2-cyanophenyl)sulfonamido)methyl)phenyl 2- 
 
chlorobenzoate. 
1
H NMR (400 MHz, Chloroform-d) δ 8.23 – 8.14 (m, 1H), 8.01 – 7.94 
 
(m, 1H), 7.89 – 7.82 (m, 3H), 7.69 – 7.60 (m, 2H), 7.39 – 7.32 (m, 2H), 7.12 (t, J = 6.5 
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Hz, 1H), 4.86 (d, J = 6.4 Hz, 2H), 4.53 (s, 1H). 
13
C NMR (101 MHz, Chloroform-d) δ 
 
167.17, 144.43, 138.58, 137.11, 135.84, 135.76, 134.98, 134.71, 134.03, 133.45, 131.72, 
 
131.20, 130.68, 130.54, 130.22, 127.29, 122.06, 117.78, 115.37, 112.35, 39.61. 
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(2-(benzyloxy)-3,5-dibromophenyl)methanamine 
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N-(2-(benzyloxy)-3,5-dibromobenzyl)-2-nitrobenzamide 
 
 
 
146 
 
N-(3,5-dibromo-2-hydroxybenzyl)-2-nitrobenzamide 
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2-(2-methoxyphenyl)-N-(2-nitrophenyl)acetamide 
 
 
148 
 
2-(2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide 
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2-(3,5-dibromo-2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3-chlorobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-chlorobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3-bromobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-bromobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-fluorobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-fluorobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-methylbenzoate 
 
 
 
159 
 
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3-methylbenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-methylbenzoate 
 
 
 
 
 
 
 
161  
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,6-dichlorobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,6-dibromobenzoate 
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2,4-dibromo-6-(2-((4,5-difluoro-2-nitrophenyl)amino)-2-oxoethyl)phenyl 2- 
chlorobenzoate 
 
 
 
164  
2,4-dibromo-6-(2-oxo-2-(pyridin-2-ylamino)ethyl)phenyl 2-chlorobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-nitrobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl benzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-methoxybenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-iodobenzoate 
 
 
169  
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3,5-difluoro-2- 
nitrobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromo-3-fluoro-5- 
nitrobenzoate 
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(S)-2,4-dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl 2- 
chlorobenzoate 
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2,4-dibromo-6-(2-((3-nitropyridin-4-yl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate 
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2,4-dibromo-6-(2-oxo-2-(pyrimidin-4-ylamino)ethyl)phenyl 2-chlorobenzoate 
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2-(3,5-dibromo-2-((2,6-dichlorobenzyl)oxy)phenyl)-N-(2-nitrophenyl)acetamide 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,5- 
dichloroisonicotinate 
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2,4-dibromo-6-(2-((2,3-difluorophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate 
 
 
177  
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3,6-dichloropicolinate 
 
 
 
178  
2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 5-fluoro-2- 
nitrobenzoate 
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2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromo-4- 
fluorobenzoate. 
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2,4-dibromo-6-(2-((3-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate 
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2,4-dibromo-6-(2-((4-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate 
 
 
182  
2,4-dibromo-6-(picolinamidomethyl)phenyl 2-chlorobenzoate 
 
 
 
183  
2,4-dibromo-6-(((2-nitrophenyl)sulfonamido)methyl)phenyl 2-nitrobenzenesulfonate 
 
 
184  
2,4-dibromo-6-(picolinamidomethyl)phenyl 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1- 
yl)butanoate. 
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2,4-dibromo-6-(picolinamidomethyl)phenyl 2-nitrobenzoate 
 
 
 
186  
2,4-dibromo-6-((2-nitrobenzamido)methyl)phenyl 2-nitrobenzoate 
 
 
187  
2,4-dibromo-6-((2,3-difluorobenzamido)methyl)phenyl 2-chlorobenzoate 
 
188  
2,4-dibromo-6-((2-chloro-N-((2-nitrophenyl)sulfonyl)benzamido)methyl)phenyl 2- 
chlorobenzoate 
 
 
189  
2,4-dibromo-6-(((2-nitrophenyl)sulfonamido)methyl)phenyl 2-chlorobenzoate 
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Chapter 5 
 
Lipoxin A4 augments host defense in sepsis and reduces P. aeruginosa virulence 
through quorum sensing inhibition 
 
Introduction 
In bacterial infections, signaling through pathogen associated molecular pattern 
(PAMP) recognition receptors activate the innate immune system
1
. The subsequent 
increased release of inflammatory mediators such as cytokines, arachidonic acid 
metabolites and free radicals is critical for bacterial clearance, but if sustained, can cause 
tissue injury, multiple organ failure and death. Alternatively, a sustained inflammatory 
response may lead to a delayed dysregulation of inflammatory response, characterized by 
an inability of populations of lymphocytes and/or monocytes/macrophages to secrete 
inflammatory cytokines when stimulated
2-7
. In this immunocompromised condition, the 
host is susceptible to opportunistic infections or cannot clear preexisting infections. It is 
important to resolve infection as continued bacterial load will cause persistent pro- 
inflammatory or dysregulated inflammatory response without returning to homeostasis. 
 
Therefore, an appropriate infection resolution can be defined as one which clears 
the infectious agent without causing tissue injury and/or an immunosuppressed state. The 
role of neutrophils in severe infections is complex. Neutrophils are first activated to 
combat the infectious agent. They migrate to the site of infection, release a host of pro- 
inflammatory mediators such as free radicals and leukotrienes, phagocytose bacteria 
before dying by apoptosis. Sustained neutrophil activation however can cause tissue 
injury and organ damage
8-10
. On the other hand, a paradoxical dysregulation in neutrophil 
function can also occur in later phases of severe infections/sepsis
11-14
. Indeed, insufficient 
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neutrophil phagocytic activity and impaired neutrophil migration is an indicator of poor 
outcome in sepsis
12,15,16
. 
Inflammation resolution is an active process which involves inhibition of 
neutrophil activation, increased macrophage recruitment and macrophage phagocytosis of 
apoptotic neutrophils
17-19
. Specialized pro-resolving mediators (SPMs) such as the 
Lipoxins and Resolvins have been shown to resolve inflammation in sterile models of 
inflammation
20-23 
while reducing inflammatory response and bacterial load in various 
infectious models
24-30
. We have previously reported that Lipoxin A4 (LXA4) reduced 
blood bacterial load, decreased systemic inflammatory response and increased survival in 
the cecal ligation puncture (CLP) model of polymicrobial sepsis
29,30
. LXA4 increased 
bacterial clearance at least partially through promotion of neutrophil phagocytic 
function
31
. Fcg receptor I (FcgRI;CD64) is an important neutrophil receptor in 
infection
15,16,32 
where it functions to increase uptake of bacteria
33,35
. As increased 
expression has been reported to be a prognosticator of good outcome in sepsis
15
, we 
investigated if LXA4 promoted neutrophil phagocytic activity through stimulation of 
FcgRI mediated phagocytosis. 
During infection, in addition to host signaling pathways regulating inflammatory 
response there are also separate chemical regulatory pathways at work in the bacterial 
pathogen that are critical for the establishment and propagation of the infection. This 
bacterial population density-dependent process of chemical signaling is called quorum 
sensing (QS). The process of QS involves the bacterial production, release and detection 
of structurally specific small molecules and enables the bacterial pathogen to regulate its 
virulence by switching on genes that increase biofilm formation, toxin release and/or 
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antibiotic resistance
36,43
. As anti-inflammatory agents may cause immunosuppression 
where the host is not able to clear pathogen and standard antibiotics do not affect 
inflammatory response, the most efficient treatment modality for severe bacterial 
infections would be to resolve inflammation and reduce bacterial virulence. 
A large number of structurally distinct QS molecules in both gram-negative and 
gram-positive bacteria have been identified including oligopeptides, acylhomoserine 
lactones (AHLs), the furanosyl borate ester (AI-2), and a-amino/hydroxy ketones
36,44
.  
The gram-negative bacteria pathogen, Pseudomonas aeruginosa utilizes at least three 
separate chemical signals in its regulation of a diverse array of virulence factors such as 
pyocyanin, elastase, HCN, rhamnolipids and biofilms. This network of QS regulation is 
arranged hierarchically with the LasR quorum sensing receptor which recognizes the 
AHL signaling molecule, N-3-oxododecanolyl homoserine lactone (3-oxo-C12 HSL) as 
its native agonist representing the master QS circuit in this bacteria
41
. Binding of 3-oxo- 
C12  HSL  to  the  LasR  QS  receptor  results  in  the  activation/repression  of  numerous 
downstream genes through the action of the ligand-bound LasR as a transcription factor 
which upregulates the expression of virulence factors. Due to the central role of LasR in 
the virulence of this bacteria, inhibition of QS signaling in P. aeruginosa represents a 
novel target to reduce bacterial virulence
45,46
. As some synthetic inhibitors/activators of 
LasR have similar chemical structure to LXA4, we reasoned that LXA4 may have quorum 
sensing inhibitory activity. 
In this study, we investigated if the SPM, LXA4, could modulate FcgRI mediated 
phagocytosis of neutrophils in the CLP model of sepsis. Additionally, we examined if 
LXA4 could interfere with bacteria signaling and reduce virulence. The goal of the   study 
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was to elucidate if LXA4 has the unique property of modulating both host defense to 
increase bacterial clearance as well as reduce pathogen virulence. Such a compound  
could contribute a therapeutic advantage as an antimicrobial. 
Results 
 
Blood bacterial load: There is clear evidence of bacterial infection in the blood 
of CLP mice (Figure 1). LXA4 (7 mg/kg) given 1h after CLP surgery reduced bacterial 
load significantly. 
Neutrophil apoptosis and free radical production: Decreased neutrophil 
apoptosis as a result of infection has been well established
51-53
. This increased life span of 
neutrophils with attendant overproduction of inflammatory mediators is thought to 
contribute to tissue injury associated with severe infections and sepsis
8-10,51-53
. In our 
studies, blood leukocytes were isolated 24h after surgery from sham controls, CLP mice 
given vehicle saline or CLP + LXA4 mice. The leukocytes were stained with  the 
apoptosis marker Annexin V and Gr-1 as a marker for neutrophils. Neutrophil apoptosis 
significantly decreased at 24h after CLP surgery compared to sham controls (Figure 2a). 
LXA4 completely reversed the decreased neutrophil apoptosis in CLP mice. Neutrophil 
ability to produce free radicals was evaluated by measuring the superoxide mediated 
oxidation of non-fluorescent DHR 123 to the fluorescent rhodamine 123 after PMA 
stimulation. CLP reduced neutrophil free radical generation ability and LXA4 
administration did not further affect superoxide generation after CLP (Figure 2b). 
Neutrophil phagocytic ability and CD64 expression: As neutrophil phagocytic 
ability is essential for bacterial clearance, we evaluated the effect of LXA4 on neutrophil 
ability  to  engulf  fluorescently  labeled  E.coli  in  sham  control  or  septic  mice.  Blood 
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leukocytes were isolated from sham controls, CLP or CLP + LXA4 treated mice, 24h  
after surgery. Cells were incubated with pHrodo E.coli for 1h before being stained with 
fluorescent Gr-1 antibody to label neutrophils. Blood neutrophils from CLP mice had 
greater phagocytic ability compared to sham controls and LXA4 administration increased 
phagocytic ability further (Figure 3a). As CD64 is a high affinity receptor which is 
critically important in the initiation of neutrophil phagocytosis, its expression was 
measured. We also measured the expression of FcgRIII and II using CD16/32 mouse 
antibodies. CLP increased the percentage of CD64 expressing neutrophils compared to 
sham controls and LXA4 increased this further. CD16/32 expression was not affected by 
CLP or LXA4 (Figure 3b). 
CD64 blocking antibody studies: To confirm that CD64 is important in the 
LXA4 induced increase in neutrophil phagocytosis, we incubated leukocytes with CD64 
blocking antibody or vehicle saline. The results show that CD64 antibody completely 
abolished LXA4-induced increase in phagocytosis (Figure 4) suggesting that the LXA4 
induced increase in neutrophil phagocytosis is mediated by CD64. 
Ex vivo studies: To investigate if LXA4 increased neutrophil phagocytosis 
directly, we isolated leukocytes from CLP or sham control mice 1h after surgery and 
incubated these cells with LXA4 or vehicle saline for 3h before addition of fluorescent 
E.coli to measure phagocytic ability. To confirm the specificity of LXA4, some cells were 
incubated with WRW4 a specific blocker of the LXA4 formyl peptide receptor 2 
(FPR2)(54). As expected, CLP mice had substantially greater percentage of neutrophils 
which expressed CD64 compared to sham controls (Figure 5a). Interestingly, LXA4 did 
not increase the percentage of neutrophils expressing CD64. This is in contrast to the in 
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vivo actions of LXA4 which significantly increased the percentage of CD64 expressing 
cells. These data suggest that LXA4 does not directly promote neutrophil CD64 
expression. In CLP mice, LXA4 increased neutrophil phagocytosis and this increase was 
completely abolished by the specific LXA4 receptor antagonist (Figure 5b). LXA4 
however, had no effect on phagocytic ability of control neutrophils where there was 
minimal CD64 expression (Figure 5c). Taken together with CD64 data, the results  
support the postulate that LXA4 increases CD64-dependent neutrophil phagocytosis but 
does not directly increase expression of CD64. 
Inhibition of pyocyanin expression by LXA4: To evaluate if LXA4 directly 
influences bacterial virulence we evaluated expression levels of the exotoxin, pyocyanin, 
in the prominent bacterial pathogen P. aeruginosa (PA-14)
55
. While absorbance based 
methods for the quantification of pyocyanin have been reported, we found this assay to  
be complicated by low detection limit and requirement for multiple sample manipulation 
steps. Accordingly, we utilized a UPLC-MS-MS based approach to determine the 
concentration of pyocyanin in bacterial cultures. This method provides direct ion    counts 
of the molecular ion for pyocyanin after UPLC separation from other culture constituents 
and the identity of pyocyanin is further confirmed through analysis of the fragmentation 
pattern of the isolated molecular ion. Further, no mathematical correction needs to be 
applied as the concentration of pyocyanin is directly correlated to a calibration curve 
generated using pure pyocyanin. In this analysis, we found that in the presence of 1-5 nM 
of LXA4, pyocyanin concentration in bacterial culture was decreased (Figure 6). 
Interestingly, we found that increasing the concentration of LXA4 further (8 nM) 
abolished this effect. Taken together these results suggest a bell-shaped inhibitory    curve 
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for LXA4 on the expression of the bacterial virulence factor pyocyanin. This pattern of 
LXA4 inhibition has been noted in other systems
56,57
. 
Inhibition of LasR QS by LXA4: The regulation of virulence factor expression, 
including pyocyanin expression, in P. aeruginosa occurs through a complex regulatory 
network. The master QS receptor, LasR, plays a central role in this regulatory network 
and we looked to evaluate if the observed inhibition of pyocyanin by LXA4 might be 
occurring through inhibition of LasR. Upon analysis using a GFP-based reporter strain  
for the activity of the transcription factor LasR, we found potent antagonism of LasR by 
LXA4 at concentrations above 1.8 nM (Figure 7a). Generating a full dose-response curve 
to evaluate the antagonist activity of LXA4 on LasR we observed partial antagonism, 
achieving approximately 57% inhibition at the highest concentration tested (100 nM) as 
compared to the known LasR antagonist, Br-HSL at 10 mM. While only partial 
antagonism was observed, the potency of inhibition as defined by the IC50 of LXA4 
(57nM) (Table 1, supplemental data), makes LXA4 the most potent antagonist of LasR  
yet described
43
. We turned to evaluate the binding kinetics of the LasR inhibitory activity 
of LXA4 using competition binding assays, locking the concentration of LXA4 while 
titrating the native LasR agonist, 3-oxo-C12 HSL. In this assay we observed a shift in the 
EC50 value for the LasR agonist 3-oxo-C12 HSL in the presence of increasing 
concentrations of LXA4 (Figure 8; Table 2, supplemental data). Together, these results  
are consistent with LXA4 acting as a highly potent reversible partial antagonist of the P. 
aeruginosa master QS regulator, LasR. LXA4 is also a partial LasR agonist. The partial 
agonist activity of LXA4 is anticipated from the previous assay demonstrating partial 
antagonist activity for this compound. In this assay the native agonist was not fully 
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titrated leading to the incomplete dose-response curve for this control compound, 
however the different levels of maximal activation expected from LXA4 acting as a  
partial agonist are clearly defined. 
Discussion 
 
Effective resolution of infection and/or inflammation is now believed to be an 
active process
18,19,58
. As part of the early innate immune system, neutrophils are activated 
to help clear the invading pathogen. Excessive neutrophil activation however, may lead to 
tissue injury and damage while impaired neutrophil activity which can occur later in 
sepsis, may result in reduced bacterial clearance
11-14
. Ideally therefore, neutrophil 
activation and subsequent apoptosis are critical for inflammation resolution and to 
achieve homeostasis in the host
44,59,60
. 
SPMs have been reported to have significant pro-resolution effects in various 
non-infectious, infectious and sepsis models
20-22,25,26,28-30,45,61-64
. The underlying 
mechanism for these beneficial effects is believed to be due to the resolution effects on 
different populations of cells including neutrophils and macrophages
25-27,29,30,60,61,65-67
. 
With respect to infection, we and others have consistently shown that SPMs such as 
LXA4 could simultaneously reduce bacterial load and inflammatory response
28-30
. The 
timing of administration may be of importance because overly robust down regulation of 
neutrophil function may produce unwanted bacterial spread
54
. 
CD64 expression is important for neutrophil activation and phagocytic ability 
(33,68). There is evidence that neutrophil CD64 expression can be used as a selective 
biomarker for infection where highest levels of expression were found in patients with 
infection  compared  to  patients  with  autoimmune  disorders  which  were     themselves 
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significantly higher than normal patients or patients with inactive disease
69
. In addition, 
studies have now linked increased neutrophil CD64 expression with better outcome in 
sepsis
15
. The possible reason for this is because neutrophil phagocytic action is increased 
and may augment bacterial clearance. In our studies, in vivo administration of LXA4 to 
CLP mice increased neutrophil phagocytic ability and CD64 expression without altering 
CD16/32 expression. In addition, use of CD64 blocking antibody abolished the increase  
in phagocytic ability in neutrophils isolated from LXA4-treated animals. These results 
correlated with a significant decrease in blood bacterial load suggesting that augmented 
CD64-dependent neutrophil phagocytic ability may be partially responsible for the 
decreased bacterial load with LXA4 administration. The increase in phagocytic ability is 
consistent with the action of a related SPM, Resolvin E1 which was also reported to 
increase neutrophil phagocytic ability
25
. 
To study the effects of LXA4 on neutrophils further, peripheral blood   neutrophils 
taken from CLP mice after 1h, were incubated with different concentrations of LXA4. 
Under these conditions, LXA4 increased neutrophil phagocytic ability without affecting 
expression of CD64. Importantly, LXA4 did not affect neutrophil phagocytic ability in 
cells taken from control animals where CD64 expression was minimal. These results 
suggest that LXA4 directly increased CD64-dependent neutrophil phagocytic ability 
providing evidence that concentrations of LXA4 that produce a significant biological 
effect in neutrophils only affected the phagocytic activity of already activated  
neutrophils. These results are consistent with in vitro studies showing that  LXA4  
inhibited stimulated neutrophil chemotactic responses
65 
but do not directly affect 
quiescent  neutrophil  phagocytic  activity
66
.  Use  of  a  specific  LXA4  receptor (FPR-2) 
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blocker completely abolished LXA4 effects on neutrophil phagocytic ability confirming 
the receptor binding specificity of the LXA4 in these studies. These ex vivo results differ 
from our in vivo data in that administration of LXA4 in vivo resulted in an increased  
CD64 expression in neutrophils. The mechanism for this difference is unknown but may 
indicate that LXA4 by itself is unable to increase CD64 expression in neutrophils or that 
neutrophils from LXA4 treated septic mice are more responsive to CD64 inducing agents 
such as IFN-g or G-CSF. Although the incubation time of 3h for these ex vivo studies was 
shorter than the 24h of the in vivo experiments, it is unlikely that the shorter time frame 
contributed to the fact that LXA4 did not augment CD64 expression. This is because 
CD64 expression can clearly be enhanced in the time period used, as can be seen in 
Figure 5 where neutrophils taken 1h after CLP had substantially greater CD64 expression 
compared to neutrophils taken from control mice. These results would argue that the 
conditions allowed enough time for there to be an increase in CD64 expression. 
Apart from increasing peripheral blood neutrophil phagocytic ability, LXA4 
reversed the decline in blood apoptosis commonly found in sepsis and did not affect  
PMA stimulated superoxide generation. These results confirm previous work by us that 
LXA4 increases neutrophil phagocytic activity and restores apoptosis activity without 
excessive free radical production in CLP rats
31
. 
P. aeruginosa is a virulent bacterial strain which causes various infections that  
can result in sepsis especially in immunocompromised individuals
70
. The coordinated 
behavior for colonization of higher organisms and virulence of P. aeruginosa is mediated 
by binding of 3-oxo-C12 HSL to its native QS receptor, the bacterial transcription factor 
LasR. Through this receptor signaling mechanism, P. aeruginosa bacteria coordinate  the 
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gene expression and release of virulence factors such as exoproteases, siderophores, 
exotoxins and secondary metabolites
42,44,71-74
). In addition, biofilm formation is also 
coordinated through this mechanism
42,43
. Apart from coordinating signals between 
bacteria, 3-oxo-C12 HSL activates the hosts’ immune system through stimulation of T- 
cell production of interferon-gamma (IFN-g) in resting cells
75
. On the other hand, if 
macrophages are co-stimulated with bacterial endotoxin, 3-oxo-C12 HSL increases 
production of IL-10, an anti-inflammatory cytokine
76 
which has been shown to reduce 
neutrophil phagocytic ability. These results strongly suggest that 3-oxo-C12 HSL is not 
only an important mediator of bacterial virulence by stimulating the expression and 
release of virulence factors but can also modulate host, immune responses. Our results 
here add to this intriguing inter-kingdom chemical communication crosstalk by 
demonstrating that LXA4 with primary activity in the resolution of inflammatory 
signaling in the host inhibits the activity of a bacterial QS receptor, LasR, and decreases 
the expression of virulence factors in this bacteria. The potency of this inhibition by 
LXA4 as evaluated by comparison of IC50 values is several orders of magnitude greater 
than any reported LasR antagonist
77
, and occurs at physiologically relevant 
concentrations of LXA4 
64
. Interestingly, not only is LXA4 an antagonist but it also has 
partial agonist activity against LasR (Figure 8b). This property is particularly intriguing 
because there is very little structural similarity between LXA4 and a known antagonist, 
Br-HSL (Figure 8a) or the endogenous agonist 3-oxo-C12 HSL. The results suggest   that 
LXA4 acts as a partial agonist and a competitive antagonist at the LasR binding site. 
Investigation of related lipid mediators to examine the specificity of LXA4 for LasR is a 
subject of current study. 
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Pyocyanin is an exotoxin produced by P. aeruginosa. It is one of many virulence 
factors regulated by quorum sensing pathways and the release of pyocyanin is completely 
necessary for P.aeruginosa lung infections
78
. It is therefore a good marker of P. 
aeruginosa virulence. In vitro studies have shown that pyocyanin inhibits cell respiration 
and disrupts calcium homeostasis
79
. Our results show that LXA4 reduced pyocyanin 
release from P. aeruginosa at concentrations of 1 – 5 nM LXA4. Taken together with our 
results showing that LXA4 inhibits the activity of expression of pyocyanin mediated by 
the QS receptor LasR, these observations strongly suggest that LXA4 at physiologically 
relevant concentrations can reduce P. aeruginosa virulence. 
It is noteworthy that there was a concentration-dependent effect of LXA4 on 
pyocyanin release until the highest concentration of LXA4 (8 nM). This bell shaped curve 
is characteristic and consistent of previous reports showing that LXA4 effects stop at 
higher concentrations
56,57
. This effect may be due to the partial agonist activity of LXA4 
on LasR at higher concentrations of this ligand or could result from potential  interactions 
with cellular targets in P. aeruginosa in addition to LasR. 
 
Importantly, P. aeruginosa has been reported to possess a secretable 15- 
lipoxygenase enzyme which has been demonstrated to convert arachidonic acid to 15- 
hydroxyeicosatetraenoic acid (15-HETE)
80
. This would suggest that when P. aeruginosa 
is in the vicinity of host neutrophils (which possess the 5-lipoxygenase enzyme), 
transcellular biosynthesis of LXA4 can occur. Taken together with our studies, host- 
bacteria cross-talk may occur to control virulence. 
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Experimental Section 
 
All experiments were performed in adherence to protocols approved by the 
Institutional Animal Care and Use Committee of Rowan University and strictly complied 
with the National Institutes of Health guidelines on the use of experimental animals. 
Synthesis of LXA4 
 
LXA4 was prepared synthetically by previously published methods
47
. The purity  
of the compound was measured by HPLC-Mass Spectrometry and determined to be > 
98% and 1 mg was dissolved in 500 ml sterile saline on days of experiment. 
CLP-sepsis model: 
 
CLP was performed on male CD1 mice (25 – 30g) using modified methods as 
previously published (29,30,48). On day of surgery, mice were anesthetized with 2.5% 
isofluorane (with oxygen). A 1-cm-long midline incision was made in the abdomen to 
expose the cecum. The distal half of the cecum was ligated with 3.0 surgical silk.  Using  
a 21-gauge needle, the cecum was punctured twice, through and through.  A small  
amount of fecal matter was massaged out of the cecum through these holes, to ensure 
patency of the punctures. The cecum was placed back into the abdomen, which was then 
closed in 2 layers. For sham controls, ceca were isolated but not ligated or punctured. 
Saline (4 ml/100g; s.c.) was injected to replace any fluids lost during surgery. 1h after 
surgery, CLP mice were anesthetized and injected with LXA4 (7 mg/kg), or saline 
vehicle, intravenously via the tail vein. This concentration of LXA4 was derived from 
published in vivo work in rodents 
29,30,49
. 
 
The CLP model is widely regarded as the gold standard to study sepsis because it 
can be manipulated to different levels of severity and demonstrates bacteremia, a pro- 
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inflammatory phase and an immunosuppressive phase 
5,7,48
. 
Isolation of blood leukocytes. 
After 24h, mice were anesthetized with ketamine/xylazine (50/10 mg/kg, i.p.). 1 
mL of whole blood was drawn by cardiac puncture into 0.05 M EDTA (final 
concentration). Blood was lysed using RBC lysis buffer and filtered through a 100 m 
cell strainer. Lysed blood was centrifuged (500 x g, 5 min, room temperature), cells were 
resuspended in 2 mL of PBS/10% fetal calf serum kept on ice and total cell counts (gated 
at > 7 m), were performed (Beckman Coulter counter Z4; Brea, CA, USA). 
Bacterial load 
 
1:10 serial dilutions of blood were made and aseptically spread on tryptic soy agar 
plates (Sigma-Aldrich; St. Louis, MO, USA) to measure aerobic bacteria growth. The 
plates were incubated overnight at 37
0
C. At the end of the incubation period, colony 
forming units (CFU) were counted by operators blind to the treatment groups. 
Neutrophil free radical production and apoptosis assays 
 
To determine effects of LXA4 on neutrophil free radical production during sepsis, 
we performed dihydrorhodamine 123 (DHR123) flow cytometry assays. Initially, 0.5 g 
of phycoerythrin (PE) labeled anti-mouse granulocyte antibody, Gr-1 (Biolegend, San 
Diego, CA, USA), was added to 100 l of total leukocytes from blood. Debris was gated 
out according to their forward and side scatter parameters. The remaining non-debris 
population was designated as total leukocyte population. Neutrophils were initially 
identified by forward and side scatter parameters (low forward, high side scatter), 
followed by Gr-1 surface immunostaining for flow cytometry. Results are reported as Gr- 
1
+  
cells  derived  from  Gr-1
+  
cells  gated  from  total  leukocyte  population.  The   Gr-1 
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antibody (RB6-8C5 clone) has high affinity for Ly6G and low affinity for Ly6C 
(manufacturer’s details). Furthermore, the epitope recognized by this Gr-1 Ab overlapped 
with Ly6G but not with Ly6C and has been used as a blood neutrophil marker (49). 
To determine the appropriate voltage for cells positive for rhodamine, total 
leukocytes (1x10
6
/mL) were incubated with 1 M phorbol 12-myristate 13-acetate  
(PMA; Sigma, St, MO) at 37
0
C for 15 min, followed by addition of DHR123 (Invitrogen, 
Grand Island NY, USA)(5 M), at 370C for 5 min. The reaction was stopped by washing 
cells twice with ice cold PBS (500xg, 3 min). Cells from sham, CLP, CLP+LXA4 mice 
were stained with DHR123 only (37
0
C, 5 min), Cells undergoing apoptosis and/or 
necrosis were determined by staining with Annexin V (4 ml/sample) as recommended  by 
manufacturer (Biolegend, San Diego, CA, USA), while non-viable/necrotic cells were 
detected with 7-amino-actinomycin D (7AAD; Biolegend, San Diego, CA, USA). 
Positive Annexin V
+ 
gating was standardized by incubating total leukocytes from each 
experimental group with staurosporine (1 M, 370C, 5% CO2, 3h). All samples were 
analyzed within 1h of adding Annexin V. In all assays, 10,000 events were collected in 
total leukocyte population for each sample using an Accuri C6 flow cytometer (BD 
Biosciences; Franklin Lakes, NJ, USA). All assays for determination of neutrophil free 
radical and apoptosis were performed in duplicate for each animal and an average for 
each parameter was determined for each individual animal. 
Neutrophil Phagocytic ability 
 
E. coli bioparticles (pHrodo; Invitrogen, Grand, Island, NY, USA) were 
opsonized with E. coli opsonizing reagent for 1h at 37
0
C (1:1 ratio). pHrodo bioparticles 
were  washed  twice  (1200  x  g,  15  min)  to  remove  any  unbound  IgGs.    Opsonized 
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bioparticles were added to unlabeled total leukocytes from peritoneum and blood (3:1 
ratio, bioparticles to leukocytes). Incubations (1h, 37
0
C; 1h, on ice) were stopped by 
washing with ice cold PBS twice. Three different time points (30, 60 and 90 min) were 
carried out to determine the optimal incubation period for phagocytosis assay. It was 
determined that 60 min was the optimum incubation time. Cells that internalized E. coli 
were separated from cells that did not internalize E. coli by comparing voltage intensities 
between samples placed on ice (negative control) and 37
0
C. Samples were resuspended 
and fixed with 0.4% paraformaldehyde and analyzed by flow cytometry the following 
day. Immunostaining of Gr-1, FcgRI (CD64) and FcgRIII/II (CD16/32) were   performed 
after the phagocytosis assays as described above. Similar to free radical and apoptosis, 
phagocytosis assays were performed in duplicate for each individual mouse and an 
average of the duplicates were calculated. The phagocytic ability is expressed as 
phagocytic index. Mean number of E. coli ingested by neutrophils containing E.coli = 
mean fluorescence intensity. Therefore 
Phagocytic index = % neutrophils ingesting at least 1 E. coli cell X mean florescence 
intensity 
In separate studies, 8 mg of CD64 blocking Ab or isotype antibody controls was 
incubated for 1h with cells isolated from CLP + LXA4 mice prior to phagocytosis assays. 
Ex vivo experiments 
1h after performing CLP or sham surgery, total leukocytes from blood were 
processed according to methods mentioned above. For ex vivo studies, total leukocytes 
(10
5 
cells) were suspended in 1 ml RPMI media. Either LXA4 (1, 10 nM) or PBS were 
added and the cells incubated at 37
0
C, 5% CO2 for 3h. To confirm the specificity of 
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LXA4 actions, a specific LXA4 receptor blocker (50 mM WRW4; Tocris, Loughborough, 
UK) was incubated together with cells prior to phagocytosis assays. Reactions were 
stopped by adding ice cold PBS/2% fetal calf serum, followed by two washes (500 x g, 
room temperature, 4 min). Samples were kept on ice before performing assays in 
duplicate to measure phagocytic index as described above for in vivo studies. Cells were 
then stained for Gr-1 and CD64. All assays were performed in duplicate and the average 
of the duplicates calculated. 
Pyocyanin analysis 
 
Overnight P. aeruginosa PA-14 cultures were prepared in cation-adjusted 
Mueller-Hinton broth at 37°C with shaking at 300 rpm. The overnight culture was diluted 
100 fold into the same medium with the appropriate compounds. The positive control for 
pyocyanin included DMSO at the highest concentration used in the assay. LXA4 was 
added at 8 nM, 5 nM, 1 nM, and 0.2 nM. All solutions were prepared in duplicates and 
were incubated at 37°C with shaking at 300 rpm for 36h. For High Performance Liquid 
Chromatography Mass Spectrometry Mass Spectrometry (HPLC-MS-MS) quantification, 
1 mL from each overnight culture was transferred into a 2 mL microcentrifuge tubes and 
centrifuged at 12,000 X g for 15 min at 21°C. Using a syringe, 500 µL of the cell-free 
supernatant was removed and transferred into new tubes. Chloroform (400 µL) was  
added to each tube and then centrifuged at 12,000 x g for 1 min. A portion of the bottom 
organic layer (200 uL) was transferred into a vial for Ultra Performance Liquid 
Chromatography Mass Spectrometry Mass Spectrometry (UPLC-MS-MS) analysis. The 
samples were subjected to HPLC separation through an in-line Waters 2795 Separations 
Module  on  a  BETASIL  5  mm  Phenyl-Hexyl  HPLC  column  (Thermo        Scientific, 
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Waltham, MA, USA) using a linear gradient of ACN/H2O (0.1% formic acid modified, 
5% to 95% ACN) and were analyzed in positive ion mode on a Waters Micromass 
Quattro MS-MS by evaluating the TIC for the presence of pyocyanin molecular ion at  
m/z 211.28. The identity of pyocyanin was further confirmed by monitoring the presence 
of a characteristic fragmentation peak at m/z 168.33. The concentration of pyocyanin was 
determined by recording the TIC for m/z 211.28 of triplicate injections of the duplicate 
samples by comparison to an external calibration curve generated using pure pyocyanin 
(Aldrich, St. Louis, MO, USA). 
LasR Reporter Strain Bioassay 
 
The LasR reporter strain bioassay was performed as described previously (43) 
with modifications. The reporter strain was kindly provided by Bonnie L. Bassler 
(Princeton University). This E. coli strain was grown overnight at 37oC in Luria broth 
(LB) (Fisher Scientific) maintained with 100 µg/mL ampicillin and 50 µg/mL of 
kanamycin. The overnight culture was subcultured 1:40 for bioassay analysis. For agonist 
assays compounds were added to the diluted overnight reporter strain in 96-well black 
microplates with clear bottoms (Corning) at the starting concentrations described and 
titrated by serial dilution. Plates were incubated with shaking at 37
o
C for 4-6h and were 
 
evaluated for fluorescence (ex485/em538) and absorbance (A600) using a Molecular 
Devices SpectraMax M5 microplate reader. The native LasR agonist, N-3-oxo- 
dodecanoyl-L-homoseriene lactone was utilized as the positive control for this assay. For 
antagonism assays, the native LasR agonist, 3-oxo-C12 HSL was employed at a constant 
concentration of 50 nM. The previously described antagonist, (S)-2-(4-bromophenyl)-N- 
(2-oxotetrahydrofuran-3-yl)  acetamide  (Br-HSL)  was  used  as  the  positive  control for 
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antagonism (50). LXA4 or control compounds were added to the diluted overnight 
reporter strain containing 3-oxo-C12 HSL, titrated by serial dilution and analyzed as 
described for the agonist assay. 
Statistical analyses: 
 
One way analysis of variance (ANOVA) was used to analyze all data with more 
than 2 groups, using GraphPad Prism 6 software. Differences between groups were then 
ascertained using Newman-Keuls test of significance. In cases when there were only 2 
groups, significance was analyzed using the unpaired t-test. For bacteria load, the Mann- 
Whitney U test for non-parametric data was used. In ex vivo studies, changes were 
expressed as percentage increase from controls samples incubated without LXA4. Dose- 
response curves for the LasR-reporter strain studies were fit to the data using standard 
nonlinear regression data fitting settings in GraphPad Prism 6. Differences between 
groups are considered significant at p < 0.05. 
Conclusion 
 
This study provides evidence that LXA4 increases host response against infection 
by augmenting neutrophil CD64 mediated phagocytic ability as well as reducing bacterial 
virulence. This novel dual property of LXA4 working on both host defense and pathogen 
virulence warrants further investigation. Future studies on LXA4 and related pro- 
resolving mediators may lead to discovery of a new class of antimicrobial which 
upregulates host defense and simultaneously reduces bacterial virulence. 
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Figure 22. LXA4 inhibits the 
expression of P. aeruginosa 
virulence factor, pyocyanin. 
Pyocyanin concentrations were 
determined by integration of the LC- 
MS total ion chromato- gram (m/z, 
211.2) on the basis of the correlation 
with a standard curve that was 
prepared by using pure pyocyanin. 
The data are presented as means 6 SD 
of n = 3. *P , 0.05; **P , 0.01. 
 
 
 
 
 
 
 
 
 
 
Figure 23. A) LXA4 inhibits the 
LasR QS receptor. Inhibition 
values determined employing  
the green fluorescent protein 
(GFP)–based LasR antagonist 
bioassay. Inhibition of LasR at 
the compound concentrations 
indicated is shown as means 6  
SD of n = 3. B) Antagonism 
dose-response  curve  for  LXA4 
                                                                                                  and Br-HSL (known LasR 
antagonist) in the presence of 50 
nM of the native LasR agonist, 
3-oxo-C12 HSL. OD, optical 
density. Data points are means 
of n=3.**P,0.01. 
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Figure 24. A) Competition binding 
assay for LXA4 inhibition of LasR. 
The native LasR agonist, 3-oxo-C12 
HSL, was titrated against fixed 
concentrations of LXA4. Increasing 
values for the titration of the native 
agonist in the presence of increasing 
concentrations of inhibitor is 
consistent with LXA4 acting as a 
reversible antagonist of this 
receptor. B) LasR agonist as- says 
were performed by using LXA4, 3- 
oxo-C12 HSL, and DMSO. LXA4 is 
a partial agonist of LasR in P. 
aeruginosa in which maximum 
response is less than the maximum 
response of the endogenous ligand, 
3-oxo-C12 HSL. GFP, green 
fluores- cent protein; OD, optical 
density. All data points are means 6 
SD of n = 3. 
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